Use an existing #coa instrument or develop a new one? Watch ICON and Mapi Research Trust discuss the evidence and considerations behind fit-for-purpose instrument selection. www.iconplc.com/news-events/events/webinars/getting-coa-s…
#coa #clinicaltrials #regulatorystrategy
Icon plc
Icon plc (stylized as "ICON") is an Irish-headquartered multinational clinical research organisation (CRO). Icon conducts clinical trials on behalf of pharmaceutical and biotechnology companies and provides services related to drug development and guiding clinical trial progress. More on Wikipedia
-
ICON Plc
@ICONplc
-
ICON Plc
@ICONplc
We are pleased to be included on TIME’s World’s Most Impactful Companies 2026 list.
This recognition reflects the dedication of our colleagues and partners advancing clinical research and improving patient outcomes worldwide.
time.com/article/2026/05/12/worlds-most-impactful-compani…
#iconcares #cop31 -
ICON Plc
@ICONplc
ICON supports #worlddiabetesday. From Type 1 & Type 2 diabetes, adult to pediatric populations—we’ve conducted 187metabolic trials, including 51 focused on diabetes. Learn more. #worlddiabetesday www.iconplc.com/therapeutics/endocrine-metabolic-disorders
-
ICON Plc
@ICONplc
With #worlddiabetesday approaching, what’s next for metabolic R&D? Explore how evolving GLP-1 strategies, new mechanisms and broader endpoints are shaping diabetes and obesity drug development. www.drugdiscoverytrends.com/shifting-glp-1-research-and-d…
-
ICON Plc
@ICONplc
Heading to the 19th EBF Open Symposium in Barcelona? ICON will be there from 17–19 November at the Hyatt Regency Barcelona Tower. Stop by booth B1 to explore how our bioanalytical services help bring therapies to market with speed and scientific rigor. meetings.e-b-f.eu/open/
-
ICON Plc
@ICONplc
As biosimilar pathways evolve, success for innovator companies will increasingly depend on differentiation rather than exclusivity. Read insights from ICON. pm360online.com/think-tank-biosimilar-rulings-impact/
#biosimilars #drugdevelopment -
ICON Plc
@ICONplc
Sponsors need regulatory partners that combine expertise, broad capabilities and global delivery.
ICON has been named a Leader in the Everest Group Life Sciences Regulatory Affairs Services PEAK Matrix® Assessment 2026. Read more www.everestgrp.com/report/egr-2026-54-r-8442/ -
ICON Plc
@ICONplc
Meet us at #obesityweek, Nov 14–17, booth 212 to discuss how ICON uses real-world evidence to uncover prescriber behavior, payer influence & patient needs—identifying subpopulations & quantifying impact to build stronger value. obesityweek.org
-
ICON Plc
@ICONplc
When Congress deadlines, extension and notifications dates change, will you know? PubsHub Journals & Congresses incorporates user-defined watchlists that can send alerts in the case of deadline updates, extensions and other changes. www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
Regulatory pathways for immunotherapies outside oncology are evolving, with differing regional expectations between the US and EU. Gain insights into navigating shifting requirements, accelerated pathways, and indication selection in the whitepaper: www.iconplc.com/insights/therapeutics/internal-medicine-i…
-
ICON Plc
@ICONplc
The 2024 accelerated approval of trastuzumab deruxtecan as the first tumor-agnostic ADC signals that pan-cancer development is within reach. Expanding access across diverse histologies, however, will require more precise patient selection. Read more. www.biopharminternational.com/view/biomarker-patient-sele…
-
ICON Plc
@ICONplc
Biomarker-based enrolment can compress early-intervention trial timelines, but it can also exclude patients a therapy is meant to help. The precision–inclusivity trade-off is critical in early chronic disease development. Explore the implications. www.iconplc.com/insights/therapeutics/internal-medicine-i…
-
ICON Plc
@ICONplc
Struggling to keep up with global regulatory change? ICON's Newsletter delivers the latest summaries of key updates from authorities including the FDA, EMA and more, helping you stay informed on developments that could impact your strategy and trials. www.iconplc.com/insights/regulatory-intelligence/regulato…
-
ICON Plc
@ICONplc
How do you accelerate obesity trial enrolment without sacrificing retention?
Watch our on-demand webinar for practical strategies to maintain study momentum whilst protecting participant engagement. www.iconplc.com/news-events/events/webinars/obesity-studi… -
ICON Plc
@ICONplc
Evolving biosimilar regulation is accelerating competition. ICON experts explore how manufacturers can respond through evidence generation, portfolio planning and market access.
Read the Q&A: www.iconplc.com/insights/blog/2026/11/03/qa-icons-centre-…
#biosimilars #biologics -
ICON Plc
@ICONplc
Endometriosis innovation is gaining momentum across therapeutics, diagnostics and digital health. But turning scientific progress into meaningful advances requires a connected approach to development.
Read the blog. www.iconplc.com/insights/blog/2026/11/04/advancing-endome… -
ICON Plc
@ICONplc
Reduce the publishing risk from predatory journals. PubsHub Journals & Congresses screens for predatory practices and suspicious journals and congresses. Trust it to protect your research work and help you make better informed publishing decisions. www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
For the second consecutive year, ICON is recognised by TIME for sustainability leadership. A testament to our commitment to responsible growth and measurable impact.
See our awards www.iconplc.com/news-events/awards
#sustainabilityleadership #esg #clinicaltrials #iconcares #unsdg #cop31 -
ICON Plc
@ICONplc
Europe’s biosimilar requirements are evolving, but tailored clinical development is not a general removal of evidence requirements. Product-specific justification remains essential.
Learn more: www.iconplc.com/insights/blog/2026/10/20/oncology-biosimi…
#regulatoryaffairs #biosimilars #esmo -
ICON Plc
@ICONplc
What do the latest EMA and FDA biosimilar guidances mean for bioanalytical teams? Explore practical considerations for development, validation and regulatory planning. www.bioprocessintl.com/biosimilars/how-evolving-biosimila…
#bioanalyticalscience #biosimilars #clinicalresearch #pharmaceuticalindustry -
ICON Plc
@ICONplc
ICON has launched the FIRECREST AI-directed video engine, helping sponsors create high-quality clinical trial videos faster and at scale.
Production timelines are reduced by ~10x, from days to hours, while maintaining control and governance. www.iconplc.com/news-events/press-releases/icon-launches-… -
ICON Plc
@ICONplc
We're proud to contribute research across multiple poster sessions at #isporeurope2026.
Meet the team at booth #1615 to discuss the future of outcomes research and evidence generation.
www.ispor.org/conferences-education/conferences/upcoming-…
#ispor #heor #clinicalresearch -
ICON Plc
@ICONplc
Which journals have the biggest impact? We can tell you. PubsHub Journals & Congresses gives you access to over 10,000 options for publishing your work, with 50 important data fields to consider and compare. Fast and easy. Arrange for a demo today: www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
Women represent ~80% of patients with autoimmune diseases, making women’s health a crucial frontier for expanding immunotherapies. Explore key development considerations, from fertility preservation to foetal safety, in our whitepaper. www.iconplc.com/insights/therapeutics/internal-medicine-i…
-
ICON Plc
@ICONplc
Attending #aasld26? Visit ICON at booth 1861 to explore how our experience-driven feasibility and site selection, hepatology-specific recruitment and retention, central laboratory services, and advanced imaging can help support your clinical trials. www.aasld.org/tlm-26/home
-
ICON Plc
@ICONplc
The regulatory environment for biomarker-based patient enrolment and outcomes assessment is shifting. Early adopters may be better positioned to advance breakthrough early-intervention therapies for chronic disease. Download the whitepaper. www.iconplc.com/insights/therapeutics/internal-medicine-i…
-
ICON Plc
@ICONplc
Spend less time managing the publishing process. PubsHub PMSolution offers all of the features you need to address the challenges of scientific publishing. Discover how PMSolution will help your team improve their efficiency and process. www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
Visit ICON at #obesityweek, Nov 14–17 (Booth 212) to discover how our AI-powered site selection and Accellacare Network accelerate obesity trials with ready-to-go sites and diverse patient populations. obesityweek.org
-
ICON Plc
@ICONplc
Standing out in a crowded biosimilars market requires agility, early planning and readiness for complex molecules. Explore the key considerations driving competitive advantage. www.bioprocessintl.com/biosimilars/biosimilar-success-in-…
#biosimilar #bioprocessing #pharmainnovation #manufacturing -
ICON Plc
@ICONplc
Recent regulatory changes could streamline biosimilar development and intensify competition. ICON’s Kim Salgado explains why differentiation and market access will be critical. pm360online.com/think-tank-biosimilar-rulings-impact/
#biosimilars #biologics -
ICON Plc
@ICONplc
When a data issue is closed, how do you know it’s been resolved?
Join Shabeeb Kannattkuni at the PHUSE Single Day Event in North Carolina, where he’ll share a SAS-based solution to checking data issue resolutions and identifying those that need review.
events.phuse.global/event/SDE/cary_nc- -
ICON Plc
@ICONplc
ICON will be at #ebf, 17–19 November. Visit booth #b1 to meet our bioanalytical experts and learn how we support drug development with regulatory-compliant solutions. meetings.e-b-f.eu/open/
-
ICON Plc
@ICONplc
Advancing a #mash trial? Meet ICON experts at #aasld26, booth 1861 discover how ICON’s medical imaging expertise can support your study with quantitative imaging biomarkers, multimodal imaging and standardised delivery across sites. www.aasld.org/tlm-26/home
-
ICON Plc
@ICONplc
Visit ICON at #octdach this 3–4 November. Meet our team at booth #6 to explore how we help sponsors navigate regulatory complexity, optimize trial delivery, and accelerate market access. www.arena-international.com/event/octdach/
-
ICON Plc
@ICONplc
Congress participation decisions made easier. Meetings are expensive, arrangements are time consuming. With 50+ data fields to compare details, PubsHub Journals & Congresses makes your decision making faster and easier. Request a demo: www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
Identify evidence gaps early
JCA can span multiple populations, comparators, outcomes and national standards of care. A joined-up, cross-functional strategy is essential to identify evidence gaps early. www.pharmexec.com/view/countdown-jca-apac-us-drug-develop…
#hta #jca #evidencegeneration -
ICON Plc
@ICONplc
One FDA meeting can shape the future of your AI-enabled medical device.
Our latest blog covers what to include in a Pre-Sub request and the common mistakes to avoid. www.iconplc.com/insights/blog/2026/10/15/what-ai-enabled-…
#ai #medicaldevices #fda #medtech -
ICON Plc
@ICONplc
Clinical outcomes. Patient perspectives. Regulatory insights. AI-enabled research.
These are just some of the topics ICON and Mapi Research Trust will be presenting at #isporeurope2026.
Visit booth #1615.
www.ispor.org/conferences-education/conferences/upcoming-…
#ispor #evidencegeneration -
ICON Plc
@ICONplc
Struggling to keep up with global regulatory change? ICON's Newsletter delivers the latest summaries of key updates from authorities including the FDA, EMA and more, helping you stay informed on developments that could impact your strategy and trials. www.iconplc.com/insights/regulatory-intelligence/regulato…
-
ICON Plc
@ICONplc
Attending #obesityweek? Visit ICON at booth #212 to explore how our cross-functional obesity expertise and integrated scientific and operational support can help advance your program. obesityweek.org
-
ICON Plc
@ICONplc
On demand content for your scientific materials. Highly configurable organization and search capabilities speed your research and improve collaboration. Experience the difference it could make for you with a demo: www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
Endpoint selection, validation & global deployment are often treated as separate activities. Bring them together in one early-stage #coa strategy, from planning through implementation.
One week left to register for our webinar: www.scientist.com/webinar/getting-coa-strategy-right-from… -
ICON Plc
@ICONplc
Prepare for 2028. Orphan medicinal products enter JCA in January 2028, with all remaining medicines following by 2030. Sponsors in phase 2 should align evidence and trial plans now. www.pharmexec.com/view/countdown-jca-apac-us-drug-develop…
#raredisease #jca #marketaccess -
ICON Plc
@ICONplc
Expanding into new markets brings new pharmacovigilance challenges. From compliance to safety oversight, here's what sponsors need to know: www.thepharmaletter.com/expert-view/managing-post-marketi…
-
ICON Plc
@ICONplc
Meet ICON’s hepatology experts at #aasld26 to discuss how our experience across hepatology, MASH and obesity can help you navigate clinical development, from trial design and patient identification to study execution. Arrange a meeting: www.iconplc.com/contact
-
ICON Plc
@ICONplc
Building an AI-enabled medical device?
A focused FDA Pre-Sub can help reduce uncertainty, strengthen your regulatory strategy and avoid costly delays. Read our latest blog: www.iconplc.com/insights/blog/2026/10/15/what-ai-enabled-…
#ai #samd #digitalhealth #fda -
ICON Plc
@ICONplc
Current preclinical models are imperfect predictors of human immunity, making clinical translation the single largest obstacle for gonorrhoea vaccine candidates. Incorporating patient-reported outcomes will be essential to proving meaningful efficacy. www.calameo.com/read/008183692f4956964cb6c
-
ICON Plc
@ICONplc
Rare disease feasibility starts with understanding where patients receive care and barrier to participation. Meet ICON at #worldorphaneu, booth 313 to discuss targeted site identification and patient-centred study delivery.
Arrange a meeting: www.iconplc.com/contact -
ICON Plc
@ICONplc
Europe’s #oncology biosimilar market is entering its next phase. As science and regulation evolve, developers must connect evidence generation with manufacturing, market access and commercial planning.
Read the blog: www.iconplc.com/insights/blog/2026/10/20/oncology-biosimi…
#esmo26 #esmomeetings #biosimilars -
ICON Plc
@ICONplc
As regulatory pathways evolve, biosimilar sponsors may have new opportunities to streamline development through stronger analytical evidence. Read more: www.bioprocessintl.com/biosimilars/how-evolving-biosimila…
#biosimilars #regulatoryaffairs #lifesciences #biotech -
ICON Plc
@ICONplc
Meet scientific publication security and compliance with increased confidence. PubsHub PMSolution features audit trail support for GPP2022 and ICMJE guidelines to meet best practices. Ask for your demo: www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
FDA Pre-Subs remain one of the most effective ways to reduce uncertainty for AI-enabled SaMD programmes. Our latest whitepaper explores best practices, common pitfalls and key considerations for successful regulatory engagement. Download now: www.iconplc.com/insights/digital-disruption/software-medi…
#fda #samd -
ICON Plc
@ICONplc
What's next for evidence generation?
Join us at booth #1615 during #isporeurope2026 to explore new research from ICON and Mapi Research Trust and discuss the evolving evidence landscape.
www.ispor.org/conferences-education/conferences/upcoming-…
#ispor #heor #patientoutcomes -
ICON Plc
@ICONplc
Oncology delivery starts with informed feasibility and the right site strategy. Meet ICON at #esmo26, booth #8005, to discuss site access, patient recruitment and study delivery. Connect with our team at ESMO: www.iconplc.com/news-events/events/industry/esmo-2026
-
ICON Plc
@ICONplc
Use the time before the clock starts
The final JCA scope can leave developers roughly three months to submit a dossier. Evidence searches, subgroup analyses and indirect comparisons must be planned much earlier.
www.pharmexec.com/view/countdown-jca-apac-us-drug-develop… -
ICON Plc
@ICONplc
Immunotherapies originally developed for cancer may benefit many patients with chronic disease. Read more to find out how different categories of immunotherapy, including CAR therapies, T cell engagers and ICIs, are being applied to new indications. www.iconplc.com/insights/therapeutics/internal-medicine-i…
-
ICON Plc
@ICONplc
Q: When should key COA decisions be made?
A: Before the endpoint is locked.
Learn how early #coa selection & development decisions can strengthen evidence, reduce risk + support regulatory strategy.
Register for the webinar now: www.iconplc.com/news-events/events/webinars/getting-coa-s… -
ICON Plc
@ICONplc
How hard do you work to choose the right research publishing platform? Probably too hard. We can make it easier for you. PubsHub Journals and Congresses has information on over 10,000 entries with over 50 fields of data for each. Take a demo. www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
Where can AI provide practical value in oncology development? Meet ICON at #esmo26, booth #8005, to discuss applications across biomarkers, patient selection, trial design and evidence generation. Schedule a meeting: www.iconplc.com/news-events/events/industry/esmo-2026
-
ICON Plc
@ICONplc
Approval does not guarantee reimbursement
EMA marketing authorisation does not guarantee reimbursement. JCA evidence must address relative clinical effectiveness, safety and patient-relevant outcomes for European decision-making. www.pharmexec.com/view/countdown-jca-apac-us-drug-develop… -
ICON Plc
@ICONplc
For drug developers advancing immunotherapies into chronic diseases, understanding the unique needs of different patient populations is essential. Explore key considerations across autoimmune disease, cardiometabolic conditions, and women’s health. www.iconplc.com/insights/therapeutics/internal-medicine-i…
-
ICON Plc
@ICONplc
Heading to Boston for The MedTech Conference? Meet ICON's MDDR team to discuss strategies for devices, diagnostics, wearables, digital health technologies and combination products, from development through post-market evidence generation. themedtechconference.com #mtc26
-
ICON Plc
@ICONplc
Drop by booth #69 at #octnewengland2026, 27– 28 October. Meet the ICON team to explore new solutions to common issues within clinical trials.
www.arena-international.com/event/octnewengland/ -
ICON Plc
@ICONplc
Join ICON at booth #6 at #octdach, 3–4 November at the Congress Center, Basel. As a trusted partner to biotech and pharma across the DACH region, ICON delivers integrated clinical development solutions. www.arena-international.com/event/octdach/
-
ICON Plc
@ICONplc
Cardiovascular innovation requires specialised expertise.
ICON supports device sponsors from early feasibility through pivotal and post-market studies with dedicated medical device teams and deep therapeutic experience.
See us at #medtechcon. themedtechconference.com -
ICON Plc
@ICONplc
ICON is heading to Copenhagen for #octnordics on 20–21 October. Stop by booth #41 to meet our team and explore how we’re supporting sponsors across the Nordics with faster, smarter, and more patient-focused clinical trials. Learn more: www.arena-international.com/event/octnordics/
-
ICON Plc
@ICONplc
Liver disease research depends on reliable biomarkers and imaging endpoints. This #nationalliverawarenessmonth, discover how ICON's medical imaging expertise helps support MASH/MASLD studies with advanced quantitative imaging and global trial experience. www.iconplc.com/solutions/medical-imaging/imaging-therape…
-
ICON Plc
@ICONplc
Stay up-to-date with watchlists that you define. PubsHub Journals & Congresses watchlists send you updates on your priority list as updated information is available. Deadline changes, location confirmation, factors that affect your publishing decision. www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
This October 15- 18, booth #406 at the #gsss the Accellacare team will show you how it is providing clinical research as care option. sitesolutionssummit.com/event/global/
-
ICON Plc
@ICONplc
ICON’s Dublin laboratory has achieved My Green Lab® Certification, earning Gold for Specialised Testing and Silver for Automated Areas. mygreenlab.org
-
ICON Plc
@ICONplc
We're looking forward to sharing new research at #isporeurope2026 covering outcomes assessment, regulatory science, systematic reviews, quality-of-life research and AI-enabled methodologies.
Visit ICON at booth #1615.
www.ispor.org/conferences-education/conferences/upcoming-…
#ispor #heor #evidencegeneration -
ICON Plc
@ICONplc
Struggling to keep up with global regulatory change? ICON's Newsletter delivers the latest summaries of key updates from authorities including the FDA, EMA, MHRA and more. Subscribe for free today: www.iconplc.com/insights/regulatory-intelligence/regulato…
#regulatoryintelligence #regulatoryaffairs -
ICON Plc
@ICONplc
Observational data showing cross-protection from meningococcal B vaccines (like 4CMenB) provided a proof-of-concept for gonorrhoea prevention. Read the article to explore the evolving pipeline. www.calameo.com/read/008183692f4956964cb6c www.calameo.com/read/008183692f4956964cb6c
-
ICON Plc
@ICONplc
Autoimmune and chronic disease therapies face rising competition. Read the whitepaper to gain insights for sponsors bringing immunotherapies to the market in this space, including the regulatory landscape, timelines and indication selection. www.iconplc.com/insights/therapeutics/internal-medicine-i…
-
ICON Plc
@ICONplc
CSRs require scientific judgement, not just content generation.
See why augmenting medical writers with AI can accelerate development while protecting quality: www.iconplc.com/insights/blog/2026/09/03/why-augmentation… -
ICON Plc
@ICONplc
A deferred #coa decision can return as a validation gap, a missing translation or an unsupported endpoint. Join our Nov. 5 webinar to learn how to address these issues before they lead to amendments or delays.
Register: www.iconplc.com/news-events/events/webinars/getting-coa-s…
#clinicaltrials -
ICON Plc
@ICONplc
Early clinical trials in neurodegenerative diseases require smart strategy. Join our webinar on Oct 14 to explore study design, patient engagement & biomarker selection. xtalks.com/webinars/strategic-approaches-for-early-clinic…
-
ICON Plc
@ICONplc
Find the gaps in your publication plans. Knowledge Manager offers improved ability to track and analyze publication plan gaps for improved decision support. Your demo is waiting: www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
This 14-15 October in Boston, ICON is sponsoring the #worldpatientsafety Congress, uniting 2,000+ drug safety professionals. Learn how our real-world evidence, AI signal detection & risk management drive safer outcomes at booth #636. www.terrapinn.com/conference/world-patient-safety-congres…
-
ICON Plc
@ICONplc
We are pleased to be included on TIME’s World’s Most Impactful Companies 2026 list.
This recognition reflects the dedication of our colleagues and partners advancing clinical research and improving patient outcomes worldwide.
time.com/article/2026/05/12/worlds-most-impactful-compani…
#iconcares #clinicalresearch -
ICON Plc
@ICONplc
Heading to #toprasym26 next week? Met our team at ICON booth #37 in Utrecht, 19 to 21 October. Learn more: www.topra.org/AsiCommon/Controls/Shared/FormsAuthenticati…
-
ICON Plc
@ICONplc
ICON has been named a Leader in the Everest Group Life Sciences Regulatory Affairs Services PEAK Matrix® Assessment 2026, which evaluates providers across market impact, vision and capability. Explore the assessment www.everestgrp.com/report/egr-2026-54-r-8442/
-
ICON Plc
@ICONplc
Select quality management activities, 2025
- 901 customer audits
- 2,770 internal audits
- 201 regulatory inspections
- 120 supplier audits
Quality remains a core part of how we deliver for customers and patients.
[www2.iconplc.com/2025_ESG_Report]
#iconcares #quality #compliance -
ICON Plc
@ICONplc
Pharyngeal gonorrhoea infections rarely show symptoms, creating ideal conditions for N. gonorrhoeae and commensal species to exchange antimicrobial resistance genes. Learn more www.calameo.com/read/008183692f4956964cb6c
-
ICON Plc
@ICONplc
As therapies enter real-world use, pharmacovigilance becomes increasingly complex. Read Dr. Quintin van Wyk's latest article on managing post-marketing safety obligations across global markets. www.thepharmaletter.com/expert-view/managing-post-marketi…
-
ICON Plc
@ICONplc
Updated biosimilar guidance is increasing the focus on analytical rigour and bioanalytical strategy. Learn how evolving EMA and FDA expectations are reshaping development programmes. www.bioprocessintl.com/biosimilars/how-evolving-biosimila… #biosimilars #bioanalytics #drugdevelopment #biopharma
-
ICON Plc
@ICONplc
Meet ICON at ACoP 2026 in Maryland. Visit Booth #19 to connect with our experts, see live demonstrations, and discuss clinical pharmacology and model-informed drug development. Learn how ICON can support your development programs. acop2026.eventscribe.net
-
ICON Plc
@ICONplc
ICON’s Dublin laboratory has achieved My Green Lab® Certification, earning Gold for Specialised Testing and Silver for Automated Areas. mygreenlab.org
-
ICON Plc
@ICONplc
Discover Accellacare’s clinical trial operations at the #gsss 2026. Meet us at the Signia by Hilton Orlando Bonnet Creek, booth #406. sitesolutionssummit.com/event/global/
-
ICON Plc
@ICONplc
Which audience will be most interested in your research? Find out with PubsHub Journals & Congresses. Over 10,000 journals and conferences to consider and incorporate 50+ accessible points of metadata to provide the answer. Schedule a demo. www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
How can natural history studies strengthen rare disease development? Join ICON at #worldorphaneu on 27 Oct, 14:10 CET to explore patient-centred design, natural history data and strategies for developing external controls.
www.terrapinn.com/conference/world-orphan-drug-congress/i… -
ICON Plc
@ICONplc
ICON is proud to sponsor #octnordics on 20–21 Oct in Copenhagen. Visit booth #41 to meet our experts and explore how we’re advancing clinical development through innovation and operational excellence. Let’s connect: www.arena-international.com/event/octctsnordics/
-
ICON Plc
@ICONplc
Oncology biotechs need development strategies that can respond to rapid decisions and scale as programs advance. Meet the ICON Biotech and oncology experts at #esmo26, booth #8005. Arrange a meeting: www.iconplc.com/news-events/events/industry/esmo-2026
-
ICON Plc
@ICONplc
Early clinical trials in neurodegenerative diseases require smart strategy. Join our webinar on Oct 14 to explore study design, patient engagement & biomarker selection. xtalks.com/webinars/strategic-approaches-for-early-clinic…
-
ICON Plc
@ICONplc
PPWR compliance requires early planning across packaging, regulatory affairs and supply chains. Learn how pharma and medtech organisations can prepare for evolving requirements in this article by ICON's SMEs.
www.pharmamanufacturingiq.com/the-ppwr-mandate-essential-… #ppwr #sdg12 -
ICON Plc
@ICONplc
Meet the ICON team at the #worldpatientsafety Congress, in Boston, booth #636 to see how we help biopharma and medical device companies meet regulatory demands, apply advanced analytics, and strengthen #patientsafety. www.terrapinn.com/conference/world-patient-safety-congres…
-
ICON Plc
@ICONplc
Clinical trial recruitment for non-oncology immunotherapies can be challenging, hindered by risk aversion and high competition. Discover strategies for supporting enrolment, such as community coordination and hub and spoke model selection. www.iconplc.com/insights/therapeutics/internal-medicine-i…
-
ICON Plc
@ICONplc
As clinical development evolves, statistical programming teams face increasing pressure to deliver faster while maintaining quality and oversight.
Discover how WorkBench brings AI & automation into a unified statistical computing environment: www.iconplc.com/solutions/technologies/workbench -
ICON Plc
@ICONplc
A successful biosimilar strategy requires more than strong science. It requires alignment across analytical, clinical and regulatory functions. Explore six practical recommendations for sponsors: www.iconplc.com/insights/blog/2026/07/17/evolving-bioanal…
#biosimilars #drugdevelopment #bioanalyticalscience -
ICON Plc
@ICONplc
Heading to #isporeurope2026? Visit ICON booth #1615 to discuss evidence generation, patient-centred research, outcomes assessment and AI-enabled approaches to evidence development. We'll also be presenting new research across multiple poster sessions.
www.ispor.org/conferences-education/conferences/upcoming-… -
ICON Plc
@ICONplc
Early #coa planning can lead to better endpoint decisions, stronger evidence + less downstream risk.
Join ICON & Mapi Research Trust for a Nov. 5 webinar on building a COA strategy that supports development through #regulatory review.
Register: www.iconplc.com/news-events/events/webinars/getting-coa-s… -
ICON Plc
@ICONplc
Scientific publishing made easier. Managing the publication process is complex and time-consuming. PMSolution provides an integrated start-to-finish solution that saves you time, automates workflows, and streamlines processes. Take a demo: www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
What comes after AI-powered radiology?
The next frontier may combine imaging, diagnostics and wearable data to support more personalised healthcare decisions. Explore the future of AI-enabled SaMD in our latest whitepaper. www.iconplc.com/insights/digital-disruption/software-medi…
#healthcareinnovation #samd -
ICON Plc
@ICONplc
Our team will be hosting an interactive workshop at ACoP on October 11, exploring the latest methods available in NONMEM 7. Join us for a hands-on session designed to deepen your understanding, and provide practical insights you can apply immediately. acop2026.eventscribe.net
-
ICON Plc
@ICONplc
EngageAI, ICON’s AI-powered Voice of Customer solution, has won a Bronze Stevie® Award for AI in Customer Experience. By turning customer feedback into actionable insights, EngageAI helps drive continuous improvement for sponsors and sites.
www.iconplc.com/solutions/technologies/ai-icon/engageai -
ICON Plc
@ICONplc
Join ICON's presentation at WorldCDx on 8 October to explore the common pitfalls that can derail precision medicine initiatives and learn practical approaches for building robust, globally deployable biomarker and companion diagnostic (CDx) strategies. world-cdx.com
-
ICON Plc
@ICONplc
73.56% reduction in Scope 1 and 2 emissions vs 2019 base year.
6.74% reduction in Scope 3 emissions vs 2022 base year.
94% of preferred suppliers with sustainability engagement plans.
Read more in the ICON Cares 2025 Report. [www2.iconplc.com/2025_ESG_Report]
#iconcares #sustainability -
ICON Plc
@ICONplc
Biomarkers, ctDNA and liquid biopsy are reshaping patient selection and oncology trial design. Meet ICON experts at #esmo26, booth #8005, to discuss the clinical and operational implications for your program. Arrange a meeting: www.iconplc.com/news-events/events/industry/esmo-2026
-
ICON Plc
@ICONplc
Struggling to keep up with global regulatory change? ICON's Newsletter delivers the latest summaries of key updates from authorities including the FDA, EMA, MHRA and more. Subscribe for free today: www.iconplc.com/insights/regulatory-intelligence/regulato…
#regulatoryintelligence #regulatoryaffairs -
ICON Plc
@ICONplc
Modern monitoring models don't reduce oversight. They redistribute it across teams, locations and timelines. Helen Yeardley examines what this means for capacity planning in BioPharm International. www.biopharminternational.com/view/risk-based-monitoring-…
#rbqm -
ICON Plc
@ICONplc
Visit ICON at booth 8F70 at #cphimilan to learn how our integrated Manufacturing & Pharmacy Services can help you to accelerate development timelines, reduce outsourcing complexity, minimise API waste and move from formulation to the clinic faster. www.cphi.com/europe/
-
ICON Plc
@ICONplc
Meet ICON at ACoP 2026 in Maryland. Visit Booth #19 to connect with our experts, see live demonstrations, and discuss clinical pharmacology and model-informed drug development. Learn how ICON can support your development programs. acop2026.eventscribe.net
-
ICON Plc
@ICONplc
As immunotherapies transition into more risk-averse populations, careful management of safety and toxicity is critical. Explore key considerations for adverse effects, population differences, Optimal Biological Dosing (OBD), and safety monitoring. www.iconplc.com/insights/therapeutics/internal-medicine-i…
-
ICON Plc
@ICONplc
As software becomes integral to patient care, medtech companies face new clinical and regulatory challenges. ICON helps sponsors accelerate SaMD and digital health development with tailored strategies. Visit booth #635 at #mtc26. themedtechconference.com
-
ICON Plc
@ICONplc
Single-stop research publication decisioning. PubsHub Journals & Congresses provides everything you need to decide the best place to publish your work. 50+ metadata consideration points including deadlines and lead times on over 10,000 resources. www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
Meet Brittany Savoca at the #gsss, during the TA Round Table: Neurology & Alzheimer’s on October 16 at 4:45 pm. sitesolutionssummit.com/event/global/
-
ICON Plc
@ICONplc
Use an existing #coa instrument or develop a new one? What evidence supports the choice? Join ICONs Nov. 5 webinar to learn how to make fit-for-purpose instrument decisions that support your regulatory pathway. www.iconplc.com/news-events/events/webinars/getting-coa-s…
-
ICON Plc
@ICONplc
Discover how ICON exceeded enrolment goals in two pivotal HCM trials through targeted site selection and operational precision, while safeguarding key endpoints in a complex recruitment environment.
www.iconplc.com/solutions/all-case-studies/site-strategy-…
#worldheartday -
ICON Plc
@ICONplc
Risk-based monitoring doesn't mean less monitoring. It means focusing oversight where it matters most. Helen Yeardley explores the implications for quality, efficiency and capacity planning in BioPharm International. www.biopharminternational.com/view/risk-based-monitoring-…
#clinicalresearch -
ICON Plc
@ICONplc
Improved research accuracy and integrity. Knowledge Manager centralized content management avoids content duplication and ensures article accuracy and data integrity. See how it could help your work. Get more information and a demo: www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
Early clinical trials in neurodegenerative diseases require smart strategy. Join our webinar on Oct 14 to explore study design, patient engagement & biomarker selection. xtalks.com/webinars/strategic-approaches-for-early-clinic…
-
ICON Plc
@ICONplc
ICON continues to invest in development, engagement and opportunity across our global workforce. [www.iconplc.com/about/environmental-social-and-governance…]
#iconcares #talentdevelopment #inclusion #sdg5 #sdg8 #sdg10 #sdg17 -
ICON Plc
@ICONplc
Oncologic immunotherapies are expanding into non-oncologic indications, but lower risk tolerances mean the transition may not be smooth. Read the whitepaper to learn how development strategies must adapt to bring immunotherapies to new patient populations. www.iconplc.com/insights/therapeutics/internal-medicine-i…
-
ICON Plc
@ICONplc
Risk-based monitoring isn't reducing oversight. It's making it smarter. In BioPharm International, Helen Yeardley explores why effective capacity planning is about directing effort where it has the greatest impact on quality and risk management. www.biopharminternational.com/view/risk-based-monitoring-…
#rbqm -
ICON Plc
@ICONplc
Connect with ICON experts at #worldorphaneu, booth 313 to discuss practical approaches to development strategy, regulatory planning, patient advocacy, feasibility and patient-centred rare disease trial delivery.
Arrange a meeting: www.iconplc.com/contact -
ICON Plc
@ICONplc
Navigating MDR, IVDR and digital health requirements? ICON's MDDR team helps sponsors generate the evidence needed to advance with confidence. Meet us at The MedTech Conference, Boston, booth #635, 18-21 Oct. themedtechconference.com #mtc26
-
ICON Plc
@ICONplc
From sustainable packaging requirements to new labelling expectations, #ppwr will have wide reaching implications for pharma and medtech companies. Explore insights from ICON's SMEs: www.pharmamanufacturingiq.com/the-ppwr-mandate-essential-… #packaging #euregulations #lifesciences
-
ICON Plc
@ICONplc
We are proud to be included in TIME’s World’s Most Sustainable Companies 2026. This ranking evaluates environmental, social and governance performance across global organisations.
See our awards: www.iconplc.com/news-events/awards
#sustainability #esgmetrics #iconcares #unsdg -
ICON Plc
@ICONplc
Discover Accellacare’s clinical trial operations at the #gsss 2026. Meet us at the Signia by Hilton Orlando Bonnet Creek, booth #406. sitesolutionssummit.com/event/global/
-
ICON Plc
@ICONplc
Multiple authors or key contributors? No problem. PubsHub PMSolution makes it easy for your team to collaborate more efficiently. See for yourself and request a demo. www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
Early clinical trials in neurodegenerative diseases require smart strategy. Join our webinar on Oct 14 to explore study design, patient engagement & biomarker selection. xtalks.com/webinars/strategic-approaches-for-early-clinic…
-
ICON Plc
@ICONplc
EHDS is transforming health data governance and raising the bar for transparency, traceability and methodological rigour. Read the article: www.appliedclinicaltrialsonline.com/view/real-world-evide…
#rwe #healthdata #lifesciences -
ICON Plc
@ICONplc
AI is only as powerful as the methods behind it. ICON explores the principles needed to transform complex real-world data into credible evidence for oncology research. magazine.pharmatimes.com/collections/pharmatimes-septembe…
#ai #rwe #oncologyresearch #clinicaltrials #healthcareinnovation -
ICON Plc
@ICONplc
Pediatric oncology sites are committed to research. Early collaboration between sponsors, sites and CROs can help create studies that are operationally feasible and designed around children's needs.
Read the blog on the ACRO Informed Content Hub: www.acrohealth.org/informed-content-hub/three-partners-on… -
ICON Plc
@ICONplc
Packaging minimisation is more than a cosmetic redesign. In the final article in MedTech Insight’s PPWR series, ICON contributors discuss early planning and lower-risk opportunities for optimisation. insights.citeline.com/medtech-insight/policy-and-regulati…
#ppwr #packagingcompliance #regulatoryaffairs -
ICON Plc
@ICONplc
Translation and linguistic validation can affect when and where a #coa is implemented.
Join our webinar to learn how to plan for these requirements before they create operational challenges or study delays: www.iconplc.com/news-events/events/webinars/getting-coa-s…
#clinicaltrials -
ICON Plc
@ICONplc
Neurologic mAbs are delivering clinical benefit across MS, NMOSD and early Alzheimer’s disease. As efficacy converges, operational execution and safety governance are emerging as key differentiators.
Read more. www.rdworldonline.com/operational-discipline-is-a-critica…
#alzheimersawarenessmonth -
ICON Plc
@ICONplc
You can find your best-fit publishing source in as little as five minutes. PubsHub Journals & Congresses is the fastest and easiest tool to find the ideal publication resource for your research. Schedule a demo and try it for yourself. www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
World Patient Safety Congress Europe starts next week. Meet ICON at booth #422 in Amsterdam to discuss connected, efficient and inspection-ready pharmacovigilance solutions. www.terrapinn.com/conference/world-patient-safety-congres…
-
ICON Plc
@ICONplc
ICON is proud to be Platinum Sponsor of #toprasym26. Join us at the Royal Jaarbeurs, Utrecht, from 19 to 21 October 2026 and meet our Regulatory Affairs team at booth #37.
Learn more: www.topra.org/AsiCommon/Controls/Shared/FormsAuthenticati… -
ICON Plc
@ICONplc
Join ICON at the 15th World CB & CDx Summit, 5 – 8 October in Boston. Meet our experts at booth #4 to learn how ICON’s biomarker expertise drives smarter trials, accelerates CDx strategies & delivers patient impact. world-cdx.com
-
ICON Plc
@ICONplc
Governance is central to responsible business. Our ESG strategy is supported through Board oversight, executive leadership and a cross-functional ESG Committee.
[www.iconplc.com/about/environmental-social-and-governance…]
#iconcares #corporategovernance #esg #responsiblebusiness #sdg17 -
ICON Plc
@ICONplc
Not all #masld biomarker signals are equal. Reducing liver fat is not the same as fibrosis stage, which is a stronger predictor of adverse outcomes including MASH and hepatocellular carcinoma. The most useful risk models need to distinguish these endpoints.www.pharmavoice.com/spons/advances-in-risk-assessment-shi…
-
ICON Plc
@ICONplc
Advancing pediatric oncology takes a community. Sponsors, sites and CROs each play a critical role in designing and delivering trials that work for children, families and care teams.
Explore the blog on the ACRO Informed Content Hub: www.acrohealth.org/informed-content-hub/three-partners-on…
#pediatriconcology -
ICON Plc
@ICONplc
C5 inhibitors. Natalizumab. Anti-CD20 therapies. Anti-amyloid treatments. Four therapies, four distinct safety requirements. Learn why neurologic mAb safety frameworks must be tailored to mechanism, not replicated across indications. www.rdworldonline.com/operational-discipline-is-a-critica…
-
ICON Plc
@ICONplc
Does the publication deadline match your timing? Sort over 10,000 journals and congresses by submission date and lead times using PubsHub Journals & Congresses. Find your optimum choices quickly so you can focus on your work. It’s easy - see for yourself. www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
Struggling to keep up with global regulatory change? ICON's Newsletter delivers expert summaries of key updates from authorities including the FDA, EMA, MHRA and more. Subscribe for free today: www.iconplc.com/insights/regulatory-intelligence/regulato…
-
ICON Plc
@ICONplc
Since 2021 APAC has led global clinical trial activity shaping the future of drug development. Our whitepaper outlines how to navigate global regulatory pathways with confidence.
Get your copy www.iconplc.com/sectors/biotech/plotting-course-bring-apa…
#clinicalresearch #pharma #regulatory #lifesciences -
ICON Plc
@ICONplc
Cardiometabolic trials often need thousands of patients to capture rare events. Composite biomarkers could finally shrink those numbers, if they’re validated well. Explore what’s changing in the article. www.appliedclinicaltrialsonline.com/view/navigating-adopt…
-
ICON Plc
@ICONplc
The fourth and final article in MedTech Insight’s PPWR series examines how medtech companies can minimise packaging without compromising protection or compliance. Read commentary from ICON contributors. insights.citeline.com/medtech-insight/policy-and-regulati…
#ppwr #medtech #medicaldevices -
ICON Plc
@ICONplc
MASLD affects roughly 1 in 4 adults globally, yet the first disease-specific therapy wasn't approved until 2024. Decades of program failures were driven in part by an inability to identify the right patients early enough to intervene. Read the article: www.pharmavoice.com/spons/advances-in-risk-assessment-shi…
-
ICON Plc
@ICONplc
Real-world data offers valuable insight into how patients are treated outside clinical trials. ICON discusses how AI can help unlock that value in NSCLC while maintaining scientific rigor. magazine.pharmatimes.com/collections/pharmatimes-septembe…
#realworldevidence #aiinhealthcare #oncology #rwd #lifesciences -
ICON Plc
@ICONplc
Immunology innovation is accelerating but so is regulatory complexity. Our latest whitepaper explores global regulatory trends and strategies for success.
Read more: www.iconplc.com/insights/regulatory-intelligence/global-r…
#immunology #regulatoryaffairs #biotechThis media couldn't be displayed. See it on the original post. -
ICON Plc
@ICONplc
Speed matters in obesity development. So does keeping participants engaged.
Learn practical strategies for accelerating study delivery while protecting retention, data quality and patient experience.
Register now: www.eventsonlineregister.com/events/obesity-studies-the-e…
#obesitytrials -
ICON Plc
@ICONplc
Treating #coa strategy as a later detail can lead to many downstream trial complications. Learn which decisions can’t wait, & how to build a defensible strategy before protocol finalisation. Register for the Webinar: www.iconplc.com/news-events/events/webinars/getting-coa-s…
-
ICON Plc
@ICONplc
AI can support medical writing, but it should augment experts, not replace them. Read our blog to learn more: www.iconplc.com/insights/blog/2026/09/03/why-augmentation…
-
ICON Plc
@ICONplc
97.05% renewable electricity.
24% reduction in electricity use against our 2018 baseline.
Progress against ICON’s environmental commitments continues.
[www2.iconplc.com/2025_ESG_Report]
#iconcares #climateaction #sustainability #esg #sdg13 -
ICON Plc
@ICONplc
Generate insights into your scientific communications. PubsHub Knowledge Manager lets you track and analyze your product’s strategic communications plan. That drives better overall decision-making and more efficient workflows. www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
Early clinical trials in neurodegenerative diseases require smart strategy. Join our webinar on Oct 14 to explore study design, patient engagement & biomarker selection. xtalks.com/webinars/strategic-approaches-for-early-clinic…
-
ICON Plc
@ICONplc
Cross-border data access could unlock more robust real-world evidence across Europe. Discover what EHDS means for sponsors and CROs. www.appliedclinicaltrialsonline.com/view/real-world-evide…
#ehds #realworldevidence #clinicalresearch -
ICON Plc
@ICONplc
How will Annex 2 influence the use of real-world data? ICON's Wendy DeSpain explains that RWD is now presented as a valid clinical trial data source when sponsors demonstrate it is fit for purpose, providing greater clarity for global studies. www.clinicaltrialsarena.com/features/ich-gcp-annex-2-will…
-
ICON Plc
@ICONplc
Biomarker-based enrolment can sharpen trial power, or unintentionally exclude patient groups and limit generalisability. If you're designing around biomarkers, the article outlines the practices that can help avoid these risks. www.appliedclinicaltrialsonline.com/view/navigating-adopt…
-
ICON Plc
@ICONplc
The EU AI Act, evolving FDA expectations and emerging global frameworks are reshaping AI-enabled medical device development. Our new whitepaper provides practical guidance for navigating the changing landscape. www.iconplc.com/insights/digital-disruption/software-medi…
#medicaldevices #ai #regulatoryaffairs -
ICON Plc
@ICONplc
Can machine learning identify #masld patients before symptoms appear? ML-driven risk models synthesising imaging, lab values, and clinical variables are making early-intervention trial enrollment feasible at scale for the first time. Read the article. www.pharmavoice.com/spons/advances-in-risk-assessment-shi…
-
ICON Plc
@ICONplc
Visit ICON at booth 8F70 at #cphimilan to learn how our integrated Manufacturing & Pharmacy Services can help you to accelerate development timelines, reduce outsourcing complexity, minimise API waste and move from formulation to the clinic faster. www.cphi.com/europe/
-
ICON Plc
@ICONplc
The EU's #ppwr is reshaping packaging requirements for pharma and medtech. ICON experts Claudia Anzaldo and Véronique Boscher explore key compliance challenges and practical strategies for success. Read more: www.pharmamanufacturingiq.com/the-ppwr-mandate-essential-… #regulatoryaffairs #pharma #medtech #sdg12
-
ICON Plc
@ICONplc
Visit ICON Biotech at Booth #26 during #octsc26 on 15-16 September at Aventine, San Diego. Our team will be onsite to discuss clinical development support and share insights on efficient trial planning and execution. More info: www.arena-international.com/event/octsocal/
-
ICON Plc
@ICONplc
Biomarker‑informed enrolment is moving well beyond oncology, but regulatory uncertainty remains Explore where biomarker-based approaches are succeeding, where developers are stumbling, and how to navigate the path forward. Read the article. www.appliedclinicaltrialsonline.com/view/navigating-adopt…
-
ICON Plc
@ICONplc
Shift the publishing odds to your favour. Journals & Congresses offers comparable rejection rate insights. Review rejection rates by journal to better target the right fit for your submission. Check out our interactive dashboard and see for yourself. www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
The future of study delivery is connected. By aligning with existing site workflows and enabling better operational intelligence, our connected site model, in partnership with Advarra, helps improves collaboration and supports more efficient trial delivery.magazine.pharmatimes.com/collections/pharmatimes-septembe…
-
ICON Plc
@ICONplc
Moving beyond GLP-1s, novel, non-incretin mechanisms are emerging to treat obesity and co-morbidities. Controlled metabolic accelerators and RNA-based gene silencing therapies may achieve greater fat selectivity and therapeutic durability. Learn more. www.drugdiscoverytrends.com/shifting-glp-1-research-and-d…
-
ICON Plc
@ICONplc
Early-intervention #masld trials have historically been impractical, in part because liver biopsy, the standard for fibrosis staging, is invasive, variable, and unscalable for screening. Noninvasive, multi-parameter risk prediction is changing that. www.pharmavoice.com/spons/advances-in-risk-assessment-shi…
-
ICON Plc
@ICONplc
As therapies become more differentiated, retention is becoming a strategic measure of success.
Join our webinar: www.eventsonlineregister.com/events/obesity-studies-the-e…
#obesityresearch #glp1 #clinicaltrials -
ICON Plc
@ICONplc
Late #coa decisions can create evidence gaps, protocol changes & regulatory questions. Join our webinar Nov 5 to learn how early planning around endpoints, instruments & implementation can reduce downstream risk.
Register: www.iconplc.com/news-events/events/webinars/getting-coa-s…
#clinicaltrials -
ICON Plc
@ICONplc
How can AI help turn real-world oncology data into regulator-ready evidence? ICON explores the frameworks needed to generate credible, reproducible insights in NSCLC. magazine.pharmatimes.com/collections/pharmatimes-septembe…
#rwe #ai #oncology #clinicalresearch #lifesciences -
ICON Plc
@ICONplc
Need to accelerate recruitment for a challenging lactation study? In one recent study, ICON enrolled six participants within one week after recruitment had stalled elsewhere for more than a year. Find out more: www.iconplc.com/solutions/all-case-studies/complex-oral-s…
-
ICON Plc
@ICONplc
As regulators look to robust analytical and functional evidence, PK, PD and immunogenicity data are playing an increasingly important role in biosimilar development. Learn more in our latest blog: www.iconplc.com/insights/blog/2026/07/17/evolving-bioanal…
#biosimilars #clinicalresearch #biopharma -
ICON Plc
@ICONplc
Scientific publication collaboration made easier. PMSolution is an integrated start-to-finish process designed specifically for medical communications teams. Task reminders and version control. Review and approval tracking. Customisable on-demand reports. www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
Patient safety expectations are rising. Meet ICON at booth #422 during World Patient Safety Congress Europe to discuss practical ways to strengthen pharmacovigilance quality, compliance and efficiency. www.terrapinn.com/conference/world-patient-safety-congres…
-
ICON Plc
@ICONplc
Innovation and insight come together at #scdm26! Visit ICON at booth 308, 14-17 Sept, Raleigh Convention Center, and hear from our experts Stephen Cameron, Usha Dewasthali and Ninad Mantri. scdmlive.org/annual-conference-2026/
-
ICON Plc
@ICONplc
With dual systems operating until February 2027, early preparation will be critical for companies supplying medicines to Italy. Our latest blog breaks down the new serialisation framework and what organisations should do now. www.iconplc.com/insights/blog/2026/07/14/italys-new-seria…
#eufmd #labelling -
ICON Plc
@ICONplc
Protocol complexity can drive costly amendments, delays and execution challenges. Join Dr Mark Sorrentino at #octsocal to learn how ICON and Advarra are helping sponsors build more executable protocols from day one. www.arena-international.com/event/octsocal/
-
ICON Plc
@ICONplc
Supported customers involving:
411,400+ patients.
1,370+ supported studies.
25 product approvals.
Helping accelerate the development of therapies for patients worldwide.
www.iconplc.com/about/environmental-social-and-governance…
#iconcares #clinicalresearch #patientcentricity #sdg3 -
ICON Plc
@ICONplc
Read the article to learn why operational readiness can be just as critical as clinical evidence in determining patient access. www.rdworldonline.com/operational-discipline-is-a-critica…
-
ICON Plc
@ICONplc
ICON Biotech is heading to #octsc26 on 15-16 September at the Hyatt Regency La Jolla at Aventine, San Diego. Come meet us at Booth 26. www.arena-international.com/event/octsocal/
-
ICON Plc
@ICONplc
To maximise efficacy, researchers are combining GLP-1 with hormones like GIP and glucagon to synergistically suppress appetite and increase energy expenditure. See how multi-pathway drugs are changing the landscape for obesity therapeutics. www.drugdiscoverytrends.com/shifting-glp-1-research-and-d…
-
ICON Plc
@ICONplc
Protect your work by using Journals & Congresses. PubsHub J&C applies rigorous screening to safeguard authors from predatory journals. Learn more about all of the Journals and Congresses advantages and schedule a demo: www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
Successful lactation studies require careful consideration of both science and participant experience. ICON's mother- and infant-centric approach combines flexible scheduling, home visit options, specialised support, and dedicated lactation study expertise.www.iconplc.com/solutions/early-clinical/clinical-pharmac…
-
ICON Plc
@ICONplc
As AI-enabled medical devices become more sophisticated, regulatory expectations are evolving alongside them. Explore the latest trends in ICON's Journal of mHealth article. url.uk.m.mimecastprotect.com/s/txTHCD9NvSwzMlRDTWfGxhjFlF…
-
ICON Plc
@ICONplc
Obesity trials face a difficult balancing act: meeting unprecedented demand for participation while overcoming persistent retention challenges that can jeopardise study success. www.eventsonlineregister.com/events/obesity-studies-the-e…
-
ICON Plc
@ICONplc
From interoperability to regulatory compliance, EHDS is changing how real-world evidence studies are designed and delivered. Learn more: www.appliedclinicaltrialsonline.com/view/real-world-evide…
#europeanhealthdataspace #evidencegeneration #healthcareinnovation -
ICON Plc
@ICONplc
PubsHub Knowledge Manager is an enterprise-wide document repository solution. Knowledge Manager is ideal for teams needing fast, efficient and secure access to scientific content. Empower your team to work better. Learn more and schedule a demo: www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
Regulatory readiness is becoming a competitive advantage in AI-enabled healthcare. Learn how early FDA engagement, strong evidence generation and transparent AI documentation can support successful market entry. Read the whitepaper: www.iconplc.com/insights/digital-disruption/software-medi…
#samd #ai #medtech -
ICON Plc
@ICONplc
New mechanism of action PIP requirements are coming from the EMA. Keep your pediatric strategy ahead of the curve: www.iconplc.com/insights/blog/2026/01/07/mechanism-action…
-
ICON Plc
@ICONplc
EcoVadis Platinum medal status. 87/100. Top 1% of organisations assessed by EcoVadis.
A milestone recognising our commitment to sustainability, ethics and responsible business practices. Read the report: www2.iconplc.com/2025_ESG_Report
#iconcares #ecovadis #esg #sustainability -
ICON Plc
@ICONplc
ICH GCP E6(R3) Annex 2 reinforces confidence in decentralised and hybrid trial models. Wendy DeSpain highlights the value of globally harmonised guidance for approaches such as remote consent, wearable technologies and direct-to-patient supply models. www.clinicaltrialsarena.com/features/ich-gcp-annex-2-will…
-
ICON Plc
@ICONplc
What comes next for pivotal trial design in cell and gene therapies?
As new and next generation therapies emerge, sponsors face increasingly complex questions around comparator selection, study feasibility and evidence generation strategy. Find out more: ww2.amstat.org/meetings/risw/2026/ -
ICON Plc
@ICONplc
Packaging changes in medtech can trigger extensive validation and documentation updates. ICON's Claudia Anzaldo and Véronique Boscher discuss how organisations can prepare for PPWR implementation. insights.citeline.com/medtech-insight/policy-and-regulati… #medtech #regulatorystrategy #medicaldevices #euregulations
-
ICON Plc
@ICONplc
Struggling to keep up with global regulatory change? ICON's Newsletter delivers expert summaries of key updates from authorities including the FDA, EMA, MHRA and more. Subscribe for free today: www.iconplc.com/insights/regulatory-intelligence/regulato…
-
ICON Plc
@ICONplc
Over 50% of FDA authorisations for AI-enabled SaMDs have occurred since 2022. ICON explores the regulatory trends shaping the next generation of AI-enabled healthcare. url.uk.m.mimecastprotect.com/s/txTHCD9NvSwzMlRDTWfGxhjFlF…
-
ICON Plc
@ICONplc
Using ctDNA as a surrogate endpoint may open an accelerated pathway, but a confirmatory trial obligation follows approval. For biotechs, the cost and feasibility of this strategy may be prohibitive. Learn more about ctDNA endpoint strategy in our article. pharmaphorum.com/oncology/establishing-ctdna-validated-pr…
-
ICON Plc
@ICONplc
For neurologic mAbs, approval and access aren't the same thing. For example, Medicare coverage for anti-amyloid Alzheimer's therapies depends on registry enrollment before the first dose. www.rdworldonline.com/operational-discipline-is-a-critica…
-
ICON Plc
@ICONplc
What could acceptance of biomarker-based surrogates mean for biotechs pursuing tumor-agnostic therapies? Find out more in our article exploring how liquid biopsy based biomarkers are being leveraged in tumor agnostic trial designs. pharmaphorum.com/oncology/liquid-biopsy-and-future-tumour…
-
ICON Plc
@ICONplc
Rebound weight gain is a major hurdle for first-gen GLP-1s, with patients typically regaining lost weight within 1.7 years post-cessation. Read the article to learn how obesity drug development is shifting to overcome this and other key limitations. www.drugdiscoverytrends.com/shifting-glp-1-research-and-d…
-
ICON Plc
@ICONplc
Research publishing made easier. PubsHub PMSolution automates project management support. The system offers a streamlined interface and review process with robust reporting capabilities to keep your work and contributors on task and on track.www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
As AI-enabled medical devices advance from detection to diagnosis and treatment guidance, regulatory expectations are evolving. Read ICON's latest BioSpace article on navigating today's AI-enabled SaMD landscape. www.biospace.com/how-ai-enabled-software-as-medical-devic…
-
ICON Plc
@ICONplc
Regulators may accept surrogate endpoints, payers often want more. In Drug & Device World, ICON explore how payer–regulator misalignment can limit the value of accelerated approval and how smarter indication strategy can help. druganddeviceworld.com/2026/07/14/navigating-the-risks-an…
-
ICON Plc
@ICONplc
Global authorisation is rarely straightforward. In PharmaTimes, ICON discusses the regulatory realities facing APAC biopharma companies seeking approval through FDA and EMA pathways. Read the article: magazine.pharmatimes.com/collections/pharmatimes-july-202…
#biopharma #clinicaldevelopment #drugdevelopment #apac -
ICON Plc
@ICONplc
Article three of MedTech Insight's #ppwr series explores the practical impact of new packaging symbols and sorting information requirements. ICON contributors explain why early planning and artwork assessments are key. Read the article: insights.citeline.com/medtech-insight/policy-and-regulati…
#euregulations -
ICON Plc
@ICONplc
Know up-front how AI use will impact your research acceptance. PubsHub Journals & Congresses incorporates AI policy guidelines in publication criteria to help select the right resource for publishing your research. See for yourself with a demo: www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
AI-enabled medical devices are evolving from detection tools to systems that can help inform diagnosis and treatment decisions. What does that mean for regulators and developers? Read ICON's latest Journal of mHealth article. url.uk.m.mimecastprotect.com/s/txTHCD9NvSwzMlRDTWfGxhjFlF…
-
ICON Plc
@ICONplc
The ICON Cares 2025 Report is now live. Sharing progress across clinical research people, communities and ESG priorities. Read more: www.iconplc.com/about/environmental-social-and-governance #iconcares #esg #clinicalresearch #sustainability #sdg3
-
ICON Plc
@ICONplc
During #niam, we're recognising the impact of vaccines and the research behind them. With 30+ years of experience, ICON has supported vaccine development for biotech, pharma, government, and NGO clients across a wide range of infectious diseases. www.iconplc.com/therapeutics/vaccines
-
ICON Plc
@ICONplc
Biosimilar development is evolving. Regulatory agencies are placing greater emphasis on analytical comparability, CMC evidence and bioanalytical performance to support biosimilarity assessments. Read more: www.iconplc.com/insights/blog/2026/07/17/evolving-bioanal…
#biosimilars #bioanalysis #drugdevelopment -
ICON Plc
@ICONplc
ICON is sponsoring #scdm26! Join us 14-17 Sept at the Raleigh Convention Center. Stop by booth 308 to meet our team and explore how ICON is shaping the future of clinical trials. Don’t miss the conversations that matter most. See you in Raleigh! scdmlive.org/annual-conference-2026/
-
ICON Plc
@ICONplc
Validating ctDNA as a primary surrogate endpoint will require collaboration across sponsors, regulators, diagnostic developers, and researchers. Developers should focus on building the broader evidence base, not just advancing their own pipelines.
pharmaphorum.com/oncology/establishing-ctdna-validated-pr… -
ICON Plc
@ICONplc
ICH GCP E6(R3) Annex 2 is an important milestone for global clinical research.
Wendy DeSpain explains that harmonised expectations for DCTs and RWD can reduce uncertainty and strengthen sponsor confidence when running global studies. Read the article www.clinicaltrialsarena.com/features/ich-gcp-annex-2-will… -
ICON Plc
@ICONplc
AI-enabled medical devices are reshaping healthcare and regulatory pathways alike. ICON explores FDA trends, global regulations, clinical considerations, and what's next for AI-enabled SaMDs in this new BioSpace article. Read more:www.biospace.com/how-ai-enabled-software-as-medical-devic…
-
ICON Plc
@ICONplc
EHDS is creating a new framework for secure, standardised health data access across Europe. Read how CROs can prepare for the transition. www.appliedclinicaltrialsonline.com/view/real-world-evide…
#rwe #healthdata #lifesciences -
ICON Plc
@ICONplc
The third article in #medtech Insight's #ppwr series examines a major challenge for medtech manufacturers: fitting new PPWR labelling requirements onto packaging already crowded with #mdr and IVDR information.
Read commentary from ICON experts: insights.citeline.com/medtech-insight/policy-and-regulati… -
ICON Plc
@ICONplc
The gap between scientific progress and operational readiness is a costly, but not inevitable, challenge in neurologic mAb development. Learn how treating safety frameworks and operations as development decisions from phase 2 onwards can help close it. www.rdworldonline.com/operational-discipline-is-a-critica…
-
ICON Plc
@ICONplc
There is no blanket exemption for medtech under the EU's new packaging rules. ICON experts Claudia Anzaldo and Véronique Boscher outline the key considerations for manufacturers. insights.citeline.com/medtech-insight/policy-and-regulati…
#medicaldevices #packaging #sustainability #ppwr -
ICON Plc
@ICONplc
Successful immunology programs depend on early and proactive regulatory planning.
Explore key insights in our latest whitepaper: www.iconplc.com/insights/regulatory-intelligence/global-r…
#clinicalresearch #regulatorystrategy #lifesciences -
ICON Plc
@ICONplc
The GLP-1 landscape is changing, and R&D is shifting from basic weight loss to precision medicine and comorbidity resolution. Learn about the next phase of obesity drug development, including addressing first-gen shortcomings like rebound weight gain. www.drugdiscoverytrends.com/shifting-glp-1-research-and-d…
-
ICON Plc
@ICONplc
AI-enabled SaMD is moving beyond detection and triage towards diagnosis and treatment planning. Is your regulatory strategy keeping pace? Our latest whitepaper explores FDA, EU, UK and APAC requirements for next-generation AI-enabled medical devices.
www.iconplc.com/insights/digital-disruption/software-medi… -
ICON Plc
@ICONplc
Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest clinical trial regulatory updates current. www.iconplc.com/insights/regulatory-intelligence/regulato…
#regulatoryintelligence #regulatorycompliance #regintel #medicaldevices #biotech #fda #ema -
ICON Plc
@ICONplc
How will the European Health Data Space reshape real-world evidence generation? ICON explores the opportunities, challenges and implications for CROs. www.appliedclinicaltrialsonline.com/view/real-world-evide…
#ehds #realworldevidence #clinicalresearch -
ICON Plc
@ICONplc
Article 2 in MedTech Insight's PPWR series explores a key question for medical device companies: are you a packaging manufacturer, a producer or both? ICON experts explain why the distinction matters. insights.citeline.com/medtech-insight/policy-and-regulati…
#ppwr #medtech #regulatoryaffairs #medicaldevices -
ICON Plc
@ICONplc
It’s National Immunisation Awareness Month (#niam). ICON is proud to have participated in 147 vaccine studies across key indications over the past five years. Learn more about our vaccine research experience: www.iconplc.com/therapeutics/vaccines
-
ICON Plc
@ICONplc
In April 2026, an FDA panel rejected a phase III study of ctDNA-guided therapy switching in late-stage breast cancer despite a fourfold quality-of-life improvement. The decision highlights the challenges of securing acceptance for ctDNA endpoints.
pharmaphorum.com/oncology/establishing-ctdna-validated-pr… -
ICON Plc
@ICONplc
The rapid emergence of immunotherapies in autoimmune disease is creating new opportunities and new statistical challenges. At ICON, we're proud to contribute to conversations that help shape the future of drug development. Learn more: ww2.amstat.org/meetings/risw/2026/
-
ICON Plc
@ICONplc
Clinical efficacy is no longer the differentiator for neurologic mAbs. Operational infrastructure is. ICON’s Bill Holt explains why operational safety governance plays a critical role in bringing treatments to patients. Read more.
www.rdworldonline.com/operational-discipline-is-a-critica… -
ICON Plc
@ICONplc
Could Europe be the smartest route to global market access for Chinese biopharma sponsors?
Learn why early EMA planning and Europe-ready study design can help reduce delays and support successful approvals.
www.biospectrumasia.com/opinion/48/28100/why-europe-not-a… -
ICON Plc
@ICONplc
The EU's PPWR is reshaping medical device packaging requirements. ICON explains why manufacturers need to prepare now and balance sustainability goals with patient safety and compliance. Read more: insights.citeline.com/medtech-insight/policy-and-regulati…
#medtech #ppwr #regulatoryaffairs #medicaldevices -
ICON Plc
@ICONplc
From packaging redesign to data governance, Italy's new serialisation requirements will have far-reaching implications across the pharmaceutical supply chain. Explore the key changes and timeline in our latest blog. www.iconplc.com/insights/blog/2026/07/14/italys-new-seria…
#serialisation #regulatoryaffairs -
ICON Plc
@ICONplc
As clinical requirements evolve, analytical comparability and manufacturing excellence are taking centre stage in biosimilar approvals. Discover what today’s developers need to know. www.bioprocessintl.com/biosimilars/biosimilar-success-in-…
#biosimilar #regulatoryscience #drugdevelopment #lifesciences -
ICON Plc
@ICONplc
COPD is no longer a one-size-fits-all disease. Advances in disease biology are reshaping how therapies are developed, evaluated and positioned. Discover the opportunities for sponsors in the precision medicine era. www.iconplc.com/insights/blog/2026/07/13/new-era-drug-dev…
#copd #clinicaltrials -
ICON Plc
@ICONplc
Drawing on insights from BIO International Convention and DIA China, Deepali Suri discusses the trends shaping biotech's next growth cycle in a new BioPharma Dive article. Read more about investor readiness, AI and global development opportunities: www.biopharmadive.com/spons/from-confidence-to-capital-po…
-
ICON Plc
@ICONplc
Sustainability in action. ICON is recognised again in TIME’s World’s Most Sustainable Companies 2026, reflecting our focus on sustainability transparency, accountability and impact.
See our awards www.iconplc.com/news-events/awards
#iconcares #sustainablebusiness #esg #unsdg -
ICON Plc
@ICONplc
Developers of modern neurologic mAb therapies must deploy scalable and fully compliant operational protocols from the first day of launch. Bill Holt shares insights on the strict dual mandate required for success of CNS monoclonal antibody therapies. www.biopharminternational.com/view/clinical-success-cns-mabs
-
ICON Plc
@ICONplc
During #niam, we're highlighting the complexities of vaccine guidance for rare autoimmune diseases. Learn how treatment modality, disease mechanism, and the affected system can influence vaccine decisions in this article. www.infectioncontroltoday.com/view/uncertainty-strategy-g…
-
ICON Plc
@ICONplc
Access to precision medicine remains uneven, with fewer therapies approved for early-stage than metastatic disease. ctDNA-based endpoints could help change that, but gaining regulatory acceptance is more challenging than many developers expect. Read more. pharmaphorum.com/oncology/establishing-ctdna-validated-pr…
-
ICON Plc
@ICONplc
APAC biotech's growth story is creating a new challenge: talent. ICON's survey of APAC biotech leaders were nearly 3x more likely than their global peers to report talent shortages. Reuters recently explored the issue, with insights from Yao Zhong. www.reuters.com/business/healthcare-pharmaceuticals/chine…
-
ICON Plc
@ICONplc
Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest clinical trial regulatory updates current. www.iconplc.com/insights/regulatory-intelligence/regulato…
#regulatoryintelligence #regulatorycompliance #regintel #medicaldevices #biotech #fda #ema -
ICON Plc
@ICONplc
Accelerated approval is not a free pass. ICON’s Dr Elizabeth Madichie and Dr. Jack Martin outline why confirmatory trial design, payer expectations and surrogate validity must be addressed early to avoid costly failures. druganddeviceworld.com/2026/07/14/navigating-the-risks-an…
-
ICON Plc
@ICONplc
As the COPD pipeline expands, differentiation depends on the right evidence strategy. ICON helps sponsors optimise patient selection, trial design and execution to advance next-generation respiratory therapies. www.iconplc.com/insights/blog/2026/07/13/new-era-drug-dev…
#copd #clinicaldevelopment #biotech -
ICON Plc
@ICONplc
How can APAC sponsors improve their chances of successful global regulatory approval? Our latest PharmaTimes article examines trial design, regulatory expectations and the value of planning for multi-regional authorisation from day one.
magazine.pharmatimes.com/collections/pharmatimes-july-202… -
ICON Plc
@ICONplc
ICON today announced a multi-year collaboration with Anthropic to bring Claude’s AI capabilities across the clinical trial lifecycle. www.iconplc.com/news-events/press-releases/icon-announces…
-
ICON Plc
@ICONplc
A more connected, data-driven future for clinical trials is emerging. Yet global regulatory alignment on real-time models remains uncertain. How should sponsors respond? Read our latest blog www.iconplc.com/insights/blog/2026/06/11/real-time-clinic…
#lifesciences #regulatoryaffairs #innovation #clinicaldevelopment -
ICON Plc
@ICONplc
Italy's pharmaceutical serialisation framework is evolving. A new hybrid model will combine EU FMD requirements with existing national safeguards, creating new considerations for packaging, compliance and supply chain operations. Read more: www.iconplc.com/insights/blog/2026/07/14/italys-new-seria… #serialisation
-
ICON Plc
@ICONplc
Safety monitoring for anti-amyloid therapies requires rigid adherence to routine MRI schedules to detect dangerous imaging abnormalities. Explore how operational planning for the "MRI metronome" is crucial for Alzheimer's disease management. www.biopharminternational.com/view/clinical-success-cns-mabs
-
ICON Plc
@ICONplc
From CAR T to mRNA therapies, immunology development is evolving rapidly. Learn how to navigate regulatory pathways in our new whitepaper: www.iconplc.com/insights/regulatory-intelligence/global-r…
#immunology #drugdevelopment #pharma -
ICON Plc
@ICONplc
Agentic AI is delivering its clearest ROI in HTA dossier generation and evidence synthesis, but human judgment remains non-negotiable for strategy, interpretation, and trust. Read more from ICON: www.scientist.com/blog/june-2026-pulse-check
#ai #heor #healtheconomics #marketaccess -
ICON Plc
@ICONplc
Precision medicine is redefining COPD research. Biomarker-enriched trials, targeted therapies and innovative study designs are helping sponsors generate stronger evidence and accelerate development. Learn more: www.iconplc.com/insights/blog/2026/07/13/new-era-drug-dev…
#copdtrials -
ICON Plc
@ICONplc
PPWR is driving a new era of packaging transformation in the EU. Early action will be critical to manage regulatory complexity and avoid supply risk. Learn more: www.iconplc.com/insights/blog/2026/06/16/navigating-eu-pa…
#ppwr #compliance #lifesciences #supplychain #euregulation #sdg12 -
ICON Plc
@ICONplc
Why is Japan becoming a global hub for regenerative medicine?
From clear regulatory pathways to rich real-world data and strong patient access, Japan offers unique advantages for therapy development.
Read more: www.iconplc.com/insights/blog/2026/07/17/why-japan-global… -
ICON Plc
@ICONplc
Accelerated approval can shorten timelines – but weak biomarker foundations can undermine long-term success. In Drug & Device World, ICON’s Dr Elizabeth Madichie and Dr. Jack Martin examine the risks and rewards of biomarker-based surrogate endpoints. druganddeviceworld.com/2026/07/14/navigating-the-risks-an…
-
ICON Plc
@ICONplc
The real-world success of CNS monoclonal antibodies depends heavily on rigorous clinical operational protocols and safety governance. Read to learn which considerations are most critical to successfully navigating these unique patient safety risks. www.biopharminternational.com/view/clinical-success-cns-mabs
-
ICON Plc
@ICONplc
Navigating fragmented global frameworks for combination products? Our latest article breaks down key regulatory trends and practical approaches to approval. www.pharmafocusasia.com/articles/integrated-by-design
#lifesciences #medicaldevices #pharmaceuticals #qualitysystems -
ICON Plc
@ICONplc
For APAC biotechs pursuing global growth, selecting the right regulatory pathway is a critical decision. In PharmaTimes, ICON explores the challenges and opportunities associated with FDA and EMA authorisation. magazine.pharmatimes.com/collections/pharmatimes-july-202… #clinicalresearch #drugdevelopment
-
ICON Plc
@ICONplc
Agentic AI is moving beyond automation.
In this Bio-IT World article, Tony Clarke, SVP of Enterprise AI at ICON, explores how autonomous, workflow-driven AI is redefining the digital workforce – enhancing efficiency while keeping humans at the center.
www.bio-itworld.com/news/2026/06/12/from-automation-to-au… -
ICON Plc
@ICONplc
When regulations are constantly evolving, compliance can feel like a moving target.
ICON brings together real-time intelligence, global expertise and expert review to support faster, more accurate decision-making in pharmacovigilance.
Watch the video: www.iconplc.com/solutions/clinical-scientific-operations/… -
ICON Plc
@ICONplc
EU JCAs are reducing some duplication, but differing PICO requirements continue to create evidence-planning challenges across member states. As Mia Malmenäs notes, early planning, joint advice, and flexible evidence strategies are critical for success. www.scientist.com/blog/june-2026-pulse-check
-
ICON Plc
@ICONplc
Regulatory changes are streamlining biosimilar development pathways, benefitting sponsors but also making the landscape more competitive. Find out how the biosimilars market is being impacted, and what sponsors can do, in ICON’s article. www.pharmtech.com/view/faster-doesn-t-mean-easier-develop…
-
ICON Plc
@ICONplc
Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest clinical trial regulatory updates current www.iconplc.com/insights/regulatory-intelligence/regulato… #regulatoryintelligence #regulatorycompliance #regintel #clinicaltrials #medicaldevices #biotech #pharma
-
ICON Plc
@ICONplc
Join us tomorrow at the #scdm India Single Day Event in Hyderabad, where ICON's Gangotri Boni will serve as Event Co Chair and lead the session, 'Transforming information into insights'.
Register: mcigroup.eventsair.com/scdm-2026-india-single-day-event/l… -
ICON Plc
@ICONplc
Taking a therapy from APAC to global markets requires strategy alignment and regulatory insight. Discover best practices for FDA and EMA submissions in our latest whitepaper.
Download now www.iconplc.com/sectors/biotech/plotting-course-bring-apa…
#biotechinnovation #globaltrials #drugdevelopment #regulatory -
ICON Plc
@ICONplc
Join us on 11 July in Hyderabad for the #scdm India Single Day Event. ICON’s Gangotri Boni, Event Co-Chair, will lead the session 'Transforming Information into Insights', exploring how data can improve clinical development decisions.
Register: mcigroup.eventsair.com/scdm-2026-india-single-day-event/l… -
ICON Plc
@ICONplc
ICON has been named one of TIME’s World’s Most Sustainable Companies 2026 for the second year running. Proud to be the top ranked CRO and 4th among Irish companies.
See our awards www.iconplc.com/news-events/awards
#sustainability #esg #clinicalresearch #iconcares #unsdg -
ICON Plc
@ICONplc
Biosimilar development is changing. Advanced modalities, streamlined regulations and rising competition are redefining how developers approach market entry. Read more on the strategies shaping success. www.bioprocessintl.com/biosimilars/biosimilar-success-in-…
#biosimilar #biologics #cmc #pharmadevelopment -
ICON Plc
@ICONplc
The detection of minimal residual disease with ctDNA may open a window to test interventions at pre‑metastatic stages when long‑term benefit is more plausible. Discover the design implications for tumor-agnostic trial designs. pharmaphorum.com/oncology/liquid-biopsy-and-future-tumour…
-
ICON Plc
@ICONplc
Winning Best Clinical Trial Supplier – Site Innovation at ABEA 2026 reinforces our focus on advancing research where it matters most: at the site and for patients.
Read more: info.imapac.com/awards/abea2026-winners/
#clinicaldevelopment #siteinnovation #imapac #weareicon -
ICON Plc
@ICONplc
Imaging‑dependent outcomes assessment can curtail the agility tumor‑agnostic programs need. Emerging designs that use ctDNA-based biomarkers to track therapeutic response could provide real-time efficacy signals to support earlier decision-making. pharmaphorum.com/oncology/liquid-biopsy-and-future-tumour…
-
ICON Plc
@ICONplc
How can #clinicaltrials achieve real progress in representation?
On #acro’s #goodclinicalpodcast, ICON’s Tinaya Gray shares ways to tackle barriers, strengthen protocol design, and collaborate to deliver more representative, real‑world data.
Listen: www.acrohealth.org/informed-content-hub/moving-from-aware… -
ICON Plc
@ICONplc
Stronger assurance, smarter testing and #regulatorystrategies built for modern biologics.
Explore key considerations for implementing updated viral safety guidance in this PharmTech article by ICON. www.pharmtech.com/view/viral-safety-2-0-plant-ready-actio…
#lifesciences #biopharmamanufacturing #viralclearance -
ICON Plc
@ICONplc
Driving meaningful change in #clinicalresearch needs action. In #acro’s #goodclinicalpodcast, ICON's Tinaya Gray shares how to turn intent into execution for representative trials—improving design, collaboration, and real-world relevance.
Listen here: www.acrohealth.org/informed-content-hub/moving-from-aware… -
ICON Plc
@ICONplc
Tumor‑agnostic enrollment that relies solely on NGS results may fail to reliably identify likely responders. Combining genomic calls with inflammatory markers that also modulate a targeted therapy’s mechanism could improve patient selection. Learn more. pharmaphorum.com/oncology/liquid-biopsy-and-future-tumour…
-
ICON Plc
@ICONplc
Drug-device combination products require new regulatory thinking. Discover 3 CMC strategy pathways and how to align with evolving global expectations. www.pharmafocusasia.com/articles/integrated-by-design
#pharmainnovation #regulatorystrategy #drugdevelopment
#medtech -
ICON Plc
@ICONplc
Lower barriers. Faster timelines. Greater competition. The latest #ema and #fda biosimilar updates are reshaping development pathways. Learn what’s next: www.iconplc.com/insights/blog/2026/05/13/streamlining-bio…
#biosimilars #lifesciences #drugdevelopment #ema #fda -
ICON Plc
@ICONplc
From delayed data flows to near real-time insights, clinical development is evolving. But increased transparency brings new challenges in governance and control. Explore the implications: www.iconplc.com/insights/blog/2026/06/11/real-time-clinic…
#clinicalresearch #healthtech #drugdevelopment #aiinhealthcare -
ICON Plc
@ICONplc
Finding patients is a major bottleneck for tumor‑agnostic trials. More accessible screening methods leveraging ctDNA NGS could widen the eligibility funnel, and accelerate enrollment. Read the article for more. pharmaphorum.com/oncology/liquid-biopsy-and-future-tumour…
-
ICON Plc
@ICONplc
Harmonised labelling. Recyclability targets. New compliance demands. The EU Packaging & Packaging Waste Regulation brings significant change for pharma organisations. Explore what it means www.iconplc.com/insights/blog/2026/06/16/navigating-eu-pa…
#ppwr #regulatoryaffairs #packaging #sustainability #pharma #sdg12 -
ICON Plc
@ICONplc
Japan’s PMDA has prioritised creating an environment for multi-regional clinical trials that aligns more closely with global regulatory expectations. Explore these reforms, as well as those to approval pathways and consultation, in our blog. www.iconplc.com/insights/blog/2026/06/05/japans-clinical-…
-
ICON Plc
@ICONplc
Join us tomorrow at 11:45am where Padma Varadharajan will speak at #ctoec26 in Boston on the “Practical considerations for navigating the landscape of global oncology trials in 2026 and beyond.” www.arena-international.com/event/ctrdiseases/
-
ICON Plc
@ICONplc
High‑concentration, citrate‑free, and device enabled #biosimilars can improve patient experience, but bring new formulation challenges. ICON’s Kim Salgado and Venkat Reddy Sunkara share how to balance innovation, comparability and commercial viability: www.pharmtech.com/view/overcoming-formulation-challenges-…
-
ICON Plc
@ICONplc
Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest clinical trial regulatory updates current www.iconplc.com/insights/regulatory-intelligence/regulato… #regulatoryintelligence #regulatorycompliance #regintel #clinicaltrials #medicaldevices #biotech #pharma
-
ICON Plc
@ICONplc
Critical care studies bring added complexity: heterogeneous populations, challenging endpoints, and rapid clinical change.
Thoughtful design and operational alignment are key to delivering meaningful outcomes in critical care research.
Read more: www.iconplc.com/insights/blog/2026/06/10/navigating-compl… -
ICON Plc
@ICONplc
Since 2021 APAC has led global clinical trial activity shaping the future of drug development. Our whitepaper outlines how to navigate global regulatory pathways with confidence.
Get your copy www.iconplc.com/sectors/biotech/plotting-course-bring-apa…
#clinicalresearch #pharma #regulatory #lifesciencesThis media couldn't be displayed. See it on the original post. -
ICON Plc
@ICONplc
ICON is excited to be at #scdmchina in Shanghai, July 3-4! Stop by booth #6 to connect with our team & discover how we're transforming clinical research with innovative, data-driven solutions. Program scdmlive.org/china-conference-2026/program/
-
ICON Plc
@ICONplc
ICON reports first quarter 2026 results. Quarter one revenue of $2,034.0 million. Net business wins in the quarter of $2,880 million; a net book-to-bill of 1.42. Read more www.iconplc.com/news-events/press-releases/icon-reports-f…
-
ICON Plc
@ICONplc
In March 2026, the EMA and FDA both published new guidance for biosimilars development. Explore the impact of these and other recent regulatory shifts, including for data generation and competitive landscape, in our article, www.pharmtech.com/view/faster-doesn-t-mean-easier-develop…
-
ICON Plc
@ICONplc
The EU PPWR is set to reshape packaging across the life sciences sector. From sustainability standards to labelling requirements, the impact is wide-ranging.
Read the full analysis: www.iconplc.com/insights/blog/2026/06/16/navigating-eu-pa…
#ppwr #pharma #lifesciences #packaging #euregulation #sdg12 -
ICON Plc
@ICONplc
What do updated viral safety expectations mean for today’s biologics and #manufacturing models? This article outlines how manufacturers can apply risk based controls, prior knowledge and new technologies with confidence. Click to read. www.pharmtech.com/view/viral-safety-2-0-plant-ready-actio…
#biotech #cmc -
ICON Plc
@ICONplc
Real-time clinical trials are gaining momentum. The FDA’s latest initiative signals a shift towards continuous data visibility and AI-enabled decisions. What does this mean for global development?
Read more: www.iconplc.com/insights/blog/2026/06/11/real-time-clinic…
#clinicaltrials #ai #pharma #regulation -
ICON Plc
@ICONplc
Critical care trials demand approaches beyond traditional models.
Tight enrolment windows, evolving patient status, and complex consent pathways shape feasibility and execution in ICU studies.
Learn more:
www.iconplc.com/insights/blog/2026/06/10/navigating-compl… -
ICON Plc
@ICONplc
Combination products are reshaping healthcare, but regulatory pathways remain complex. Our latest article explores CMC strategy, PMOA and integrated quality expectations. Read more: www.pharmafocusasia.com/articles/integrated-by-design
#combinationproducts #regulatoryaffairs #cmc #pharma -
ICON Plc
@ICONplc
ICON Biotech is sponsoring #ctoec26, taking place 30 June – 1 July at the Boston Marriott Burlington, MA. Visit us at Booth 18 to learn how ICON supports oncology programs across the full clinical development lifecycle. www.arena-international.com/event/ctrdiseases/
-
ICON Plc
@ICONplc
Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest #clinicaltrial regulatory updates current. www.iconplc.com/insights/regulatory-intelligence/regulato…
#regulatoryintelligence #regulatorycompliance #biotech #pharma #foodanddrugadministration #europeanmedicinesagency -
ICON Plc
@ICONplc
ICON joins #acro’s Good Clinical Podcast on advancing rare disease research through AI and patient trust.
We share where AI is already making a difference and where careful application still matters in small, complex datasets.
www.acrohealth.org/informed-content-hub/advancing-rare-di… -
ICON Plc
@ICONplc
Recent changes to biosimilar regulatory approaches will reduce the time and resources required to develop biosimilars, but they also represent a fundamental shift for development strategy. Learn about the implications of recent regulatory guidance www.pharmtech.com/view/faster-doesn-t-mean-easier-develop…
-
ICON Plc
@ICONplc
#fattyliverday is June 11. With cases expected to triple to 357M by 2030, advancing fatty liver disease research is critical. Discover how ICON supports clients in reaching their hepatology clinical development goals to improve liver health worldwide. www.iconplc.com/therapeutics/hepatology
-
ICON Plc
@ICONplc
From clinical development to post-marketing surveillance, global safety requirements are complex and constantly changing.
ICON’s regulatory intelligence service provides the clarity needed to manage that complexity with confidence.
Watch the video: www.iconplc.com/solutions/clinical-scientific-operations/… -
ICON Plc
@ICONplc
Updated #biologics guidance signals a shift toward risk based #viralsafety, modern analytics and clearer clearance strategies. ICON’s John Muganga shares practical insights for manufacturers navigating these #regulatory changes. Read more in PharmTech. www.pharmtech.com/view/viral-safety-2-0-plant-ready-actio…
-
ICON Plc
@ICONplc
Artificial intelligence is a powerful tool for enhancing trial accuracy, predictive modeling, and patient safety in vaccine innovation. Read the article to learn how AI is driving the next phase of clinical research: thejournalofmhealth.com/reimagining-vaccine-development-w…
-
ICON Plc
@ICONplc
Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest #clinicaltrial regulatory updates current. www.iconplc.com/insights/regulatory-intelligence/regulato…
#regulatoryintelligence #regulatorycompliance #biotech #pharma #foodanddrugadministration #europeanmedicinesagency -
ICON Plc
@ICONplc
From complex trial designs to vast patient data, vaccine R&D faces significant operational hurdles. Discover how integrating AI can help developers solve legacy challenges in our article: thejournalofmhealth.com/reimagining-vaccine-development-w…
-
ICON Plc
@ICONplc
Biosimilar regulations are evolving. New guidance could remove certain clinical study requirements and simplify global trials. Explore the implications: www.iconplc.com/insights/blog/2026/05/13/streamlining-bio…
#biosimilars #regulatoryaffairs #biopharma #clinicalresearch -
ICON Plc
@ICONplc
ICON is attending #cyto 2026 in West Palm Beach, FL on 6–10 June. Visit us at booth #715 to connect with our flow cytometry experts and learn how our globally aligned capabilities support innovative and complex clinical trials. www.cytoconference.org
-
ICON Plc
@ICONplc
Vaccine development has traditionally taken years, but a technology-driven mindset is completely redefining the timeline. Explore how artificial intelligence is streamlining workflows and accelerating delivery in our article: thejournalofmhealth.com/reimagining-vaccine-development-w…
-
ICON Plc
@ICONplc
High interest does not equal smooth enrolment in psychedelic trials. Expect tighter criteria, more screen failures, and added complexity. A few practical considerations for sponsors: www.iconplc.com/insights/blog/2026/05/04/navigating-psych…
-
ICON Plc
@ICONplc
As #biosimilardevelopment shifts toward analytical comparability over clinical confirmation, CMC strategy is more critical than ever.
In PharmTech, Venkat Reddy Sunkara and Kim Salgado explore impacts on formulation, timelines and #regulatory success. www.pharmtech.com/view/overcoming-formulation-challenges-… -
ICON Plc
@ICONplc
Visit us at ASCO, booth #35093 to learn about ICON’s purpose built technology suite supports AI powered site identification, streamlined activation, contract drafting and site collaboration, helping sponsors move forward with efficiency and confidence. www.iconplc.com/news-events/events/industry/asco-2026
-
ICON Plc
@ICONplc
Psychedelic trials show promise but bring operational risk. ICON’s support of a global programme across 150+ sites and 12 countries show what’s possible when complexity is planned for from day one. Learn more: www.iconplc.com/solutions/all-case-studies/global-full-se…
#mentalhealthawarenessmonth -
ICON Plc
@ICONplc
Meet the ICON team on 9 – 10 June at #octuk26 in London. We're gearing up for impactful discussions on advancing clinical trials. 13th Annual Outsourcing in Clinical Trials UK & Ireland 2026 - Arena International. www.arena-international.com/event/octuk/
-
ICON Plc
@ICONplc
Advancing #dermatology research: ICON co-authored the ViSENPsO® scale, a validated, user-friendly visually guided tool for evaluating nail #psoriasis severity to help improve consistency across clinical studies. idp.springer.com/transit?redirect_uri=https%3A%2F%2Flink.…
#clinicalresearch #healthcareinnovation -
ICON Plc
@ICONplc
Honoured to be recognised by IMAPAC at ABEA 2026 for Site Innovation.
This award reflects the dedication of our APAC teams and our shared mission to accelerate clinical development for patients worldwide. info.imapac.com/awards/abea2026-winners/
#clinicalresearch #innovation #apac -
ICON Plc
@ICONplc
May is #mentalhealthawareness Month. Over the past 5 years ICON has conducted over 100 mood disorder studies involving over 13,900+ patients in key indications including Depression, Bipolar Disorder and Schizophrenia. Learn more. www.iconplc.com/therapeutics/central-nervous-system
-
ICON Plc
@ICONplc
#ema and #fda updates in March 2026 are set to streamline biosimilar development and reduce costs — but increase competition. What does this mean for your strategy?
Read more: www.iconplc.com/insights/blog/2026/05/13/streamlining-bio…
#biosimilars #drugdevelopment #clinicaltrials -
ICON Plc
@ICONplc
Designing FIH studies for oligonucleotide therapies?
Learn how to manage structural complexity, safety, and translational risk in our upcoming webinar.
Register here: xtalks.com/webinars/insights-into-first-in-human-study-de…
#earlyphase #clinicaldevelopment #oligonucleotides -
ICON Plc
@ICONplc
By easing the burden of participating in a clinical trial, In-Home Services improves patient recruitment and retention with a patient centric approach. Speak with ICON experts at #asco26, booth #35093 to learn more. www.iconplc.com/news-events/events/industry/asco-2026
-
ICON Plc
@ICONplc
On #clinicaltrialsday, ICON recognises the researchers, site teams, and participants whose dedication keeps progress moving forward. We’re committed to supporting research that’s built on trust, quality, and patient focus. www2.iconplc.com/2026_international_clinical_trials_day_i…
#researchrising -
ICON Plc
@ICONplc
As products reach patients, #pharmacovigilance demands rise. Data grows, regulations evolve and post‑approval scrutiny intensifies.
ICON helps sponsors manage post‑marketing pharmacovigilance at scale, supporting #patientsafety and global compliance. www.iconplc.com/solutions/clinical-scientific-operations/… -
ICON Plc
@ICONplc
Psychedelic clinical trials are not standard CNS studies. Recruitment dynamics, bias, and regulatory demands all change the playbook. A quick read on what sponsors should factor in: www.iconplc.com/insights/blog/2026/05/04/navigating-psych… #mentalhealthawarenessmonth
-
ICON Plc
@ICONplc
Are you working with NONMEM or PDx-Pop? Don’t miss the chance to connect with our team at PAGE in Croatia. Visit us at booth #2.
Whether you're a long-time user or just getting started, we can support your modeling journey.
www.page-meeting.org -
ICON Plc
@ICONplc
Developers of neurologic mAbs must integrate operational considerations, accessibility strategies, and safety planning early. Learn how you can ensure clinical practices are equipped with the checklists and infrastructure they need from day one. www.iconplc.com/insights/therapeutics/central-nervous-sys…
-
ICON Plc
@ICONplc
ICON collaborated with global #dermatology experts to co-author the ViSENPsO® scale - a new visual scale to assess nail #psoriasis severity designed to support more standardized outcomes in clinical trials. Read more: idp.springer.com/transit?redirect_uri=https%3A%2F%2Flink.…
#clinicalresearch -
ICON Plc
@ICONplc
The FDA’s support for a single confirmatory study sidesteps the duplication trap to generate stronger evidence faster.
Compare the risks and advantages of running one study: www.iconplc.com/insights/blog/2026/05/11/doubling-down-si… -
ICON Plc
@ICONplc
Treatment with ART suppresses HIV replication and transmission, but does not fully restore immune dysfunction. What does that mean for populations aging with HIV? Learn more in our article. www.infectioncontroltoday.com/view/aging-hiv-what-next-ma…
-
ICON Plc
@ICONplc
We’re gearing up for ISPOR 2026 - what HEOR or real world evidence challenges are you focused on this year?
Stop by Booth #1017 at #isporannual to exchange ideas and explore how ICON can support your evidence strategy. www.ispor.org/conferences-education/conferences/past-conf…
#heor #rwe #ispor2026 -
ICON Plc
@ICONplc
AI is rapidly reshaping how life sciences companies generate insight, accelerate development, and scale smarter decision making. This @BioSpectrumAsia piece highlights the AI tools leading organisations are already putting to work www.biospectrumasia.com/opinion/120/27567/ai-tools-life-s…
-
ICON Plc
@ICONplc
#biosimilar formulation is becoming more complex as patient-centric design and regulatory demands increase. ICON experts Kim Salgado and Venkat Reddy Sunkara share how analytics, QbD and early regulatory engagement keep development on track. www.pharmtech.com/view/overcoming-formulation-challenges-…
#cmc -
ICON Plc
@ICONplc
This #mentalhealthawarenessmonth, psychedelic therapies are gaining momentum, but the trials behind them are complex. Explore the case study to learn how ICON recently supported a global programme with 150+ sites and 12 countries: www.iconplc.com/solutions/all-case-studies/global-full-se…
-
ICON Plc
@ICONplc
Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest clinical trial regulatory updates current www.iconplc.com/insights/regulatory-intelligence/regulato…
#regulatoryintelligence #regulatorycompliance #regintel #clinicaltrials #medicaldevices #biotech #pharma -
ICON Plc
@ICONplc
Clinical success for neurologic monoclonal antibodies requires mature operational norms, such as Risk Evaluation and Mitigation Strategies, patient-centric access and rigid imaging cadences. Read further to find out more. www.iconplc.com/insights/therapeutics/central-nervous-sys…
-
ICON Plc
@ICONplc
Are you working with NONMEM or PDx-Pop? Don’t miss the chance to connect with our team at PAGE in Croatia. Visit us at booth #2.
Whether you're a long-time user or just getting started, we can support your modeling journey.
www.page-meeting.org -
ICON Plc
@ICONplc
Oligonucleotide drugs offer durable effects—but FIH development is complex.
Join our webinar on FIH antisense & siRNA studies, covering PK/PD, toxicity, dose escalation & safety strategies.
Register here: xtalks.com/webinars/insights-into-first-in-human-study-de…
#fih #earlyphase #oligonucleotides -
ICON Plc
@ICONplc
Meet ICON experts at #asco26, booth #35093 to learn about our Centre for Pediatric Clinical Development’s expertise in supporting oncology studies involving pediatric participants including neonates, children, adolescents, young adults, and pregnant women. www.iconplc.com/news-events/events/industry/asco-2026
-
ICON Plc
@ICONplc
Cronbach’s alpha has long been the default for COA reliability but is it still fit for purpose?
Join Steve Maher, Principal, Patient Centred Outcomes at ICON, for this ISPOR breakout exploring modern approaches to reliability assessment. www.ispor.org/conferences-education/conferences/past-conf… -
ICON Plc
@ICONplc
Recent changes in the #biosimilars landscape have introduced heightened competition. Read the whitepaper to learn how biosimilar developers can prepare for successful market entry in the current environment. www.iconplc.com/insights/therapeutics/biosimilars/making-…
-
ICON Plc
@ICONplc
Visit ICON at Booth #1017 during #isporannual to learn how our experienced specialists design, validate, and implement Clinical Outcomes Assessments to support regulatory submissions, label claims, and real world decision making. www.ispor.org/conferences-education/conferences/past-conf…
-
ICON Plc
@ICONplc
Visit ICON Biotech at Booth 25 during #octec26 (12–13 May).
Our team will be onsite to discuss clinical development support and share insights on efficient trial planning and execution. More info: www.arena-international.com/event/octeastcoast/ -
ICON Plc
@ICONplc
Converting innovative monoclonal antibodie into accessible CNS therapies requires a rigorous development playbook prioritising safety and clinical operability. Read through the essential implementation checklists for successful therapy development: www.iconplc.com/insights/therapeutics/central-nervous-sys…
-
ICON Plc
@ICONplc
This 11 – 14 May ICON will participate in the #aaps NBC in San Diego. Be sure to visit us at booth #404 to discuss how ICON’s comprehensive bioanalysis and early clinical manufacturing solutions can support your research and development goals. www.aaps.org/nbc
-
ICON Plc
@ICONplc
Emerging analytical processes are redefining biosimilar innovation. Access the full spotlight to learn more: icon.widen.net/s/jq7wzpwmqg/spotlight-evolving-bioanalyti…
#biologics #regulatoryscience #bioanalyticalmethods #pharmaresearch -
ICON Plc
@ICONplc
ICON understands the rapidly advancing landscape and the unique challenges of navigating the patient, site, product and regulatory journeys in delivering CGT therapies. Meet us at #asco26, booth #35093 to learn how we can help support your trial. www.iconplc.com/news-events/events/industry/asco-2026
-
ICON Plc
@ICONplc
Successful development of neurologic monoclonal antibodies now depends on strict clinical operational protocols, not just their biological mechanisms. Read the whitepaper to discover more: www.iconplc.com/insights/therapeutics/central-nervous-sys…
-
ICON Plc
@ICONplc
Are you working with NONMEM or PDx-Pop? Don’t miss the chance to connect with our team at PAGE in Croatia. Visit us at booth #2.
Whether you're a long-time user or just getting started, we can support your modeling journey.
www.page-meeting.org -
ICON Plc
@ICONplc
Heading to Philadelphia for #isporannual?
Our ICON HEOR and RWE teams will be on-site sharing the latest thinking on patient-centred outcomes, comparative effectiveness research, and innovative evidence synthesis.
Let’s connect in Booth #1017.
www.ispor.org/conferences-education/conferences/past-conf… -
ICON Plc
@ICONplc
Ankita Minhas will speak on 6 May at OCT Europe in Barcelona at 12:00pm in Stream C. Her session will explore how leading biotechs manage rising complexity through AI-driven innovation, smarter trial designs, and stronger operational discipline. www.arena-international.com/event/octeurope/
-
ICON Plc
@ICONplc
If recruitment and retention matter, site satisfaction must be treated as a prerequisite. In this Journal for Clinical Studies article, Brian Mallon explains why start-up success is shaped by human factors, not technology alone.
Read the full article: issuu.com/senglobal1/docs/2026-jcs-spring/30) -
ICON Plc
@ICONplc
Congratulations to Rose Kidd, President of Operational Delivery at ICON, winner of Excellence in senior leadership – life sciences at the Women in Pharma Awards 2026.
A well‑deserved recognition of her leadership and impact across clinical research. womeninpharmaawards.ie/shortlist -
ICON Plc
@ICONplc
Meet the ICON team at SCDM #emea26 and discover how we’re driving innovation in clinical data science and helping organisations build more resilient clinical programmes. Visit booth #11 to see how ICON applies data science across the product lifecycle. scdm.org/scdm-2026-emea-conference/
-
ICON Plc
@ICONplc
ICON is a proud supporter of #worldimmunisationweek. Discover how we are supporting research into #vaccines and #infectiousdiseases including the development of 15 vaccines, leading to FDA/EMA approvals. www.iconplc.com/therapeutics/vaccines
-
ICON Plc
@ICONplc
Less than a week to go! We’re looking forward to #raps in Lisbon. Meet Gabriel Bohl and Laurent Valentin at booth 21 to discuss key EU and global regulatory challenges, including MDR, ICH and evolving evidence requirements. www.raps.org/europe-2026/home
-
ICON Plc
@ICONplc
A valid #pediatric COA must span the developmental range from toddlers to adolescents while producing data that remain interpretable across ages. Our latest blog outlines six criteria for selecting a fit‑for‑purpose #hrqol tool and evaluates the PedsQL™: www.iconplc.com/insights/blog/2026/03/31/framework-pediat…
-
ICON Plc
@ICONplc
Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest clinical trial regulatory updates current www.iconplc.com/insights/regulatory-intelligence/regulato…
#regulatoryintelligence #regulatorycompliance #regintel #clinicaltrials #medicaldevices #biotech #pharma -
ICON Plc
@ICONplc
Participant-centric study design has advanced, but site-centric execution has not kept pace. In the Journal for Clinical Studies, Brian Mallon examines how unclear expectations, administrative burden and contract delays are undermining start-up timelines.
issuu.com/senglobal1/docs/2026-jcs-spring/30) -
ICON Plc
@ICONplc
Great discussion at European Pharmaceutical Review webinar, “Harnessing AI for more efficient clinical trials.”
ICON’s SVP, Enterprise AI Tony Clarke joined an industry panel to share how AI is being applied to drive trial efficiency.
Watch the webinar: www.europeanpharmaceuticalreview.com/webinars/harnessing-… -
ICON Plc
@ICONplc
Meet ICON’s experts at #asco26, booth #35093 to discuss how our extensive testing capabilities, clinical research experience and scientific expertise can support global oncology and haematology research programmes. www.iconplc.com/news-events/events/industry/asco-2026
-
ICON Plc
@ICONplc
On 5 May at SCDM EMEA, ICON’s Kevin Devenny will chair a session on why strong business processes and culture still matter as automation and AI advance—highlighting the critical factors beyond technology that underpin effective clinical data operations. scdm.org/scdm-2026-emea-conference/
-
ICON Plc
@ICONplc
On May 12 at 9:15 AM, Mindy Hurd will speak at #octec26 on the future of clinical outsourcing models. The session will cover new approaches to integrated partnerships, and how CROs set themselves apart through consistent delivery and specialized expertise. www.arena-international.com/event/octeastcoast/
-
ICON Plc
@ICONplc
Implementing NMA in R requires structured workflows, from data preparation to model evaluation and output interpretation.
The whitepaper outlines this process using established packages. Discover more: www.iconplc.com/insights/value-based-healthcare/building-…
#rstats #nma #evidencesynthesis #healtheconomics -
ICON Plc
@ICONplc
In the US sponsors generally follow one of two standards sets when conducting early phase trials: Good Manufacturing Practice (GMP) or United States Pharmacopeia (USP).
In this blog we look at each practice set and weigh their relative advantages: www.iconplc.com/insights/blog/2026/03/20/why-incorporatin… -
ICON Plc
@ICONplc
Biosimilar uptake is affected by several factors, including clinician perceptions and payer policies. Learn what considerations to be aware of and what developers can do to encourage biosimilar prescription in the whitepaper. www.iconplc.com/insights/therapeutics/biosimilars/making-…
-
ICON Plc
@ICONplc
On 5 May at SCDM EMEA, ICON’s Stephen Cameron will chair a session on what AI‑enabled inspections mean for clinical trial oversight, inspection readiness and quality—and how organisations can prepare while maintaining strong processes and human judgement. scdm.org/scdm-2026-emea-conference/
-
ICON Plc
@ICONplc
More than 10 million people worldwide are living with Parkinson’s disease (PD). Discover how @ICONplc is working to improve drug development and advance treatments for # Parkinson's disease. www.iconplc.com/therapeutics/central-nervous-system #parkinsonsawareness
-
ICON Plc
@ICONplc
Don’t miss this ISPOR breakout with Steve Maher, Principal, Patient Centred Outcomes, covering when alpha is appropriate, when it can mislead, and how modern reliability methods can strengthen COA submissions, clinical trials, and labelling claims.
www.ispor.org/conferences-education/conferences/past-conf… -
ICON Plc
@ICONplc
It’s #worldimmunisationweek. ICON is proud to support research that helps bring lifesaving vaccines to people of all ages. Our new vaccine whitepaper explores how clinical trial tokenisation supports longitudinal patient insights and long term follow up. www.iconplc.com/insights/therapeutics/infectious-diseases…
-
ICON Plc
@ICONplc
ICON will be at #aaps NBC on 11 – 14 of May in San Diego. We invite you to visit us at booth #404 to discuss how ICON can help you navigate the complexities of the pharmaceutical landscape. www.aaps.org/nbc
-
ICON Plc
@ICONplc
On 28 April at the 13th Annual Clinical Trials in Oncology West Coast 2026 in San Francisco, Avnika Agarwal will be speaking at 9:30 AM, presenting “Beyond outsourcing: Rethinking the CRO-biotech partnership.” www.arena-international.com/event/oncologywestcoast/
-
ICON Plc
@ICONplc
Visit ICON at Booth #1017 during #isporannual to learn how our specialized language services ensure high‑quality translations for HEOR, RWE, PROs/ePROs, and global regulatory submissions.
www.ispor.org/conferences-education/conferences/past-conf… -
ICON Plc
@ICONplc
ICON Biotech is exhibiting and presenting at #octeu26, 6–7 May in Barcelona. Visit us at Booth 52 to explore how our biotech focused model accelerates clinical development and supports emerging innovators. www.arena-international.com/event/octeurope/
-
ICON Plc
@ICONplc
Population adjustment methods such as MAIC and STC address imbalance when individual and aggregate data must be reconciled. The whitepaper explains where their limitations arise and why ML NMR can extend capability. Download today: www.iconplc.com/insights/value-based-healthcare/building-…
#maic #stc #mlnmr -
ICON Plc
@ICONplc
Meet ICON’s Gabriel Bohl and Laurent Valentin at #raps, booth 21, to discuss how ICON strengthens regulatory readiness and supports strategic decision making across clinical trials. www.raps.org/europe-2026/home
-
ICON Plc
@ICONplc
ICON Biotech is heading to #octeastcoast on 12–13 May at the Hyatt Regency New Brunswick. Come meet us at Booth 25. www.arena-international.com/event/octeastcoast/
-
ICON Plc
@ICONplc
ICON will attend #biokorea from 28–30 April in Seoul. Visit booth #g25 to meet our team and discuss how ICON’s clinical, real world and commercialisation expertise supports more efficient development of new therapies. www.biokorea.org
-
ICON Plc
@ICONplc
Visit ICON Biotech’s booth #2 at #ctowc26, 28–29 April in Burlingame, CA, USA, to discuss oncology clinical development support. Our team will be available to share insights across oncology trial planning and execution. www.arena-international.com/event/oncologywestcoast/
-
ICON Plc
@ICONplc
At SCDM #emea26, meet the ICON team at booth #11 to learn how we are driving innovation in clinical data science and shaping the future of clinical trials. scdm.org/scdm-2026-emea-conference/
-
ICON Plc
@ICONplc
The future of HEOR is here and ICON is helping shape it.
Join us at #isporannual to discuss innovative approaches in economic modeling, value demonstration, and market access insights. Stop by Booth #1017 to meet our team. www.ispor.org/conferences-education/conferences/past-conf…
#heor #ispor2026 #rwe -
ICON Plc
@ICONplc
Join ICON at EMWA 2026 for a poster presentation on 'AI and Medical Writing: Insights from those on the front line'.
Hear from Marina Cimpean, Mauro Meloni, Sara Fernandes, and Rona Grunspan as they share practical perspectives. emwa.org/conference-barcelona-may-2026/ -
ICON Plc
@ICONplc
Join Paul Cariola of Symphony Health, an ICON plc company, and Anne Smith of HealthWise Data for a podium presentation at PMSA on how combining real world claims with provider as consumer insights is advancing HCP segmentation and targeting.
Learn more: www.pmsa.org/events/annual-conference/2026-agenda -
ICON Plc
@ICONplc
The ability to collect data on appropriate biomarkers and endpoints is central to choosing a strategy for long-term follow-up in vaccines. Learn when developers should use active surveillance, RWD and tokenisation, or a combination in our article. www.appliedclinicaltrialsonline.com/view/study-end-long-t…
-
ICON Plc
@ICONplc
Frequentist NMA enables efficient computation across complex networks, while Bayesian models provide posterior distributions suited to economic modelling.
The whitepaper provides a concise comparison for those who want deeper insight. www.iconplc.com/insights/value-based-healthcare/building-…
#bayesianmethods -
ICON Plc
@ICONplc
Meet ICON at #biokorea in Seoul from 28–30 April. Our experts will be at booth #g25 to discuss how our integrated clinical and commercial solutions help accelerate innovation and advance programmes across the product lifecycle. www.biokorea.org
-
ICON Plc
@ICONplc
Connect with us at #ctowc26, 28–29 April in Burlingame, California. Visit booth #2 to learn how ICON Biotech supports oncology programs with development strategy and evidence generation expertise. www.arena-international.com/event/oncologywestcoast/
-
ICON Plc
@ICONplc
ICON is proud to win Best Clinical Trial Supplier: Site Innovation at the Asia‑Pacific Biopharma Excellence Awards 2026, for the second year in a row.
Discover more: info.imapac.com/awards/abea2026-winners/
#clinicaltrials #siteinnovation #biopharma #apac #imapac -
ICON Plc
@ICONplc
Specialised patient groups, such as geriatric, pediatric, or immunocompromised populations, have unique needs that can impact long-term follow-up for vaccines. Read the article to learn more: www.appliedclinicaltrialsonline.com/view/study-end-long-t…
-
ICON Plc
@ICONplc
ICON are joining #raps from 5–8 May in Lisbon. Visit booth 21 to meet our team and discuss how ICON supports global regulatory strategy and market access. Learn more @ www.raps.org/europe-2026/home
-
ICON Plc
@ICONplc
Evidence networks, forest plots and league tables support clearer interpretation of comparative findings. The whitepaper describes how each visualisation contributes to decision ready outputs. Further detail is available in the full paper: www.iconplc.com/insights/value-based-healthcare/building-…
#metaanalysis -
ICON Plc
@ICONplc
New mechanism of action PIP requirements are coming from the EMA. Keep your pediatric strategy ahead of the curve: www.iconplc.com/insights/blog/2026/01/07/mechanism-action…
-
ICON Plc
@ICONplc
Robust bioanalysis is essential for accurate comparability in biosimilar programmes. Read how new approaches are shaping the future of development: icon.widen.net/s/jq7wzpwmqg/spotlight-evolving-bioanalyti…
#bioanalyticaltesting #biosimilardevelopment #lifesciences -
ICON Plc
@ICONplc
Selecting the right #biosimilar to develop is key to seeing market success. Read our whitepaper to explore market trends, considerations for developing advanced modalities and other factors to guide development decisions: www.iconplc.com/insights/therapeutics/biosimilars/making-…
-
ICON Plc
@ICONplc
In the US sponsors generally follow one of two standards sets when conducting early phase trials: Good Manufacturing Practice (GMP) or United States Pharmacopeia (USP).
In this blog we look at each practice set and weigh their relative advantages: www.iconplc.com/insights/blog/2026/03/20/why-incorporatin… -
ICON Plc
@ICONplc
A valid #pediatric COA must span the developmental range from toddlers to adolescents while producing data that remain interpretable across ages. Our latest blog outlines six criteria for selecting a fit‑for‑purpose #hrqol tool and evaluates the PedsQL™: www.iconplc.com/insights/blog/2026/03/31/framework-pediat…
-
ICON Plc
@ICONplc
The length of vaccine follow-up can vary widely depending on several factors, including modality, the goal of follow-up or the vaccine’s expected length of effectiveness. Find out how timeframe impacts the best long-term follow-up strategy in our article. www.appliedclinicaltrialsonline.com/view/study-end-long-t…
-
ICON Plc
@ICONplc
Network meta analysis strengthens precision when multiple studies contribute evidence, provided consistency and low heterogeneity are maintained.
The whitepaper outlines how these conditions are assessed. Read more: www.iconplc.com/insights/value-based-healthcare/building-…
#nma #evidencesynthesis -
ICON Plc
@ICONplc
On #worldparkinsonsday, we’re spotlighting the importance of strong operational strategy in complex neurodegeneration research.
See how ICON helped a sponsor keep a challenging global Parkinson’s study on course:
www.iconplc.com/solutions/all-case-studies/navigating-com…
#clinicalresearch #parkinsons -
ICON Plc
@ICONplc
Long-term follow-up is a necessity for vaccine development, but deciding on the right approach can be challenging. Explore key questions developers should ask to guide the choice between traditional onsite follow-up and tokenisation in our article. www.appliedclinicaltrialsonline.com/view/study-end-long-t…
-
ICON Plc
@ICONplc
As the 20th #wrib approaches, ICON is preparing to meet colleagues in Dallas from 13–17 April. Visit booth #31 to discuss how our bioanalytical and lab expertise supports reliable data and smooth regulatory progress. www.wrib.org/index.php
-
ICON Plc
@ICONplc
At #amcp2026, ICON will be at booth #1412 to discuss rigorous RWE methods and study designs that support reliable formulary and coverage evaluations. Meet us in Nashville to explore evidence solutions that strengthen access decisions. amcpannual.org
-
ICON Plc
@ICONplc
As part of the PharmaSUG India Single Day Event on 11 April at the Eli Lilly office in Bangalore, Dimpy Modak, Director of Biometrics, will deliver a presentation titled “The future of statistical programming in the age of AI.”
pharmasug.org/sde/pharmasug-sde-india-2026/ -
ICON Plc
@ICONplc
Speak with ICON experts at the GLP-1-Based Therapeutics Summit to gain valuable insights on obesity clinical development and learn about our ready-to-deploy infrastructure designed to accelerate obesity and comorbidity programs. Arrange a meeting: www.iconplc.com/contact
-
ICON Plc
@ICONplc
Are you going to the EHRA Congress?
If so come along to Lennaert Hoek’s poster presentation on the validity and reliability of a smartwatch single-lead ECG for monitoring QT interval prolongation during an interventional study with moxifloxacin. www.escardio.org/events/congresses/ehra-congress/ -
ICON Plc
@ICONplc
ML NMR synthesises individual and aggregate data within one framework, enabling predictions for any target population. Our whitepaper outlines when this matters and how the method works: LINK
#mlnmr #indirectcomparisons #nma #heor -
ICON Plc
@ICONplc
Join Madhan Kumar N., Statistical Programmer II, for his presentation at #pharmasug on 11 April in Bangalore, India. He will speak on “Explore More with dataviewer: The next step beyond view”: pharmasug.org/sde/pharmasug-sde-india-2026/
-
ICON Plc
@ICONplc
Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest clinical trial regulatory updates current: www.iconplc.com/insights/regulatory-intelligence/regulato…
#regulatoryintelligence #regulatorycompliance #regintel #clinicaltrials #medicaldevices #biotech #pharma -
ICON Plc
@ICONplc
ICON’s 45+ Patient Centred Outcomes specialists delivered a strong 2025 including 12 papers, 2 educational events and broad COA experience across major therapy areas. We continue to produce focused, science‑led evidence for better decisions. Discover more: icon.widen.net/s/lrwbzmfcjm/patient-centred-outcomes-2025…
-
ICON Plc
@ICONplc
Which modalities dominate China’s biotech pipelines?
ICON’s 2025 China biotech survey report reveals where organisations are focusing R&D resources and how these choices shape long‑term investment planning.
See the full pipeline breakdown: www.iconplc.com/sectors/biotech/2025-china-biotech-survey… -
ICON Plc
@ICONplc
Meet ICON at the 20th #wrib in Dallas. Visit booth #31 to discuss our bioanalytical, biomarker and flow cytometry expertise supporting reliable, compliant data across development. Looking forward to connecting with attendees. www.wrib.org/index.php
-
ICON Plc
@ICONplc
Meet ICON’s Gomathi S., Statistical Programmer I at PharmaSUG India on 11 April and view her poster on “Evolving submission standards: Transitioning from XPT to DatasetJSON”. pharmasug.org/sde/pharmasug-sde-india-2026/
-
ICON Plc
@ICONplc
Attending the GLP-1-Based Therapeutics Summit in Boston? Join @iconplc’s Alan Baldridge as he discusses “Is there anything GLP‑1s can’t do? Unlocking the next generation of metabolic treatments.”
Learn more 4/15 at 12:00 pm. glp-1-based-therapeutics.com -
ICON Plc
@ICONplc
Bayesian NMA offers posterior distributions and rank probabilities valuable for economic modelling. The whitepaper clarifies how these outputs support decision making. www.iconplc.com/insights/value-based-healthcare/building-…
#bayesianmethods #nma #heor #evidencesynthesis -
ICON Plc
@ICONplc
High risk medical devices are entering the EU JCA process for the first time.
Learn what this means for developers and how to prepare. Read our blog:
www.iconplc.com/insights/blog/2026/03/13/lessons-learned-…
#euhta #htar #jca #regulatoryaffairs #marketaccess -
ICON Plc
@ICONplc
Scientific rigor remains central to payer evaluations. At #amcp2026, ICON will be at booth 1412 to discuss robust RWE methods, transparent study design and analytical frameworks that strengthen formulary and access decisions. amcpannual.org
-
ICON Plc
@ICONplc
Join @ICONplc’s Dinah Knotts-Keeterle at #wvcdc as she discusses “AI and the future of vaccine studies from reaction to readiness”. Learn more on 4/1, 12:10 pm. www.terrapinn.com/conference/world-vaccine-congress-washi…
-
ICON Plc
@ICONplc
ICON’s 45+ Patient Centred Outcomes specialists delivered a strong 2025 including 12 papers, 2 educational events and broad COA experience across major therapy areas. We continue to produce focused, science‑led evidence for better decisions.
Learn more: icon.widen.net/s/lrwbzmfcjm/patient-centred-outcomes-2025… -
ICON Plc
@ICONplc
In the US sponsors generally follow one of two standards sets when conducting early phase trials: Good Manufacturing Practice (GMP) or United States Pharmacopeia (USP).
In this blog we look at each practice set and weigh their relative advantages: www.iconplc.com/insights/blog/2026/03/20/why-incorporatin… -
ICON Plc
@ICONplc
In 2025, the EMA and FDA each released regulatory guidance that impacts the development and approval processes for #biosimilars. Find out what this means for analytics and bioanalytics, clinical study design and commercialisation in our whitepaper. www.iconplc.com/insights/therapeutics/biosimilars/making-…
-
ICON Plc
@ICONplc
Fixed effect or random effects? The right choice depends on the level of heterogeneity across studies. The whitepaper sets out when each model is appropriate and how this influences interpretation. Download it today: www.iconplc.com/insights/value-based-healthcare/building-…
#metaanalysis #heterogeneity -
ICON Plc
@ICONplc
Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest clinical trial regulatory updates current: www.iconplc.com/insights/regulatory-intelligence/regulato…
#regulatoryintelligence #regulatorycompliance #regintel #clinicaltrials #medicaldevices #biotech #pharma -
ICON Plc
@ICONplc
In this latest BioXconomy analysis, Yao Zhong, Vice President and General Manager for ICON China Mainland and Hong Kong, shares insights that help contextualise what this momentum means for R&D partnerships and future development strategies. www.bioxconomy.com/partnering/china-biotech-continues-its…
-
ICON Plc
@ICONplc
Bioanalytical strategies are evolving to meet the growing complexity of biosimilar development. Explore the insights in our latest spotlight: icon.widen.net/s/jq7wzpwmqg/spotlight-evolving-bioanalyti…
#biosimilars #bioanalysis #drugdevelopment #biopharma -
ICON Plc
@ICONplc
ICON will be at #amcp2026 from 13–16 April. Visit booth 1412 to discuss how our evidence generation, real world data and market access expertise help demonstrate value and support payer decision making. Looking forward to connecting in Nashville. amcpannual.org
-
ICON Plc
@ICONplc
Network meta analysis depends on strong assumptions about transitivity and consistency. Our whitepaper explains how these are assessed and why they are essential for credible comparative evidence. Learn more: www.iconplc.com/insights/value-based-healthcare/building-…
#nma #evidencesynthesis #hta #heor -
ICON Plc
@ICONplc
As ADC indications expand, regulatory innovation must keep pace. Learn how accelerated approvals and orphan pathways support global access to these complex therapies. www.biospectrumasia.com/e-magazine
#adctherapies #clinicaltrials #lifesciences #pharma -
ICON Plc
@ICONplc
ICON’s 2025 China biotech survey report explores how digital technologies are reshaping R&D and clinical trial design.
9 out of 10 respondents expect AI‑enabled innovation to significantly accelerate development timelines.
Access the full report: www.iconplc.com/sectors/biotech/2025-china-biotech-survey… -
ICON Plc
@ICONplc
Join @ICONplc’s Dinah Knotts-Keeterle at #wvcdc as she discusses “AI and the future of vaccine studies from reaction to readiness”. Learn more on 4/1, 12:10 pm. www.terrapinn.com/conference/world-vaccine-congress-washi…
-
ICON Plc
@ICONplc
ICON and Advarra are partnering to form a ‘research ready’ connected sites model, integrating ICON’s clinical trial solutions with Advarra’s site technologies. This model will reduce site burden, accelerate study start up, and broaden research access. www.iconplc.com/news-events/press-releases/icon-and-advar…
-
ICON Plc
@ICONplc
How to navigate EU MAA Regulations and Registration. Download your copy today and get set for success www.iconplc.com/insights/regulatory-intelligence/procedur…
#regulatoryaffair #euctr #euclinicaltrialregulation #europeanmedicinesagency #nmpa #biotech -
ICON Plc
@ICONplc
Early evidence planning is now essential.
With new JSC windows and increased expert involvement, 2026 will reshape how sponsors prepare for EU JCAs. Details in our latest blog: www.iconplc.com/insights/blog/2026/03/13/lessons-learned-…
#euhta #htar #jca #regulatoryaffairs #marketaccess -
ICON Plc
@ICONplc
ICON will attend the 20th #wrib on 13–17 April in Dallas. Visit booth #31 to discuss how our PK, immunogenicity, biomarker, qPCR and flow cytometry expertise can enhance the success of your drug development program. www.wrib.org/index.php
-
ICON Plc
@ICONplc
Human ADME studies are essential for understanding how investigational drugs are absorbed, distributed, metabolised and excreted.
Read the full blog to see how bile sampling is reshaping human ADME and unlocking deeper understanding of drug behaviour. www.iconplc.com/insights/blog/2026/02/19/opportunities-bi… -
ICON Plc
@ICONplc
ICON’s 2025 Global biotech survey report provides new insights into how sponsors are preparing for growth amid evolving market dynamics.
Explore global R&D spending trends: www.iconplc.com/sectors/biotech/2025-global-biotech-surve… -
ICON Plc
@ICONplc
Join Thanh-Long Nguyen and other industry experts to discuss the latest developments in flow cytometry. This panel hosted by Bioanalysis Zone will explore how innovation is reshaping assay development and clinical trial execution.
Join us: www.bioanalysis-zone.com/webinars/spt_icon_fc_panel-discu… -
ICON Plc
@ICONplc
Patient led organisations are reshaping scientific and regulatory pathways in ultra rare diseases. Our recent webinar shared how real people are accelerating progress and bringing hope to families worldwide. Watch on demand: xtalks.com/webinars/when-patients-lead-breaking-barriers-…
-
ICON Plc
@ICONplc
EU HTAR’s first year is complete and 2026 is set to scale fast.
- ~50 JCAs expected
- High risk medical devices enter scope
- PICO complexity remains a key challenge
Read the full breakdown: www.iconplc.com/insights/blog/2026/03/13/lessons-learned-…
#euhta #htar #jca #regulatoryaffairs #marketaccess -
ICON Plc
@ICONplc
The future of #multiplesclerosis care is shifting—from relapse suppression to progression focused insight.
New ICD 10 subtype codes and real world evidence are unlocking more precise MS research.
Read more: www.iconplc.com/insights/blog/2026/03/12/future-multiple-… -
ICON Plc
@ICONplc
ICON’s long Nguyen will join the upcoming Bioanalysis Zone panel. Join the discussion as we explore challenges like instrument variability, outsourcing complexities, and the future of automation, imaging flow cytometry, and cloud‑based collaboration. www.bioanalysis-zone.com/webinars/spt_icon_fc_panel-discu…
-
ICON Plc
@ICONplc
Long‑acting injectables have reshaped HIV treatment, but they still can’t overcome the limits of ART. Our latest article explores next‑generation approaches that may move us closer to durable immunity. www.infectioncontroltoday.com/view/beyond-viral-suppressi…
-
ICON Plc
@ICONplc
#biosimilars developers will need to rethink their approach to stay competitive in the coming years. Learn how regulatory shifts, advances in modality, the competitive landscape and other factors impact biosimilar strategy in the whitepaper.
Download: www.iconplc.com/insights/therapeutics/biosimilars/making-… -
ICON Plc
@ICONplc
On 25 March at 03:00 PM, Dr. Anne Behringer will present virtually at #diaeurope where she will discuss “Cross-Border Recruitment in Clinical Trials: A Perspective on Operational Reality”. Explore more. www.diaglobal.org
-
ICON Plc
@ICONplc
ICON’s experts examine the challenges of ADC development and why early scientific advice, dose optimisation and accelerated designations are vital for efficient approval. www.biospectrumasia.com/e-magazine
#drugdevelopment #regaffairs #projectoptimus #oncologyresearch -
ICON Plc
@ICONplc
ICON’s 2025 China biotech survey report highlights the impact of accelerated approval timelines on innovation and global partnerships.
Regulatory review timelines shortened from 60 to 30 days in 2025.
Explore how reform is enabling faster market entry: www.iconplc.com/sectors/biotech/2025-china-biotech-survey… -
ICON Plc
@ICONplc
Human ADME studies are essential for understanding how investigational drugs are absorbed, distributed, metabolised and excreted.
Read the full blog to see how bile sampling is reshaping human ADME and unlocking deeper understanding of drug behaviour. www.iconplc.com/insights/blog/2026/02/19/opportunities-bi… -
ICON Plc
@ICONplc
Meet the @ICONplc team 30 March - 2 April at #wvcdc, booth 222 to learn how we have been supporting our clients’ vaccine development for a wide range of highly contagious and dangerous infectious diseases. www.terrapinn.com/conference/world-vaccine-congress-washi…
-
ICON Plc
@ICONplc
From advocacy to accelerated action.
Watch our recent webinar on patient led drug development for ultra rare diseases. Recording now available: xtalks.com/webinars/when-patients-lead-breaking-barriers-… -
ICON Plc
@ICONplc
In our latest article, we break down how smart formulation strategies, thoughtful placebo design, and right‑sized stability testing help accelerate early development while safeguarding study integrity. www.pharmtech.com/view/flexible-formulation-strategies-bo…
-
ICON Plc
@ICONplc
Visit us at #adpd2026, booth #29 to learn how our decentralised clinical trial solutions are focused on delivering data quicker to gain market access and reimbursement faster. adpd.kenes.com
-
ICON Plc
@ICONplc
Despite funding challenges, optimism prevails.
ICON’s 2025 Global biotech survey report shows sustained confidence in investment delivery and product success.
92% confident in meeting milestones
91% expect product success
Learn what drives this confidence: www.iconplc.com/sectors/biotech/2025-global-biotech-surve… -
ICON Plc
@ICONplc
83% of biotech leaders in China plan to increase R&D spending in the next 1–2 years.
China’s biotech sector continues to expand, with accelerated regulatory timelines and growing collaboration shaping R&D strategy.
Explore more: www.iconplc.com/sectors/biotech/2025-china-biotech-survey… -
ICON Plc
@ICONplc
ADCs are gaining momentum globally, but varied regulatory expectations make strategy essential. ICON outlines key considerations, from agency engagement to pathways like SAKIGAKE and Project Orbis. www.biospectrumasia.com/e-magazine
#adc #oncology #regulatorystrategy #biopharma -
ICON Plc
@ICONplc
Digitised protocols and agentic AI are accelerating study workflows and bringing earlier insights to teams. The future of clinical data science is intelligent and human focused.
Read more: www.iconplc.com/insights/blog/2026/03/09/future-clinical-… -
ICON Plc
@ICONplc
Join ICON’s Dr. Anne Behringer at #diaeurope on 25 March, 03:00 PM for a virtual presentation on ‘Cross-Border Recruitment in Clinical Trials: A Perspective on Operational Reality’. Learn more www.diaglobal.org
-
ICON Plc
@ICONplc
How to navigate EU MAA Regulations and Registration. Download your copy today and get set for success www.iconplc.com/insights/regulatory-intelligence/procedur…
#regulatoryaffair #euctr #euclinicaltrialregulation #europeanmedicinesagency #nmpa #biotech -
ICON Plc
@ICONplc
Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest clinical trial regulatory updates current: www.iconplc.com/insights/regulatory-intelligence/regulato…
#regulatoryintelligence #regulatorycompliance #regintel #medicaldevices #biotech #pharma #fda -
ICON Plc
@ICONplc
Rare autoimmune diseases and their treatment can reduce vaccine response. Read the article to find out how autoimmune conditions and different immunosuppressive treatments impact planning for vaccine schedules and boosters: www.infectioncontroltoday.com/view/uncertainty-strategy-g…
-
ICON Plc
@ICONplc
Human ADME studies are essential for understanding how investigational drugs are absorbed, distributed, metabolised and excreted.
Read the full blog to see how bile sampling is reshaping human ADME and unlocking deeper understanding of drug behaviour. www.iconplc.com/insights/blog/2026/02/19/opportunities-bi… -
ICON Plc
@ICONplc
Which modalities dominate global biotech pipelines?
ICON’s 2025 Global biotech survey report highlights where global sponsors are focusing R&D efforts and how these choices shape long‑term investment planning.
See the full pipeline breakdown: www.iconplc.com/sectors/biotech/2025-global-biotech-surve…This media couldn't be displayed. See it on the original post. -
ICON Plc
@ICONplc
From feasibility to activation, study start-up delays can erode momentum and inflate costs. ICON’s Brian Mallon offers perspective and outlines practical fixes, including AI-driven contracting, early site engagement, and strategic site selection. druganddeviceworld.com/2026/01/15/examining-the-growing-d…
-
ICON Plc
@ICONplc
In our latest article, we break down how smart formulation strategies, thoughtful placebo design, and right‑sized stability testing help accelerate early development while safeguarding study integrity. www.pharmtech.com/view/flexible-formulation-strategies-bo…
-
ICON Plc
@ICONplc
Vaccine guidance for patients with rare autoimmune diseases can be challenging. Learn how factors such as modality, mechanism of disease and the affected system can impact vaccine decisions in the article: www.infectioncontroltoday.com/view/uncertainty-strategy-g…
-
ICON Plc
@ICONplc
A new ICON involved study highlights key symptom burdens and life impacts in advanced/metastatic HCC, offering a patient centric model for future PRO use. Read more: pubmed.ncbi.nlm.nih.gov/41126800/
#hcc #oncology #patientexperience #iconplc -
ICON Plc
@ICONplc
As of 31 December 2024, women make up 70% of our workforce and hold 60% of director-level and above roles—a powerful reflection of the inclusive environment at ICON. Learn more in our latest #esg report www.iconplc.com/about/environmental-social-and-governance…
-
ICON Plc
@ICONplc
Meet ICON at booth #37 to discuss how we support efficient, flexible development for biotechs. Join Shelley McLendon on 10 March at 9:30am EST, where she will share a CRO perspective on the biotech landscape. www.arena-international.com/event/octsoutheast/
-
ICON Plc
@ICONplc
On 17-21 March at #adpd2026, visit us at booth #29 to learn how ICON is working to improve drug development and advance treatments for #alzheimer’s and Parkinson’s and other neurological disorders. adpd.kenes.com
-
ICON Plc
@ICONplc
The oncology R&D landscape is rapidly evolving, driven by the growing measurable impact of AI on discovery and development.
For a focused overview of the scientific and strategic forces influencing today’s oncology pipelines, read the full article:
www.iconplc.com/insights/blog/2026/01/09/current-landscap… -
ICON Plc
@ICONplc
ICON’s industry survey of 100+ sites and commentary from Brian Mallon, EVP Site & Patient Solutions, uncover the complexity, contractual hurdles, and communication gaps slowing progress, and the site-focused solutions that work. druganddeviceworld.com/2026/01/15/examining-the-growing-d…
-
ICON Plc
@ICONplc
For some rare autoimmune conditions, treatment-related infection may pose a higher mortality risk than the condition itself. Explore the importance of vaccines for these conditions, and considerations for vaccine schedules, in the article: www.infectioncontroltoday.com/view/uncertainty-strategy-g…
-
ICON Plc
@ICONplc
China’s life‑sciences sector continues to advance rapidly. In ICON’s latest blog, Yao Zhong outlines the key factors enabling innovation and shaping the region’s role in the global research ecosystem.
Read the full article:
www.iconplc.com/insights/blog/2026/01/09/enabling-innovation -
ICON Plc
@ICONplc
Human ADME studies are essential for understanding how investigational drugs are absorbed, distributed, metabolised and excreted.
Read the full blog to see how bile sampling is reshaping human ADME and unlocking deeper understanding of drug behaviour. www.iconplc.com/insights/blog/2026/02/19/opportunities-bi… -
ICON Plc
@ICONplc
This article in Select Science explores the evolving NIT landscape, emerging regulatory perspectives, and key opportunities to optimise MASH trial design and execution. www.selectscience.net/article/how-non-invasive-tools-are-…
-
ICON Plc
@ICONplc
On #worldobesityday, we’re raising awareness of the critical role research plays in better addressing obesity. Discover how ICON’s integrated approach from imaging and diagnostics to adjudication and RWE supports decisions in obesity clinical development. www.iconplc.com/therapeutics/obesity
-
ICON Plc
@ICONplc
New evidence supports the ODI instrument as a reliable tool for assessing disability in Degenerative Disc Disease. Cognitive interviews show patient interpretations match intended meanings across sections. Full study: rdcu.be/eX99w
#clinicaltrial #odi #backpainresearch -
ICON Plc
@ICONplc
At ADPD 2026, stop by booth #29 to learn how ICON combines informatics driven feasibility, extensive recruitment capabilities, and our Accellacare Site Network to support complex neurodegenerative trials.
Contact us to arrange a meeting at the conference. www.iconplc.com/contact -
ICON Plc
@ICONplc
Tomorrow is #worldobesityday. Read the case study to learn how ICON Medical Imaging supported a phase 3 randomised, double blind MASH study that eventually resulted in the first MASH drug approval from the FDA. www.iconplc.com/solutions/all-case-studies/high-volume-me…
#medicalimaging #clinicaltrials #mashstudy -
ICON Plc
@ICONplc
Clinical trial start-up can be a stubborn bottleneck, where delays can cost patient access. ICON’s commentary from Brian Mallon, EVP of Site and Patient Solutions, reveal why timelines are stretching and how site-centric strategies can reverse the trend. druganddeviceworld.com/2026/01/15/examining-the-growing-d…
-
ICON Plc
@ICONplc
In our latest article, we break down how smart formulation strategies, thoughtful placebo design, and right‑sized stability testing help accelerate early development while safeguarding study integrity. www.pharmtech.com/view/flexible-formulation-strategies-bo…
-
ICON Plc
@ICONplc
Human ADME studies are essential for understanding how investigational drugs are absorbed, distributed, metabolised and excreted.
Read the full blog to see how bile sampling is reshaping human ADME and unlocking deeper understanding of drug behaviour. www.iconplc.com/insights/blog/2026/02/19/opportunities-bi… -
ICON Plc
@ICONplc
Join us to explore the latest best practices in global flow cytometry QC and harmonisation.
During this webinar hosted by Bioanalysis Zone ICON’s flow cytometry specialists will discuss industry best practices for harmonisation of flow cytometry data.
www.bioanalysis-zone.com/webinars/spt_icon_fc_best-practi… -
ICON Plc
@ICONplc
The recent FDA draft guidance advances Bayesian trial design, enabling more efficient, data integrated studies. Get insights from ICON's Andrew Garret and Tim Clark. www.clinicaltrialsarena.com/features/the-bayesian-challen…
-
ICON Plc
@ICONplc
Ahead of #worldobesityday, learn about our proven success designing and executing early phase studies, supported by a robust database of overweight/obese healthy volunteers and in-house clinical research units to meet key eligibility targets. www.iconplc.com/solutions/early-clinical/early-phase-obes…
-
ICON Plc
@ICONplc
Join ICON at #oct Southeast on 10–11 March to learn how we support biotechs with flexible clinical development, operational expertise and data driven decision making. Visit booth #37 to get more insights. www.arena-international.com/event/octsoutheast/
-
ICON Plc
@ICONplc
Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest clinical trial regulatory updates current: www.iconplc.com/insights/regulatory-intelligence/regulato…
#regulatoryintelligence #regulatorycompliance #regintel #medicaldevices #biotech #pharma #fda -
ICON Plc
@ICONplc
This article in Select Science explores the evolving NIT landscape, emerging regulatory perspectives, and key opportunities to optimise MASH trial design and execution. www.selectscience.net/article/how-non-invasive-tools-are-…
-
ICON Plc
@ICONplc
Join Luke Gregory at #acdm26 as he explores why artificial intelligence is only one part of a truly effective clinical data science toolkit.
Attend this session to gain clear, actionable insight into selecting the right approach for each challenge. acdmconference.org/acdm26-programme/ -
ICON Plc
@ICONplc
This Spotlight hosted by Bioanalysis Zone brings together leading experts to explore how innovative platforms and strategic partnerships are transforming clinical research and boosting the impact of cell based biomarkers in global trials.
www.bioanalysis-zone.com/spotlights/spt_icon_fc_flow-cyto… -
ICON Plc
@ICONplc
Join our upcoming webinar on 3 March at 11am EST to hear directly from parent and patient leaders whose advocacy is driving first‑ever treatments and reshaping what is possible in ultra‑rare disease development. xtalks.com/webinars/when-patients-lead-breaking-barriers-… #rarediseaseday
-
ICON Plc
@ICONplc
Rare Disease patients face compounding barriers to clinical trial participation. Explore how ICON is supporting the development of safe and effective drugs for children living with a rare disease worldwide. www.iconplc.com/therapeutics/rare-orphan-diseases
#rarediseaseday #shareyourcolours -
ICON Plc
@ICONplc
ICON supported research identifies fatigue, weight loss, weakness, appetite loss & sleep disturbance as top symptoms in advanced/metastatic hepatocellular carcinoma, with broad impacts on daily life. Learn more: pubmed.ncbi.nlm.nih.gov/41126800/
#hcc #oncology #patientexperience #iconplc -
ICON Plc
@ICONplc
Meet ICON experts at #adpd2026, booth #29 to learn about our seamless integration of digital health technologies and digital biomarkers with the Atlas platform. adpd.kenes.com
-
ICON Plc
@ICONplc
From advocacy to accelerated approvals. Don’t miss our special #rarediseaseday webinar on patient led drug development innovations. Join us 3 March: xtalks.com/webinars/when-patients-lead-breaking-barriers-…
#rarediseaseday -
ICON Plc
@ICONplc
Heading to ADPD 2026? Visit ICON at booth #29 to discuss how our early development and neuroscience teams support more informed decision making in neurodegenerative research.
Contact us to arrange a meeting with our team at ADPD. www.iconplc.com/contact -
ICON Plc
@ICONplc
This article in Select Science explores the evolving NIT landscape, emerging regulatory perspectives, and key opportunities to optimise MASH trial design and execution. www.selectscience.net/article/how-non-invasive-tools-are-…
-
ICON Plc
@ICONplc
Join us to explore the latest best practices in global flow cytometry QC and harmonisation.
During this webinar hosted by Bioanalysis Zone ICON’s flow cytometry specialists will discuss industry best practices for harmonisation of flow cytometry data.
www.bioanalysis-zone.com/webinars/spt_icon_fc_best-practi… -
ICON Plc
@ICONplc
In this article, Dr. Liz O’Brien of ICON explains how #jca is driving earlier evidence generation, stronger patient‑focused trial design and more coordinated planning to support timely access to innovative cancer treatments.
Read the full article:
www.acrohealth.org/informed-content-hub/more-than-a-stati… -
ICON Plc
@ICONplc
In our latest article, we break down how smart formulation strategies, thoughtful placebo design, and right‑sized stability testing help accelerate early development while safeguarding study integrity. www.pharmtech.com/view/flexible-formulation-strategies-bo…
-
ICON Plc
@ICONplc
A new study validates the Oswestry Disability Index instrument for patients with Degenerative Disc Disease. High alignment across ODI sections supports its reliability, with a recommended 7-day recall period for better accuracy. Find out more: rdcu.be/eX99w
#odi -
ICON Plc
@ICONplc
This Spotlight hosted by Bioanalysis Zone brings together leading experts to explore how innovative platforms and strategic partnerships are transforming clinical research and boosting the impact of cell based biomarkers in global trials.
www.bioanalysis-zone.com/spotlights/spt_icon_fc_flow-cyto… -
ICON Plc
@ICONplc
This article in Select Science explores the evolving NIT landscape, emerging regulatory perspectives, and key opportunities to optimise MASH trial design and execution. www.selectscience.net/article/how-non-invasive-tools-are-…
-
ICON Plc
@ICONplc
In this Journal of mHealth article, Ashish Koul explains how open-source R software empowers CROs to modernise statistical workflows, cut costs and deliver more transparent, scalable analyses. Read more: thejournalofmhealth.com/the-r-in-cro-how-and-why-cros-sho…
-
ICON Plc
@ICONplc
The EU Joint Clinical Assessment (#jca), launched in 2025, is reshaping how oncology and #atmp trials are designed and assessed across Europe.
Dr. Liz O’Brien, ICON, outlines how JCA is changing global protocol strategy.
Read more here: www.acrohealth.org/informed-content-hub/more-than-a-stati… -
ICON Plc
@ICONplc
Join us to explore the latest best practices in global flow cytometry QC and harmonisation.
During this webinar hosted by Bioanalysis Zone ICON’s flow cytometry specialists will discuss industry best practices for harmonisation of flow cytometry data.
www.bioanalysis-zone.com/webinars/spt_icon_fc_best-practi… -
ICON Plc
@ICONplc
Patient leadership is reshaping ultra rare disease development. Hear real-world examples of regulatory and scientific breakthroughs bringing hope and accelerated approvals to patients. Register now: xtalks.com/webinars/when-patients-lead-breaking-barriers-…
#rarediseaseday -
ICON Plc
@ICONplc
Mechanism matters. The EMA is planning MoA-based PIP requirements.
Here’s what sponsors need to know about the proposal and what we learned from the US RACE ACT: www.iconplc.com/insights/blog/2026/01/07/mechanism-action… -
ICON Plc
@ICONplc
Every child and adolescent with cancer deserves the highest standard of care and access to research that can improve outcomes. Explore how we support oncology studies involving pediatric participants. www.iconplc.com/therapeutics/pediatrics
-
ICON Plc
@ICONplc
It’s #heartfailureawarenessweek. Many risk factors can be reduced, and new therapies are emerging. ICON supports the millions affected worldwide and applies deep cardiovascular research expertise to help accelerate safer, cost effective therapies. www.iconplc.com/therapeutics/cardiovascular
-
ICON Plc
@ICONplc
DHTs are no longer optional - they’re becoming core endpoints. Read why adoption is accelerating, how digital measures become biomarkers/COAs, and what FDA/EMA signals mean in our @BioPharmaTrend article: www.biopharmatrend.com/next-gen-tools/how-digital-health-…
#digitalhealth #digitalendpoints -
ICON Plc
@ICONplc
Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest clinical trial regulatory updates current: www.iconplc.com/insights/regulatory-intelligence/regulato…
#regulatoryintelligence #regulatorycompliance #regintel #medicaldevices #biotech #pharma #foodanddrugadministration -
ICON Plc
@ICONplc
Meet PLATO 11 - a new, validated PRO tool built with real patient input to capture how obstructive sleep apnoea impacts daily life, mood, cognition, and relationships. A big step forward for patient centred sleep care. Learn more: www.iconplc.com/insights/blog/2026/02/05/advancing-patien…
#osa #patientcentricity -
ICON Plc
@ICONplc
When patients lead, innovation happens. Join our Rare Disease Day webinar on 3 March to hear how patient leaders are making unprecedented progress in ultra rare drug development. Register now. xtalks.com/webinars/when-patients-lead-breaking-barriers-…
#rarediseaseday -
ICON Plc
@ICONplc
Is your AI model biased?
Many SaMD algorithms are due to imbalanced data, historic medical practices, or misdiagnosed training examples. Learn how to avoid these pitfalls in our latest blog. www.iconplc.com/insights/blog/2026/02/05/managing-ai-mode…
#samd #aibias #medtech #aiinhealthcare #digitalhealth -
ICON Plc
@ICONplc
AI in life sciences is only as strong as the data behind it.
Our new blog breaks down what “AI ready” data really means—and how Symphony Health is building the foundations for scalable, trustworthy AI across the industry.
Read more: www.iconplc.com/insights/blog/2026/01/13/from-ai-ambition… -
ICON Plc
@ICONplc
In recognition of Heart Failure Awareness Week, Symphony Health, an ICON plc company, is highlighting a critical reality: heart failure rarely occurs on its own.
Learn more: healthverity.com/symphony-health/understand-the-patient-j… -
ICON Plc
@ICONplc
DHTs are no longer optional - they’re becoming core endpoints. Read why adoption is accelerating, how digital measures become biomarkers/COAs, and what FDA/EMA signals mean in our @BioPharmaTrend article: www.biopharmatrend.com/next-gen-tools/how-digital-health-…
#digitalhealth #digitalendpoints -
ICON Plc
@ICONplc
In this article, our data standards experts Kent Letourneau and Sandra Minjoe explain how sponsors can efficiently prepare clinical data submissions that meet both FDA and PMDA requirements.
Read more in BioSpectrum Asia: www.biospectrumasia.com/opinion/29/26937/submitting-clini… -
ICON Plc
@ICONplc
Which modalities will define biotech innovation in 2026?
ICON’s 2025 biotech survey reports examine the modalities driving global and China-specific pipelines, revealing where biotech companies are investing and how this impacts funding and partnerships. www.iconplc.com/sectors/biotech/2025-biotech-survey-report -
ICON Plc
@ICONplc
Introducing PLATO 11 - a validated, free PRO tool developed by ICON + AASM to capture the real world impact of obstructive sleep apnoea. A major step toward more patient centred sleep care. Read our blog to learn more: www.iconplc.com/insights/blog/2026/02/05/advancing-patien…
#osa #patientcentricity -
ICON Plc
@ICONplc
Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest clinical trial regulatory updates current: www.iconplc.com/insights/regulatory-intelligence/regulato…
#regulatoryintelligence #regulatorycompliance #regintel #medicaldevices #biotech #pharma #foodanddrugadministration -
ICON Plc
@ICONplc
ICON is proud to support Heart Failure Awareness Week. Over the past five year, we have participated in 24 heart failure clinical studies, enrolling 2,400+ patients and healthy volunteers at 400+ sites. www.iconplc.com/therapeutics/cardiovascular #hfweek2026
-
ICON Plc
@ICONplc
Next week ICON Biotech sponsors #octwestcoast! Drop by booth #79 to speak with our experts, including Travis Caudill VP who will be giving a special featured presentation and appearing on a panel to discuss the latest AI developments in clinical trials. www.arena-international.com/event/octwestcoast/
-
ICON Plc
@ICONplc
ICON is a proud sponsor of this year’s #iscr Annual Conference, taking place in New Dehli from 13 – 14 February. Visit the ICON team at booth #g-11 to learn about our high-quality, global services and solutions to support more informed decision making. conference.iscr.org
-
ICON Plc
@ICONplc
Will changes at the #fda and #europeanmedicinesagency around #biosimilar trial requirements have far reaching implications? We discuss www.iconplc.com/insights/blog/2025/11/24/changing-regulat…
-
ICON Plc
@ICONplc
Geopolitical uncertainty impacts biotech but not equally.
ICON’s 2025 Biotech survey reports explore how global and China-based companies perceive risk and adapt to maintain growth.
Learn how these perceptions influence global collaboration strategies: www.iconplc.com/sectors/biotech/2025-biotech-survey-report -
ICON Plc
@ICONplc
AI may be able to provide a fuller understanding of tumour biology and to identify viable biomarkers. Find out how machine learning and deep learning are being used in our new article: pharmaphorum.com/digital/precision-medicine-meets-machine…
#unitedbyunique #worldcancerday -
ICON Plc
@ICONplc
This #worldcancerday, we’re reflecting on the power of real world data to improve cancer care.
Our latest work analysing the HER2⁺ metastatic breast cancer journey revealed that 94% begin on dual agent therapy.
Read case study: www.iconplc.com/solutions/all-case-studies/understanding-… -
ICON Plc
@ICONplc
SCOPE 2026 is almost here!
ICON’s specialists in labs, site and patient solutions, and biosimilars will join industry leaders in Orlando, 2–5 February. Learn more: www.scopesummit.com?matchtype=&adgroupid=&keyword=&creati… -
ICON Plc
@ICONplc
In 2025 ICON’s Creative and Digital Services and Global Medical Communications teams were recognised for delivering impactful medical communications for clients. www.iconplc.com/insights/blog/2026/01/06/2025-awards-and-…
-
ICON Plc
@ICONplc
Public scrutiny and regulatory pressure is mounting for sponsors to demonstrate vaccine safety through longer follow-up periods. Explore considerations for long-term follow-up on vaccines in our new whitepaper. www.iconplc.com/insights/therapeutics/infectious-diseases…
-
ICON Plc
@ICONplc
Biotech pipelines are evolving rapidly but not the same way everywhere.
ICON’s latest biotech surveys reveal striking regional differences in therapeutic priorities.
Dive into the full pipeline analysis here: www.iconplc.com/sectors/biotech/2025-biotech-survey-report -
ICON Plc
@ICONplc
Accellacare Site Network expands oncology research capabilities and specialist expertise through the Brian Moran Cancer Institute at Duly Health and Care.
Together, we’re committed accelerating access to new therapies for those affected by cancer.
www.iconplc.com/news-events/press-releases/icons-accellac… -
ICON Plc
@ICONplc
As of 31 December 2024, women make up 70% of our workforce and hold 60% of director-level and above roles—a powerful reflection of the inclusive environment at ICON. Learn more in our latest #esg report www.iconplc.com/about/environmental-social-and-governance…
-
ICON Plc
@ICONplc
As follow-up timelines extend into longer studies, it becomes increasingly challenging to track participants in the long term. Read the whitepaper to learn how to leverage clinical trial tokenisation in vaccine follow-up to overcome this obstacle. www.iconplc.com/insights/therapeutics/infectious-diseases…
-
ICON Plc
@ICONplc
In 2025 ICON was recognised for its commitment to building an inclusive workplace. Learn more. www.iconplc.com/insights/blog/2026/01/06/2025-awards-and-…
-
ICON Plc
@ICONplc
Despite their central role in glucose metabolism, native GLP-1 and GIP make poor therapies. Now, long-lasting, potent nutrient-stimulated hormone receptor agonists are prompting a shift to multi-indication metabolic therapies. Explore why. issuu.com/senglobal1/docs/2025-ibi_winter_2025
-
ICON Plc
@ICONplc
Our latest surveys reveal how therapeutic priorities differ across regions, highlighting the evolving focus areas that will shape pipelines and partnerships in the coming years.
Discover the factors driving these shifts and what they mean: www.iconplc.com/sectors/biotech/2025-biotech-survey-report -
ICON Plc
@ICONplc
ICON is attending #scope2026 in Orlando, 2–5 Feb.
Our team brings expertise in labs, site & patient solutions, and biosimilars—driving smarter, faster clinical development. Let’s talk. www.scopesummit.com?matchtype=&adgroupid=&keyword=&creati…
#clinicalresearch #patientcentricity -
ICON Plc
@ICONplc
ICON’s voice of the customer platform - EngageAI sets a new benchmark for clinical trial oversight. Harness AI-driven insights to elevate sponsor experience.
Discover how ICON is setting a new standard for customer-centric clinical research. www.iconplc.com/solutions/technologies/ai-icon/engageaiThis media couldn't be displayed. See it on the original post. -
ICON Plc
@ICONplc
Advancements in HIV prevention and treatment could help to simplify HIV control. ICON’s new whitepaper highlights best practices for designing and validating therapies that reflect post‑approval realities.
Find out more: www.iconplc.com/insights/therapeutics/infectious-diseases… -
ICON Plc
@ICONplc
PubsHub Journals & Congresses now includes publication AI policy guidelines, ensuring ethical use and transparency in research. Whether you use AI to analyze data or draft manuscripts, learn what’s required for compliance. See for yourself with a demo: www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
#octwestcoast will be returning to Burlingame for the 18th annual event on 11-12 February. Pass by booth #79 and engage with ICON Biotech’s professionals on the latest in drug development. www.arena-international.com/event/octwestcoast/
-
ICON Plc
@ICONplc
Many developers aiming to capitalise on multi-indication metabolic assets would benefit from adopting trials designed to generate more holistic insights on therapeutic efficacy. Explore these innovative trial designs in our article. issuu.com/senglobal1/docs/2025-ibi_winter_2025
-
ICON Plc
@ICONplc
6 strategies for regulatory resilience to help organisation navigate shifts and embed structured processes into their labelling strategy. www.pm360online.com/pharma-communications-resilience-navi…
#dtcads #opdp #pharmacomms #compliance #foodanddrugadministration #medicallabeling -
ICON Plc
@ICONplc
In 2025 ICON was independently recognised as a leading CRO for both Ph1 and Ph 2/3 studies and was also awarded Best CRO in APAC. Learn more. www.iconplc.com/insights/blog/2026/01/06/2025-awards-and-…
-
ICON Plc
@ICONplc
For the third year in a row, ICON is on #time & #statista’s World’s Best Companies list! A huge shoutout to our amazing teams who make this possible. time.com/7315547/worlds-best-companies-of-2025/
#worldsbestcompanies -
ICON Plc
@ICONplc
Planning for long-term follow-up early in the vaccine development process is critical to effectively collecting and utilising RWD. Learn when to plan, and how to design follow-up that is appropriate to your vaccine candidate, in the whitepaper. www.iconplc.com/insights/therapeutics/infectious-diseases…
-
ICON Plc
@ICONplc
On Jan 5, 2026, ICON China joined a Beijing business dinner during Irish PM Micheál Martin’s visit. Discussions centered on China‑Ireland trade ties. ICON China remains committed to strengthening collaboration to advance clinical research.
-
ICON Plc
@ICONplc
Find out how to separate the random forests from the decision trees in our latest whitepaper on AI in SaMD. Learn about model and data best practices when developing AI-enabled SaMDs, download it today. www.iconplc.com/insights/digital-disruption/software-medi…
-
ICON Plc
@ICONplc
With over 10,000 journals and conferences to consider it’s an important question to answer. There are 50+ accessible points of metadata to use in focusing your selection for a publishing source. Schedule a demo to learn more. www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
Public scrutiny and regulatory pressure is mounting for sponsors to demonstrate vaccine safety through longer follow-up periods. Explore considerations for long-term follow-up on vaccines in our new whitepaper. www.iconplc.com/insights/therapeutics/infectious-diseases…
-
ICON Plc
@ICONplc
Compounds that mimic incretin hormones hold significant promise as therapies and research tools. Read our article to learn more about the multi-indication potential of drugs that modulate glucose metabolism. issuu.com/senglobal1/docs/2025-ibi_winter_2025
-
ICON Plc
@ICONplc
Deepali Suri shares her vision for the biotech sector in 2026 and beyond.
With over two decades of experience across pharma, biotech, and CROs, she outlines a clear strategy to strengthen innovation and streamline development.
Learn more in this blog: www.iconplc.com/insights/blog/2026/01/06/bring-biotechs -
ICON Plc
@ICONplc
ICON’s new HIV whitepaper shares insights into biological, behavioral, and sociocultural barriers to infection control — and how innovative therapeutics and trial designs can help overcome them. Explore more. www.iconplc.com/insights/therapeutics/infectious-diseases…
-
ICON Plc
@ICONplc
In 2025 ICON was recognised in global rankings by both TIME and Fortune magazines celebrating organisations excelling in financial stability and environmental sustainability. Learn more. www.iconplc.com/insights/blog/2026/01/06/2025-awards-and-…
-
ICON Plc
@ICONplc
The key to estimating biological risk in medical devices is establishing a good comparison. However, identifying the right comparison can be challenging. Learn how: www.iconplc.com/insights/blog/2025/12/11/managing-risk-me…
#regulatoryaffairs #medicaldevices #iso #medsafety -
ICON Plc
@ICONplc
Discover the differences between AI models for SaMDs. Learn the pros and cons of each, and how to work with training datasets in our latest AI in SaMD whitepaper. Download it today. www.iconplc.com/insights/digital-disruption/software-medi…
-
ICON Plc
@ICONplc
Advancements in HIV prevention and treatment could help to simplify HIV control. ICON’s new whitepaper highlights best practices for designing and validating therapies that reflect post‑approval realities.
Find out more. www.iconplc.com/insights/therapeutics/infectious-diseases… -
ICON Plc
@ICONplc
Regulatory changes at the EMA & FDA promise a boon for #biosimilar developers. But there are nuances needing careful consideration. www.iconplc.com/insights/blog/2025/11/24/changing-regulat…
-
ICON Plc
@ICONplc
EMA’s MoA PIP proposal could mean big changes for pediatric drug development.
Read our blog to learn more: www.iconplc.com/insights/blog/2026/01/07/mechanism-action…
#pediatrics #regulatorycompliance #clinicaltrials #pharmacovigilance -
ICON Plc
@ICONplc
Find out how to separate the random forests from the decision trees in our latest whitepaper on AI in SaMD. Learn about model and data best practices when developing AI-enabled SaMDs, download it today. www.iconplc.com/insights/digital-disruption/software-medi…
-
ICON Plc
@ICONplc
PubsHub Journals & Congresses makes it faster and easier for your team to identify the ideal publication venue for your work. With advanced search capabilities you can make informed decisions with confidence. Request a demo: www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
Change is accelerating. Organisations best positioned to succeed will be those that adapt quickly. Read ICON’s guide to resilient pharma comms: www.pm360online.com/pharma-communications-resilience-navi…
#dtcads #opdp #pharmacomms #compliance #foodanddrugadministration #medicallabeling -
ICON Plc
@ICONplc
ICON received a range of prestigious awards and brand recognition in 2025. Learn more: www.iconplc.com/insights/blog/2026/01/06/2025-awards-and-…
-
ICON Plc
@ICONplc
The J.P. Morgan Healthcare Conference brings together investors, industry leaders, and innovators to discuss 2026’s key trends. Want to meet our team at JPM or Biotech Showcase in San Francisco? Contact us to schedule a meeting. investor.iconplc.com/investor-contact
-
ICON Plc
@ICONplc
From patients to investigators, people play a critical role in cardiovascular outcome trials. Discover how to remove barriers, increase efficiencies, and lay the groundwork for long-term success by considering the human element of CVOTs. issuu.com/senglobal1/docs/ipi_-_volume_17_issue_4_-_winte…
-
ICON Plc
@ICONplc
Discover the differences between AI models for SaMDs. Learn the pros and cons of each, and how to work with training datasets in our latest AI in SaMD whitepaper. Download it today. www.iconplc.com/insights/digital-disruption/software-medi…
-
ICON Plc
@ICONplc
Happy Holidays from all of us at ICON.
We’re sending every best wish for health, happiness and success in 2026. -
ICON Plc
@ICONplc
CRAs are no longer just monitors, they’re strategic site partners.
Discover how tech is driving this shift in this ACT article featuring ICON’s Helen Yeardley. www.appliedclinicaltrialsonline.com/view/cra-role-evoluti… -
ICON Plc
@ICONplc
ICON drove 95% compliance & 97.7% retention in a fully remote Alzheimer’s trial with 600+ participants, completing enrolment 3 weeks early. Patient-centricity redefined. Learn more: www.iconplc.com/solutions/all-case-studies/improving-comp…
#decentralisedtrials #patientcentricity -
ICON Plc
@ICONplc
The integration of tools such as polygenic risk scoring and digital health technologies can significantly impact the people involved in cardiovascular outcome trials. Read the article for tools and human-centric strategies for shaping CVOT success. issuu.com/senglobal1/docs/ipi_-_volume_17_issue_4_-_winte…
-
ICON Plc
@ICONplc
Find out how to separate the random forests from the decision trees in our latest whitepaper on AI in SaMD. Learn about model and data best practices when developing AI-enabled SaMDs, download it today. www.iconplc.com/insights/digital-disruption/software-medi…
-
ICON Plc
@ICONplc
The J.P. Morgan Healthcare Conference brings together investors, industry leaders, and innovators to discuss 2026’s key trends. Want to meet our team at JPM or Biotech Showcase in San Francisco? Contact us to schedule a meeting. investor.iconplc.com/investor-contact
-
ICON Plc
@ICONplc
CRAs are no longer just monitors, they’re strategic site partners.
Discover how tech is driving this shift in this ACT article featuring ICON’s Helen Yeardley. www.appliedclinicaltrialsonline.com/view/cra-role-evoluti… -
ICON Plc
@ICONplc
Hybrid VMS study results: >90% ePRO, >80% actigraphy, >75% eDiary compliance. ICON shows reducing burden doesn’t mean sacrificing quality. Learn more: www.iconplc.com/solutions/all-case-studies/reducing-parti…
#vmsresearch #patientengagement -
ICON Plc
@ICONplc
One of the most valuable Journals & Congresses features is Watchlists. The system will send you updates on your priority list whenever updated information is available. Deadline changes, location confirmation, detail updates. Request a demo. www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
Metys®, from Symphony Health, an ICON plc company, is the only fully integrated platform that consolidates over 150 metrics and dimensions – giving you a complete, real-time view of the healthcare market.
Explore Metys: healthverity.com/symphony-health/health-technology-and-bu… -
ICON Plc
@ICONplc
Although advances in antiretroviral therapies are helping to curtail the HIV epidemic, there are limitations introduced by access and adherence. Find out what developers need to know when navigating these obstacles in the recent article. www.infectioncontroltoday.com/view/investing-anti-hiv-how…
-
ICON Plc
@ICONplc
How to navigate EU MAA Regulations and Registration. Download your copy today and get set for success www.iconplc.com/insights/regulatory-intelligence/procedur…
#regulatoryaffair #euctr #euclinicaltrialregulation #europeanmedicinesagency #nmpa #biotech -
ICON Plc
@ICONplc
Not all #biologics reach their target. Want to know what’s missing in next-gen drug delivery? Read our latest CMC article in BioPharm International www.biopharminternational.com/view/formulation-strategies…
#regulatoryaffairs #regulatorycompliance #patientsafety #combinationproducts -
ICON Plc
@ICONplc
Among the most challenging parts of cardiovascular outcome trials are the people involved. Learn how to strategically plan for the human element of CVOTs, including in patient selection, data capture and retention, in the article. issuu.com/senglobal1/docs/ipi_-_volume_17_issue_4_-_winte…
-
ICON Plc
@ICONplc
The key to estimating biological risk in medical devices is establishing a good comparison. However, identifying the right comparison can be challenging. Learn how: www.iconplc.com/insights/blog/2025/12/11/managing-risk-me…
#regulatoryaffairs #medicaldevices #iso #medsafety -
ICON Plc
@ICONplc
Proud to earn an RxClub Award of Excellence for the ISMPP Academy Poster! Kudos to our teams for outstanding creativity in medical communications.
#rxclubawards #designexcellence -
ICON Plc
@ICONplc
Will changes at the #fda and #europeanmedicinesagency around #biosimilar trial requirements have far reaching implications? We discuss www.iconplc.com/insights/blog/2025/11/24/changing-regulat…
-
ICON Plc
@ICONplc
Discover the differences between AI models for SaMDs. Learn the pros and cons of each, and how to work with training datasets in our latest AI in SaMD whitepaper. Download it today. www.iconplc.com/insights/digital-disruption/software-medi…
-
ICON Plc
@ICONplc
We are thrilled to win three 2025 GDUSA Health + Wellness Awards - congratulations to our talented teams!
#gdusa #designexcellence -
ICON Plc
@ICONplc
Metys®, from Symphony Health, an ICON plc company, is the only fully integrated platform that consolidates over 150 metrics and dimensions – giving you a complete, real-time view of the healthcare market.
Explore Metys: healthverity.com/symphony-health/health-technology-and-bu… -
ICON Plc
@ICONplc
Collecting data through clinical trial tokenisation enables a longitudinal view of patient health, with insights from before and after a clinical trial. Discover how tokenisation can benefit vaccine long-term follow up, and how to plan for it. www.iconplc.com/insights/therapeutics/infectious-diseases…
-
ICON Plc
@ICONplc
AI and predictive analytics are transforming clinical data risk management. CRAs are essential to successful trial.
Read more on how tech empowers, not replaces, the CRA. Read the ACT article: www.appliedclinicaltrialsonline.com/view/cra-role-evoluti… -
ICON Plc
@ICONplc
Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest clinical trial regulatory updates current: www.iconplc.com/insights/regulatory-intelligence/regulato…
#regulatoryintelligence #regulatorycompliance #medicaldevices #biotech #pharma #mhra #fda #europeanmedicinesagency -
ICON Plc
@ICONplc
As of 31 December 2024, women make up 70% of our workforce and hold 60% of director-level and above roles—a powerful reflection of the inclusive environment at ICON. Learn more in our latest #esg report www.iconplc.com/about/environmental-social-and-governance…
-
ICON Plc
@ICONplc
With PubsHub Journals & Congresses, you’ll receive real-time alerts for updates, extensions, and changes to deadlines on your personalized watch list. That means fewer surprises - and better decisions. Request a demo today. www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
Traditional trial settings often fail to reveal the added value of emerging HIV therapies. Explore how developers can plan trials that demonstrate the true advantages and utility of an HIV intervention in the article from ICON. www.infectioncontroltoday.com/view/investing-anti-hiv-how…
-
ICON Plc
@ICONplc
Find out how to separate the random forests from the decision trees in our latest whitepaper on AI in SaMD. Learn about model and data best practices when developing AI-enabled SaMDs, download it today. www.iconplc.com/insights/digital-disruption/software-medi…
-
ICON Plc
@ICONplc
CRAs are moving from data checkers to strategic partners. Learn how tech & governance are driving this shift in Pharma Times: magazine.pharmatimes.com/collections/pharmatimes-december…
-
ICON Plc
@ICONplc
Site attrition during study startup is a challenge. Read ICON’s latest whitepaper to learn how our over-selection model helps sponsors stay ahead and meet enrolment targets. Download the whitepaper: www.iconplc.com/insights/transforming-trials/bottlenecks-…
-
ICON Plc
@ICONplc
Regulatory affairs is now a boardroom imperative. Pharma must master 1. Regulatory modernisation and divergence 2. Integration of real-world evidence and digital data 3. Oversight of AI, advanced manufacturing and novel modalities. Read more: www.drugdiscoverytrends.com/regulatory-strategy-reimagine…
-
ICON Plc
@ICONplc
ICON named to @TIME World’s Most #sustainable Companies 2025. Amazing recognition for our #iconcares #esg programme: www.iconplc.com/about/environmental-social-and-governance
-
ICON Plc
@ICONplc
In the next blog in our series, we explore what ISO 10993-1 means in the context of evaluating the biological risk associated with medical devices. Learn more: www.iconplc.com/insights/blog/2025/10/31/managing-risk-me…
#regulatoryaffairs #medicaldevices #iso #medsafety -
ICON Plc
@ICONplc
From wearables to ePROs, trials are data-rich and decentralised. CRAs must evolve. ICON’s Helen Yeardley explores this evolution in Applied Clinical Trials. www.appliedclinicaltrialsonline.com/view/cra-role-evoluti…
-
ICON Plc
@ICONplc
As follow-up timelines extend into longer studies, it becomes increasingly challenging to track participants in the long term. Read the whitepaper to learn how to leverage clinical trial tokenisation in vaccine follow-up to overcome this obstacle. www.iconplc.com/insights/therapeutics/infectious-diseases…
-
ICON Plc
@ICONplc
ICON Biotech’s 2025 surveys reveal how funding pressures, therapeutic priorities, and confidence vary globally and in China’s fast-growing biotech market. Insights from 260+ leaders plus VC analysis. Download both reports: www.iconplc.com/sectors/biotech/2025-biotech-survey-report
#biotech #lifesciences -
ICON Plc
@ICONplc
Only one week to go so hurry to secure your spot to hear about how ICH GCP E6(R3) is redefining global standards and what you can do to comply. Register now: xtalks.com/webinars/ich-gcp-e6r3-preparing-for-global-imp…
#clinicaltrials #ichgcp #regulatorycompliance #regulatorysubmissions -
ICON Plc
@ICONplc
Metys®, from Symphony Health, an ICON plc company, is the only fully integrated platform that consolidates over 150 metrics and dimensions – giving you a complete, real-time view of the healthcare market.
Explore Metys: healthverity.com/symphony-health/health-technology-and-bu… -
ICON Plc
@ICONplc
New JMIR study powered by Symphony Health data shows Dario’s digital diabetes solution works:
✔ 23.5% fewer hospitalizations
✔ $5,077 annual savings per user
✔ Lower HCRU & charges
Real-world evidence matters—and Symphony Health delivers it.
Read more: www.jmir.org/2025/1/e67320/ -
ICON Plc
@ICONplc
92% of sites say sponsors and CROs must improve contract/budget support. ICON is leading the way with automation and alignment. Learn more: www.iconplc.com/insights/transforming-trials/bottlenecks-…
-
ICON Plc
@ICONplc
Discover the differences between AI models for SaMDs. Learn the pros and cons of each, and how to work with training datasets in our latest AI in SaMD whitepaper. Download it today. www.iconplc.com/insights/digital-disruption/software-medi…
-
ICON Plc
@ICONplc
Meet @ICONplc’s cardio-metabolic experts at #cvct25 to learn how we’re addressing CV trial challenges and improving outcomes through efficient trial design, digital technologies, real-world data, and optimal patient recruitment. www.globalcvctforum.com
-
ICON Plc
@ICONplc
ICON was amongst several leading Irish businesses that participated in the first Ireland-Ukraine Economic Forum: www.ireland.ie/en/ireland-and-ukraine-economic-forum-with…
-
ICON Plc
@ICONplc
The CRA role is evolving—from data checker to strategic partner. ICON’s Helen Yeardley explores how technology is reshaping clinical trial oversight. Read the Applied Clinical Trials article: www.appliedclinicaltrialsonline.com/view/cra-role-evoluti…
-
ICON Plc
@ICONplc
Therapeutic developers can reshape the future of HIV control by creating interventions that are effective despite persistent real-world challenges. Discover what developers need to take into consideration to make a real-world impact. www.infectioncontroltoday.com/view/investing-anti-hiv-how…
-
ICON Plc
@ICONplc
Planning for long-term follow-up early in the vaccine development process is critical to effectively collecting and utilising RWD. Learn when to plan, and how to design follow-up that is appropriate to your vaccine candidate, in the whitepaper. www.iconplc.com/insights/therapeutics/infectious-diseases…
-
ICON Plc
@ICONplc
“A strategic partnership is a two-way street. It requires consultants to be authoritative in their recommendations, honest in their assessments and committed to long-term client success.” Learn more: www.iconplc.com/insights/blog/2025/10/16/customer-advocac…
#customeradvocacy #futureofpharma #voiceofthecustomer -
ICON Plc
@ICONplc
Reaching the right audience is a critical decision. Use the system that does the work for you. Journals & Congresses helps you compare your options on the data points most important to you in making your decision. Get a demo. www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
Early phase neurodegenerative trials require careful planning, a patient-first approach, and biomarker strategies that drive progress. Watch the webinar: www.iconplc.com/news-events/events/webinars/strategic-app…
-
ICON Plc
@ICONplc
ICON is excited to join #scdm India, 4 – 6 December in Hyderabad! Visit us at booth #22 and learn how we’re shaping the future of clinical data management through innovation and expertise. Don’t miss ICON sessions. scdmlive.org/india25-programme/
-
ICON Plc
@ICONplc
Contract and budget delays are the #1 barrier to activation. ICON’s SmartDraft tool streamlines negotiations and reduces cycle times by up to 50%. Explore the insights: www.iconplc.com/insights/transforming-trials/bottlenecks-…
-
ICON Plc
@ICONplc
2026: JCAs expand to high-risk devices & IVDs
ICON’s guide helps you prepare for what’s coming. www.iconplc.com/insights/regulatory-intelligence/meeting-…
#medtech #ivd #hta #iconinsights -
ICON Plc
@ICONplc
Not all #biologics reach their target. Want to know what’s missing in next-gen drug delivery? Read our latest CMC article in BioPharm International www.biopharminternational.com/view/formulation-strategies…
#regulatoryaffairs #regulatorycompliance #patientsafety #combinationproducts -
ICON Plc
@ICONplc
How to navigate EU MAA Regulations and Registration. Download your copy today and get set for success www.iconplc.com/insights/regulatory-intelligence/procedur…
#regulatoryaffair #euctr #euclinicaltrialregulation #europeanmedicinesagency #nmpa #biotech -
ICON Plc
@ICONplc
Open claims data is powerful—but disruptions are inevitable. Learn how to manage them strategically in our upcoming webinar with Symphony Health.
Key takeaways:
•Spot and assess disruptions
•Collaborate effectively
•Use alerts & mitigation tools
www.iconplc.com/news-events/events/webinars/riding-data-w… -
ICON Plc
@ICONplc
The biotech landscape is evolving fast. ICON Biotech’s latest sector surveys reveal what’s
changed since 2023, which therapeutic areas are slowing down, and which modalities are
gaining momentum.
Register now to receive our survey reports. www.iconplc.com/sectors/biotech/2025-biotech-survey-report -
ICON Plc
@ICONplc
From prescriptions to patient demographics, Metys®, from Symphony Health, an ICON plc company, sees it all.
With over 150+ metrics – from diagnosis subgroups to payer mis – you get the full picture, not just a snapshot.
Explore Metys: healthverity.com/symphony-health/health-technology-and-bu… -
ICON Plc
@ICONplc
Public scrutiny and regulatory pressure is mounting for sponsors to demonstrate vaccine safety through longer follow-up periods. Explore considerations for long-term follow-up on vaccines in our new whitepaper. www.iconplc.com/insights/therapeutics/infectious-diseases…
-
ICON Plc
@ICONplc
Regulatory changes at the EMA & FDA promise a boon for #biosimilar developers. But there are nuances needing careful consideration. www.iconplc.com/insights/blog/2025/11/24/changing-regulat…
-
ICON Plc
@ICONplc
USP compounding may be fast — but is it costing you quality, compliance, and insight? Listen to the recording to discover how GMP manufacturing can improve trial outcomes, reduce risk, and support regulatory success. www.iconplc.com/news-events/events/webinars/beyond-bench-…
-
ICON Plc
@ICONplc
Bringing together safety and efficacy data from multiple studies can be complex.
This blog outlines practical approaches to preparing an Integrated Summary of Safety and Efficacy (ISS/ISE) that supports clear, consistent and submission-ready results. www.iconplc.com/insights/blog/2025/10/27/strategies-succe… -
ICON Plc
@ICONplc
Join ICON for “Science on Tap” — an evening of discovery, discussion, and holiday cheer! Explore cutting-edge research in precision medicine and bioanalytical laboratory innovation with our expert scientists.
If you are interested please register here: www.iconplc.com/news-events/events/industry/science-tap -
ICON Plc
@ICONplc
On World AIDS Day, we honour progress & confront challenges. ICON's new whitepaper explores how biological & social barriers confound HIV control, and the R&D innovations shaping future therapies. Download now. www.iconplc.com/insights/therapeutics/infectious-diseases…
#worldaidsday #hivresearch -
ICON Plc
@ICONplc
Don’t miss out! Join us 3 Dec | 10am ET for proven strategies to accelerate site activation & enrolment to become a sponsor of choice.
Secure your spot now: www.iconplc.com/news-events/events/webinars/becoming-spon…
#siteengagement #webinar #sponsorofchoice -
ICON Plc
@ICONplc
Today is World AIDS Day. HIV continues to impact millions worldwide, but progress is possible through research and education. Watch our latest video to learn why ongoing research matters and learn more about FIRECREST: www.iconplc.com/solutions/technologies/firecrest
-
ICON Plc
@ICONplc
December 1 is #worldsaidsday. According to WHO, HIV remains a major global public health issue, having claimed an estimated 42.3M lives to date. ICON has participated in 33 HIV studies in the past 5 years. Learn more.www.iconplc.com/therapeutics/infectious-diseases
-
ICON Plc
@ICONplc
Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest clinical trial regulatory updates current: www.iconplc.com/insights/regulatory-intelligence/regulato…
#regulatoryintelligence #regulatorycompliance #medicaldevices #biotech #pharma #mhra #fda #europeanmedicinesagency -
ICON Plc
@ICONplc
Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest clinical trial regulatory updates current: www.iconplc.com/insights/regulatory-intelligence/regulato…
#regulatoryintelligence #regulatorycompliance #medicaldevices #biotech #pharma #mhra #fda #europeanmedicinesagency -
ICON Plc
@ICONplc
Join ICON on 6 December at #scdmindia in Hyderabad for the closing keynote, “Reimagining Research: Where patients, sites, and technology converge,” presented by Rose Kidd, President of Operations Delivery, from 3:45 pm to 4:45 pm. scdmlive.org/india-conference-2025/
-
ICON Plc
@ICONplc
ICON provides in-house cardiac safety monitoring solutions across all phases of trials. Meet our experts at CVCT 2025 to learn how we can support your cardiovascular program. www.globalcvctforum.com
-
ICON Plc
@ICONplc
Regulatory affairs has become a boardroom imperative. Pharma must master
1. Regulatory modernisation and divergence
2. Integration of real-world evidence and digital data
3. Oversight of AI, advanced manufacturing and novel modalities.
Read more: www.drugdiscoverytrends.com/regulatory-strategy-reimagine… -
ICON Plc
@ICONplc
Join ICON for “Science on Tap” — an evening of discovery, discussion, and holiday cheer! Explore cutting-edge research in precision medicine and bioanalytical laboratory innovation with our expert scientists.
If you are interested please register here: www.iconplc.com/news-events/events/industry/science-tap -
ICON Plc
@ICONplc
Congress attendance is expensive, and arrangements are time consuming. Use Journals & Congresses to make decisioning faster and easier with 50+ data fields to compare options and make the most of your attendance. Request a demo! www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
November = #epilepsyawarenessmonth.
Millions face this chronic condition daily, and innovation is key.
Symphony Health’s Metys® platform brings near real-time data + analytics to uncover trends in the epilepsy market.
Learn more: healthverity.com/symphony-health/health-technology-and-bu… -
ICON Plc
@ICONplc
In the next blog in our series, we explore what ISO 10993-1 means in the context of evaluating the biological risk associated with medical devices. Learn more: www.iconplc.com/insights/blog/2025/10/31/managing-risk-me…
#regulatoryaffairs #medicaldevices #iso #medsafety -
ICON Plc
@ICONplc
By easing the burden of participating in a clinical trial, In-Home Services improves patient recruitment and retention with a patient centric approach. Speak with ICON experts at #ash25, booth #2161 to learn more. congress-registration1.org/ash2025/
-
ICON Plc
@ICONplc
Join ICON for “Science on Tap” — an evening of discovery, discussion, and holiday cheer! Explore cutting-edge research in precision medicine and bioanalytical laboratory innovation with our expert scientists.
If you are interested please register here: www.iconplc.com/news-events/events/industry/science-tap -
ICON Plc
@ICONplc
15+ years of healthcare data. Weekly and monthly.
Metys®, from Symphony Health, and ICON plc company, gives you unmatched historical depth to track product trends, market shifts, and lifecycle performance with precision.
Explore Metys: healthverity.com/symphony-health/health-technology-and-bu… -
ICON Plc
@ICONplc
AMR week highlights the importance of education, proper antibiotic use and global collaboration. Proper hand hygiene reduces infection risk and helps preserve the effectiveness of antibiotics—critical in the fight against antimicrobial resistance. www.iconplc.com/therapeutics/infectious-diseases
-
ICON Plc
@ICONplc
ICH GCP E6(R3) is redefining global standards. Are you ready? Join ICON’s regulatory experts on 16 Dec for a free webinar on impact, risk & implementation.
Register now: xtalks.com/webinars/ich-gcp-e6r3-preparing-for-global-imp…
#clinicaltrials #ichgcp #regulatorycompliance #regulatorysubmissions -
ICON Plc
@ICONplc
Open claims data is powerful—but disruptions are inevitable. Learn how to manage them strategically in our upcoming webinar with Symphony Health.
Key takeaways:
•Spot and assess disruptions
•Collaborate effectively
•Use alerts & mitigation tools
www.iconplc.com/news-events/events/webinars/riding-data-w… -
ICON Plc
@ICONplc
Join ICON for “Science on Tap” — an evening of discovery, discussion, and holiday cheer! Explore cutting-edge research in precision medicine and bioanalytical laboratory innovation with our expert scientists.
If you are interested please register here: www.iconplc.com/news-events/events/industry/science-tap -
ICON Plc
@ICONplc
As we mark World Antimicrobial Awareness Week, it’s time to spotlight innovative solutions to AMR. ICON’s article examines bacteriophage therapy and its potential to fight multidrug-resistant infections.
Learn more: www.infectioncontroltoday.com/view/multidrug-resistant-in… -
ICON Plc
@ICONplc
Looking to maximise your 2025 budget? Add Social Determinants of Health (SDoH) to your data strategy. Understand the “why” behind patient behavior & drive better outcomes.
Learn more: www.iconplc.com/insights/blog/2024/01/12/how-pharma-can-u… -
ICON Plc
@ICONplc
Join ICON at #scdmindia, 4–6 December in Hyderabad! Visit booth #22 to learn how we’re driving innovation in clinical data management and shaping the future of trials. Connect with our experts. scdmlive.org/india-conference-2025/
-
ICON Plc
@ICONplc
ICON is a proud supporter of #worldchildrensday. In the past 5 years, ICON has participated in 420+ clinical studies involving pediatric patients, enrolling 227,600+ patients at 19,200+ sites. Learn more: www.iconplc.com/therapeutics/pediatrics
#childrensrights -
ICON Plc
@ICONplc
ICON’s Centre for Pediatric Clinical Development are proud supporters of #worldchildrensday. We provide innovative pediatric strategy and support to all programs involving neonates, children and young adults. Learn more: www2.iconplc.com/Fact_Sheet_Paediatric_Centre
#childrensrights -
ICON Plc
@ICONplc
Meet ICON experts at #ash25, booth #2161 to learn about our Centre for Pediatric Clinical Development’s expertise in supporting oncology studies involving pediatric participants including neonates, children, young adults, and pregnant individuals. congress-registration1.org/ash2025/
-
ICON Plc
@ICONplc
Maximise your 2025 budget with payer analytics from Symphony Health, an ICON plc company:
• Understand coverage & formulary impact
• Optimise pull-through
• Support value-based care
• Fast-turn delivery with no extra data costs
Learn more: healthverity.com/symphony-health/solve-market-access-chal… -
ICON Plc
@ICONplc
PubsHub Journals & Congresses includes built-in screening to help safeguard authors from predatory journals and congresses. With rigorous checks and trusted data, the system helps ensure your work is submitted to credible, reputable venues. Request a demo. www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
In the next blog in our series, we discuss a history of risk-based thinking and common misunderstandings around risk analysis methods. Learn more www.iconplc.com/insights/blog/2025/10/20/managing-risk-me…
#regulatoryaffairs #medicaldevices #iso #medsafety -
ICON Plc
@ICONplc
Regulatory affairs is now a boardroom imperative. Pharma must master 1. Regulatory modernisation and divergence 2. Integration of real-world evidence and digital data 3. Oversight of AI, advanced manufacturing and novel modalities. Read more: www.drugdiscoverytrends.com/regulatory-strategy-reimagine…
-
ICON Plc
@ICONplc
Digital health tech can decentralize CV studies, reduce patient burden, and boost adherence. Meet ICON experts at #cvot25 to explore how DHTs enhance patient centricity. www.globalcvctforum.com
-
ICON Plc
@ICONplc
Over 300 million patients live with #copd, yet it often goes undiagnosed. Learn how ICON helps sponsors to bring life-changing treatment options to patients faster. www.iconplc.com/therapeutics/internal-medicine-immunology…
#copdawareness -
ICON Plc
@ICONplc
Sponsors face growing pressure to deliver trials that are faster, safer, and more efficient. Holistic risk management is the key. ICON’s latest blog shares insights from Citeline’s panel on how to lead with strategy, not just tools. www.iconplc.com/insights/blog/2025/10/29/enabling-holisti…
-
ICON Plc
@ICONplc
JCAs are reshaping EU market access.
ICON’s whitepaper helps you plan smarter, submit stronger, and align globally. www.iconplc.com/insights/regulatory-intelligence/meeting-…
#healthtech #clinicalstrategy #euhta #iconinsights -
ICON Plc
@ICONplc
Are your systems and processes ready for ICH GCP E6(R3)? We identified 727 potential impacts.
Gain expert insights from ICON’s line-by-line analysis and get practical guidance in our whitepaper:
www.iconplc.com/insights/regulatory-intelligence/preparin… -
ICON Plc
@ICONplc
ICON is a proud support of #worldantimicrobialawarenessweek. In the past 5 years, ICON has participated in 400+ infectious disease clinical studies enrolling 483,200+ patients and healthy volunteers (HVs) at 10,000+ sites. www.iconplc.com/therapeutics/infectious-diseases
#antimicrobialresistance -
ICON Plc
@ICONplc
Introducing PLATO: a quick, validated tool for tracking OSA symptoms & treatment response in clinical practice. It enables efficient monitoring of PROs across all treatment stages.
Read the study in JCSM: jcsm.aasm.org/doi/10.5664/jcsm.11790
#sleepmedicine #osa #patientcare -
ICON Plc
@ICONplc
Biotech and pharma sponsors need agile, scalable clinical trial monitoring.
Our latest whitepaper explores how decentralised and risk-based models are improving efficiency and site performance. Read more: www.iconplc.com/insights/transforming-trials/more-monitoring -
ICON Plc
@ICONplc
Maximize your 2025 budget with Symphony FLEX™:
• ~300M patient-level market-agnostic records
• Medial payer & remittance data
• Snowflake delivery
• 130+ elements for cross-industry insights
Designed for flexibility. Built for precision. icon.widen.net/s/rzgbmbkctp -
ICON Plc
@ICONplc
Discover how early site engagement and optimised activation can accelerate study startup and enrolment, and make you a sponsor of choice for sites.
Global experts share proven strategies during our live webinar 3 Dec at 10am ET
Register today: www.iconplc.com/news-events/events/webinars/becoming-spon… -
ICON Plc
@ICONplc
Analysts, rejoice.
Metys® offers predefined dashboards for quick answers and a powerful report builder for custom views – plus Excel integration for seamless workflows.
It’s market intelligence, your way.
Explore Metys: healthverity.com/symphony-health/health-technology-and-bu… -
ICON Plc
@ICONplc
Early clinical trials in neurodegenerative diseases require smart strategy. Join our webinar on Nov 18 (3–4 PM CET) to explore study design, patient engagement & biomarker selection. www.iconplc.com/news-events/events/webinars/strategic-app…
#neurodegeneration #clinicalresearch #ascpt -
ICON Plc
@ICONplc
Risk-based strategies aren’t optional, they’re essential. ICON’s Victoria DeVeaugh-Geiss shares six principles sponsors should consider building into their clinical trial operations. Read the blog www.iconplc.com/insights/blog/2025/10/29/enabling-holisti…
-
ICON Plc
@ICONplc
This #worlddiabetesday, we’re proud to support understanding through FIRECREST, our digital site platform that’s helped power 80+ diabetes trials globally.
Discover how we’re making science accessible: www.iconplc.com/solutions/technologies/firecrest
#diabetesawareness #patienteducation -
ICON Plc
@ICONplc
ICON supports #wdd2025 to increase diabetes awareness and education. In the past 5 years, ICON has supported 198 metabolic trials, including 57 diabetes studies including Type 1 & Type 2 adult and pediatric populations. www.iconplc.com/therapeutics/endocrine-metabolic-disorders
-
ICON Plc
@ICONplc
Flexible, risk-based monitoring strategies are transforming global trial delivery. ICON’s new whitepaper shows how smarter oversight improves quality, reduces cost and accelerates timelines. Download now: www.iconplc.com/insights/transforming-trials/more-monitoring
-
ICON Plc
@ICONplc
Advocating on behalf of our clients at regulatory authority meetings is an essential support service to ensure their clinical trial project is successful. But this is just one of numerous ways we deliver for customers: www.iconplc.com/insights/blog/2025/10/16/customer-advocac…
#customeradvocacy #futureofpharma -
ICON Plc
@ICONplc
Use Journals & Congresses to sort over 10,000 journals and congresses by submission date and lead times. Get your answer quickly so you can focus on your work. See how easy it is for yourself & request a demo. www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
#biosimilars in #apac are poised for growth — but trust is the key to adoption. ICON breaks down how education and engagement can overcome barriers and build clinical confidence. Read the blog: www.iconplc.com/insights/blog/2025/09/30/driving-biosimil…
#biologics #healthcareinnovation #clinicalresearch -
ICON Plc
@ICONplc
ICON named to @TIME World’s Most #sustainable Companies 2025. Amazing recognition for our #iconcares #esg programme: www.iconplc.com/about/environmental-social-and-governance
-
ICON Plc
@ICONplc
Heading to the 18th EBF Open Symposium in Barcelona? ICON will be there from 18–20 November at the Hyatt Regency Barcelona Tower. Stop by booth B-15 to explore how our bioanalytical services help bring therapies to market with speed and scientific rigor. meetings.e-b-f.eu/open/
-
ICON Plc
@ICONplc
New in Journal of Clinical Sleep Medicine:
PLATO, a validated 11-item tool for tracking OSA treatment response, is now available. Quick, reliable, and patient-focused. Read more: jcsm.aasm.org/doi/10.5664/jcsm.11790
#sleepmedicine #osa #patientcare #research -
ICON Plc
@ICONplc
Over 1,000 AI-enabled devices approved by FDA since 2015. But how do you plan your regulatory route? Our blog explains FDA guidance for AI in SaMD. www.iconplc.com/insights/blog/2025/06/24/fda-regulations-…
#medicaldevices #aiinhealthcare #regulatory -
ICON Plc
@ICONplc
#worlddiabetesday takes place on 14 November. From Type 1 & Type 2 diabetes, adult to pediatric populations — we’ve conducted 198 metabolic trials, including 57 focused on diabetes. Learn more. #worlddiabetesday www.iconplc.com/therapeutics/endocrine-metabolic-disorders
-
ICON Plc
@ICONplc
Strategic planning = faster access for patients.
ICON’s whitepaper shows how to align your teams and timelines for JCA success. www.iconplc.com/insights/regulatory-intelligence/meeting-…
#healthtechnology #euhta #iconplc -
ICON Plc
@ICONplc
#digitalendpoints help make #clinicaltrials more inclusive and patient-centered.
By enabling remote data collection, DHTs improve retention, reduce burden & increase diversity. Learn best practices for incorporating digital endpoints into your trials: www.iconplc.com/insights/patient-centricity/accelerating-… -
ICON Plc
@ICONplc
Connect with the ICON team at #ash25, booth #2161 to learn how we apply flexible partnership and delivery models, supported by robust tools and technologies, to help clients achieve their oncology clinical development goals. congress-registration1.org/ash2025/
-
ICON Plc
@ICONplc
ICON is proud to be named one of #time & #statista’s World’s Best Companies of 2025 — for the third year running! A huge thank you to our teams worldwide time.com/7315547/worlds-best-companies-of-2025/
#worldsbestcompanies -
ICON Plc
@ICONplc
Smarter monitoring drives better trial delivery. ICON’s whitepaper explores how evolving Clinical Research Associate roles are improving efficiency, oversight and site engagement.
Read more: www.iconplc.com/insights/transforming-trials/more-monitoring -
ICON Plc
@ICONplc
Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest clinical trial regulatory updates current: www.iconplc.com/insights/regulatory-intelligence/regulato…
#regulatoryintelligence #regulatorycompliance #regintel #medicaldevices #biotech #pharma -
ICON Plc
@ICONplc
At Citeline’s recent panel, ICON’s Victoria DeVeaugh-Geiss shared how sponsors can embed smarter risk strategies from protocol design to execution. This blog explores AI-driven insights, cross-functional alignment, and key takeaways sponsors need to know. www.iconplc.com/insights/blog/2025/10/29/enabling-holisti…
-
ICON Plc
@ICONplc
Clinical data science is redefining how we manage and interpret data in clinical trials.
Read what ICON’s Nagalakshmi Shetty, VP, Biometrics says about how intelligent, patient-focused data strategies are shaping the future of clinical research: magazine.pharmatimes.com/collections/pharmatimes-november… -
ICON Plc
@ICONplc
Metys®, from Symphony Health, an ICON plc company, delivers weekly insights up to 3 days faster than other platforms – so you can respond to competitive shifts with confidence and clarity.
Stay ahead. Stay informed.
Explore Metys: healthverity.com/symphony-health/health-technology-and-bu… -
ICON Plc
@ICONplc
Open claims data is powerful—but disruptions are inevitable. Learn how to manage them strategically in our upcoming webinar with Symphony Health.
Key takeaways:
•Spot and assess disruptions
•Collaborate effectively
•Use alerts & mitigation tools
www.iconplc.com/news-events/events/webinars/riding-data-w… -
ICON Plc
@ICONplc
Pediatric trials differ from adult trials — but spotting the differences isn't always easy. Watch our on-demand webinar to explore the regulatory key strategies as well as an interactive tool www.iconplc.com/news-events/events/webinars/pediatric-ris…
-
ICON Plc
@ICONplc
ICON has been named as one of the TIME World's Best Companies in Sustainable Growth 2025. ICON featured at number 57 in the list of 500 companies and the highest CRO globally.
Learn more: www.iconplc.com/about/environmental-social-and-governance -
ICON Plc
@ICONplc
Antimicrobial resistance is a growing global threat, making traditional antibiotics less effective. ICON’s latest article explores how bacteriophage therapy—a virus-based approach—could help tackle multidrug-resistant infections.
Read more: www.infectioncontroltoday.com/view/multidrug-resistant-in… -
ICON Plc
@ICONplc
Join ICON at booth #8 at #octdach, 12–13 November at the Kameha Grand, Zurich. As a trusted partner to biotech and pharma across the DACH region, ICON delivers integrated clinical development solutions. www.arena-international.com/event/octdach/
-
ICON Plc
@ICONplc
Everything you need to make the important decision of where to publish your work. 50+ metadata consideration points including deadlines and lead times. Links to author submission guides fast and easy. Request a demo. www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
Recently, 132 of ICON’s biopharma sponsors shared insights on the evolution of clinical monitoring. Our new whitepaper highlights the benefits: faster enrolment, reduced site burden and strategic CRA support. Read more: www.iconplc.com/insights/transforming-trials/more-monitoring
-
ICON Plc
@ICONplc
ADCs are transforming cancer treatment — but measuring free payload concentrations is critical to ensure their safety and efficacy. Discover how advanced analytical strategies are helping to navigate the complexities of ADC development in our latest blog: www.iconplc.com/insights/blog/2025/09/24/challenges-free-…
-
ICON Plc
@ICONplc
Sponsors face sweeping changes with ICH GCP E6(R3). Our regulatory experts detail impacts, the top 5 areas affected and key approaches for compliance.
Read now: www.iconplc.com/insights/regulatory-intelligence/preparin…This media couldn't be displayed. See it on the original post. -
ICON Plc
@ICONplc
Metys®, from Symphony Health, an ICON plc company, is the only fully integrated platform that consolidates over 150 metrics and dimensions – giving you a complete, real-time view of the healthcare market.
Explore Metys: healthverity.com/symphony-health/health-technology-and-bu… -
ICON Plc
@ICONplc
In the next blog in our series, we discuss a history of risk-based thinking and common misunderstandings around risk analysis methods. Learn more www.iconplc.com/insights/blog/2025/10/20/managing-risk-me…
#regulatoryaffairs #medicaldevices #iso #medsafety -
ICON Plc
@ICONplc
France, Germany, Spain… each country handles JCA findings differently. ICON’s guide breaks it down so you can plan ahead. www.iconplc.com/insights/regulatory-intelligence/meeting-…
#reimbursement #hta #jca #iconinsights -
ICON Plc
@ICONplc
Clinical trials generate more data than ever. ICON’s new blog reveals how technology—from central monitoring to predictive analytics—makes risk-based quality management more agile, efficient and focused. Discover how smarter tools support better oversight: www.iconplc.com/insights/blog/2025/10/13/smarter-rbqm-int…
-
ICON Plc
@ICONplc
Connect with ICON at Booth 824 to explore how we’re advancing HEOR, RWE, and patient-focused strategies that drive value and access. www.ispor.org/conferences-education/conferences/past-conf…
#isporeurope #heor #patientcentric -
ICON Plc
@ICONplc
ISO 14971 covers the application of risk management to medical devices. Historically there’s been disagreement as to its interpretation but more recently there’s been a drive to develop a common understanding. Read more www.iconplc.com/insights/blog/2025/10/16/managing-risk-me…
-
ICON Plc
@ICONplc
Connect with the ICON team at #aasld2025, booth 1041 to learn how we apply flexible partnership and delivery models, supported by robust tools and technologies, to help clients achieve their hepatology clinical development goals. www.aasld.org/tlm-26/home
-
ICON Plc
@ICONplc
#dhts in #clinicaltrials can reduce trial timelines by up to 5 months and cut costs by millions. Our whitepaper explains how digital endpoints improve efficiency, reduce amendments & boost ROI. Read now: www.iconplc.com/insights/patient-centricity/accelerating-…
-
ICON Plc
@ICONplc
Post-marketing pharmacovigilance plays a crucial role in maintaining patient safety once a product reaches the market. While automation can streamline tasks, its implementation must be carefully managed to avoid compromising patient safety.
Read more: magazine.pharmatimes.com/collections/0c4bd6bf-9a0a-11f0-b… -
ICON Plc
@ICONplc
Early clinical trials in neurodegenerative diseases require smart strategy. Join our webinar on Nov 18 (3–4 PM CET) to explore study design, patient engagement & biomarker selection. www.iconplc.com/news-events/events/webinars/strategic-app…
#neurodegeneration #clinicalresearch #ascpt -
ICON Plc
@ICONplc
As of 31 December 2024, women make up 70% of our workforce and hold 60% of director-level and above roles—a powerful reflection of the inclusive environment at ICON. Learn more in our latest #esg report www.iconplc.com/about/environmental-social-and-governance…
-
ICON Plc
@ICONplc
Planning an Integrated Summary of Safety and Efficacy (ISS/ISE) submission can be demanding, especially when studies differ in format or terminology. This blog explains how early preparation and the right integration strategy can simplify the process. www.iconplc.com/insights/blog/2025/10/27/strategies-succe…
-
ICON Plc
@ICONplc
The escalating cost and prolonged timelines of drug development have lead #regulatory authorities to focus on ways to accelerate the availability of innovative therapies to market. Learn more: www.iconplc.com/insights/regulatory-intelligence/accelera…
-
ICON Plc
@ICONplc
ICON understands the rapidly advancing landscape and the unique challenges of navigating the patient, site, product and regulatory journeys in delivering CGT therapies. Meet us at #ash25, booth #2161 to learn how we can help support your trial. congress-registration1.org/ash2025/
-
ICON Plc
@ICONplc
Join us on Nov 6 to explore how formulation choices impact study success, data integrity, and regulatory readiness. www.iconplc.com/news-events/events/webinars/beyond-bench-…
#pharma #earlyphase #gmp #clinicalresearch -
ICON Plc
@ICONplc
Smarter oversight starts with smarter tools. ICON’s latest blog shows how tech enables agile, risk-based quality management in clinical trials.
Explore the future of RBQM: www.iconplc.com/insights/blog/2025/10/13/smarter-rbqm-int… -
ICON Plc
@ICONplc
#ich #gcp E6(R3) = Big changes.
Impact assessments = Smart starts.
Learn how sponsors & CROs can align for success. magazine.pharmatimes.com/collections/0c4bd6bf-9a0a-11f0-b…
#clinicaltrials #ichgcp #impactassessment -
ICON Plc
@ICONplc
Sponsors with multi-indication assets can benefit from taking a precision approach to patient screening that enables stratification by relevant comorbidities and related factors. Learn more trial design considerations for today's obesity developers. drug-dev.com/clinical-trials-keeping-pace-with-shifting-d…
-
ICON Plc
@ICONplc
Intimate Partner Violence (IPV) affects millions, but remains overlooked in clinical trials.
To achieve true equity in research, we must treat IPV as a key social determinant of health and take action to support affected participants.
Read more: www.iconplc.com/insights/blog/2025/10/29/more-awareness-t…
#ipv -
ICON Plc
@ICONplc
Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest clinical trial regulatory updates current: www.iconplc.com/insights/regulatory-intelligence/regulato…
#regulatoryintelligence #regulatorycompliance #regintel #medicaldevices #biotech #pharma -
ICON Plc
@ICONplc
Meet ICON at #obesityweek, Nov 4–7 at booth 520 to learn how we accelerate obesity trials with 120 ready-to-go sites, pre-screened patients, and scalable infrastructure. obesityweek.org
-
ICON Plc
@ICONplc
From apheresis to infusion: ICON experts explore the logistical hurdles in delivering autologous CAR-T therapies across APAC. Learn more. www.biospectrumasia.com/analysis/29/26700/navigating-manu…
#celltherapy #cgt -
ICON Plc
@ICONplc
PICO isn’t just a framework—it’s your key to JCA approval. Learn how to build a dossier that meets EU HTA expectations. www.iconplc.com/insights/regulatory-intelligence/meeting-…
#healthtech #evidencegeneration #jca -
ICON Plc
@ICONplc
ICON’s new whitepaper reveals how smarter monitoring models and evolving CRA roles are reducing trial delays, improving site performance and enabling real-time oversight.
Download now: www.iconplc.com/insights/transforming-trials/more-monitoring -
ICON Plc
@ICONplc
Meet ICON experts at #aasld2025, booth 1041 to discuss how we can support your medical imaging and central lab requirements for MASH clinical trials: www.aasld.org/tlm-26/home
-
ICON Plc
@ICONplc
CMC is a critical and a ‘first step’ component in the creation of a development strategy by #biotechs for an asset. Failure to provide due consideration will impact health authorities’ approvals. Read more: www.iconplc.com/insights/blog/2025/10/03/cmc-drug-develop…
#regulatoryaffairs #regulatorycompliance #cmc -
ICON Plc
@ICONplc
Join us on Nov 6 to explore how formulation choices impact study success, data integrity, and regulatory readiness. www.iconplc.com/news-events/events/webinars/beyond-bench-…
#pharma #earlyphase #gmp #clinicalresearch -
ICON Plc
@ICONplc
Visit ICON at #octdach this 12–13 November. Meet our team at booth #8 to explore how we help sponsors navigate regulatory complexity, optimize trial delivery, and accelerate market access. www.arena-international.com/event/octdach/
-
ICON Plc
@ICONplc
While #biosimilars hold a great deal of promise for increasing access to critical treatments in #apac countries, success will be constrained while patients and providers remain unconvinced of their quality and benefits. Learn more: www.iconplc.com/insights/blog/2025/09/30/driving-biosimil…
-
ICON Plc
@ICONplc
Watch our recent webinar to learn about the regulatory strategies when developing pediatric clinical trials and an interactive “first step” tool for risk identification and mitigation. www.iconplc.com/news-events/events/webinars/pediatric-ris…
-
ICON Plc
@ICONplc
LabView360 provides real-time visibility, reducing manual errors, and accelerating results. With an intuitive mobile-responsive app, sites can scan barcodes, streamline workflows, and ensure high-quality data collection. Discover more: www.iconplc.com/solutions/technologies/labview360
-
ICON Plc
@ICONplc
PubsHub Journals & Congresses are indexed by Clarivate Analytics, with updated impact factors and Journal Citation Reports (JRC) categories annually. Use the information to pick the resource that best matches your goals. See for yourself and request a demo.www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
This 4–6 November in Boston, ICON is sponsoring the #worlddrugsafety Congress, uniting 2,000+ drug safety professionals. Learn how our real-world evidence, AI signal detection & risk management drive safer outcomes at booth #227. www.terrapinn.com/conference/world-drug-safety-us/index.stm
-
ICON Plc
@ICONplc
ADCs are transforming cancer treatment — but measuring free payload concentrations is critical to ensure their safety and efficacy. Discover how advanced analytical strategies are helping to navigate the complexities of ADC development in our latest blog: www.iconplc.com/insights/blog/2025/09/24/challenges-free-…
-
ICON Plc
@ICONplc
Choosing a #digitalendpoint? That requires more than just a #digitalhealthtechnology.
Our latest whitepaper breaks down the V3 framework: Verification, Analytical Validation & Clinical Validation, for building regulatory-ready digital measures. www.iconplc.com/insights/patient-centricity/accelerating-… -
ICON Plc
@ICONplc
Pregnant women are still largely excluded from clinical trials—leaving critical data gaps.
ICON’s Liz O’Brien emphasises the need for trust, transparency, and education to safely include this population in research. Read more: www.statnews.com/2025/10/02/clinical-trials-pregnant-wome… -
ICON Plc
@ICONplc
Oncology #biosimilars present unique potential and distinct challenges to sponsors. Read our blog to learn more about unique clinical pathways, study design and more. www.iconplc.com/insights/blog/2025/07/21/oncology-biosimi…
#grxbiosims -
ICON Plc
@ICONplc
MASH is liver health’s silent epidemic — underdiagnosed, rising fast, and deeply linked to metabolic dysfunction.
New blog:
•What’s changed in diagnosis & treatment
•Who’s most affected
•How real-world data is driving progress
Read more: www.iconplc.com/insights/blog/2025/10/27/mash-liver-healt… -
ICON Plc
@ICONplc
By integrating a short term stability program, formulation development, real-time drug product manufacturing, and clinical testing, we help you streamline the entire process—cutting up to 12+ months in development time and saving significant costs. www.iconplc.com/solutions/early-clinical/accelerated-phar…
-
ICON Plc
@ICONplc
Over the next fifteen years, #oncology #biologics with expiring patents will become increasingly complex — and developing corresponding #biosimilars will become more difficult. Read more www.drugdiscoverytrends.com/what-sets-oncology-biosimilar…
#grxbiosims -
ICON Plc
@ICONplc
The biologics’ patent cliff presents opportunity particularly in the #oncology space. But there are also pitfalls for #biosimilar drug developers. Learn more: www.iconplc.com/insights/therapeutics/oncology/future-onc…
#grxbiosimsThis media couldn't be displayed. See it on the original post. -
ICON Plc
@ICONplc
The EU’s Joint Clinical Assessments are here. Are you ready? ICON’s new whitepaper helps health tech developers plan smarter for JCA success. www.iconplc.com/insights/regulatory-intelligence/meeting-…
#jca #hta #marketaccess #iconplc -
ICON Plc
@ICONplc
Sponsors face sweeping changes with ICH GCP E6(R3). Our regulatory experts detail impacts, the top 5 areas affected and key approaches for compliance.
Read now: www.iconplc.com/insights/regulatory-intelligence/preparin… -
ICON Plc
@ICONplc
Meet us at #obesityweek, Nov 4–7, booth 520 to discuss how ICON uses real-world evidence to uncover prescriber behavior, payer influence & patient needs—identifying subpopulations & quantifying impact to build stronger value. obesityweek.org
-
ICON Plc
@ICONplc
ICON’s latest blog explores how central monitoring, predictive analytics and system-agnostic platforms enable earlier risk detection and more efficient oversight. Read how smarter tools are reshaping clinical trial monitoring: www.iconplc.com/insights/blog/2025/10/13/smarter-rbqm-int…
-
ICON Plc
@ICONplc
Proven success in early phase obesity studies. See how ICON streamlined an early phase obesity study with tailored recruitment, participant-centric support, and operational excellence to reduce
dropout rates and ensure continuity. Case study: www.iconplc.com/solutions/all-case-studies/overcoming-enr… -
ICON Plc
@ICONplc
From GMP gaps to regulatory fragmentation, ICON experts share how APAC CGT sponsors can scale smarter. Read the article www.biospectrumasia.com/analysis/29/26700/navigating-manu…
#celltherapy #cgt -
ICON Plc
@ICONplc
As the Asia-Pacific (#apac) region continues to emerge as a key player in the #biosimilar sector, it presents significant opportunity for market entry and expansion. Read how. www.iconplc.com/insights/blog/2025/07/14/navigating-post-…
#grxbiosims -
ICON Plc
@ICONplc
RWE drives smarter decisions. ICON’s experts are ready to discuss how at #isporeurope Booth 824. www.ispor.org/conferences-education/conferences/past-conf…
#valueinhealthcare #marketaccess -
ICON Plc
@ICONplc
ICON experts explore how automation, partnerships & harmonization can scale CAR-T in APAC. Read the article. www.biospectrumasia.com/analysis/29/26700/navigating-manu…
#celltherapy #cgt -
ICON Plc
@ICONplc
Developers that embrace non-traditional trial designs may be best positioned to unlock the full value of their obesity therapies. Learn why in our article. drug-dev.com/clinical-trials-keeping-pace-with-shifting-d…
-
ICON Plc
@ICONplc
ICON supports cardiovascular innovation with 40+ years of experience in interventional cardiology, structural heart, SaMD, and cardiac imaging & diagnostics.
See you at #tct2025! www.iconplc.com/sectors/medical-device
#tct2025 #cardiology #medicaldevices #clinicalresearch -
ICON Plc
@ICONplc
ADCs are transforming cancer treatment — but measuring free payload concentrations is critical to ensure their safety and efficacy. Discover how advanced analytical strategies are helping to navigate the complexities of ADC development in our latest blog: www.iconplc.com/insights/blog/2025/09/24/challenges-free-…
-
ICON Plc
@ICONplc
Join us on Nov 6 to explore how formulation choices impact study success, data integrity, and regulatory readiness. www.iconplc.com/news-events/events/webinars/beyond-bench-…
#pharma #earlyphase #gmp #clinicalresearch -
ICON Plc
@ICONplc
Join ICON at #cphifrankfurt from 28–30 October at Messe Frankfurt. Visit booth 6.1F95 to explore how our Accelerated Pharmaceutical Solutions help pharma and biotech companies deliver therapies faster.
www.iconplc.com/news-events/events/industry/cphi -
ICON Plc
@ICONplc
“A strategic partnership is a two-way street. It requires consultants to be authoritative in their recommendations, honest in their assessments and committed to long-term client success.” Learn more: www.iconplc.com/insights/blog/2025/10/16/customer-advocac…
#customeradvocacy #futureofpharma #voiceofthecustomer -
ICON Plc
@ICONplc
Attending #aasld2025? Connect with the ICON team at booth 1041 to learn about our integrated approach and full range of clinical development services to support your #hepatology #clinicaltrials: www.aasld.org/tlm-26/home
-
ICON Plc
@ICONplc
Meet the ICON team at the #worlddrugsafety Congress, in Boston, booth #227 to see how we help biopharma and medical device companies meet regulatory demands, apply advanced analytics, and strengthen #patientsafety. www.terrapinn.com/conference/world-drug-safety-us/index.stm
-
ICON Plc
@ICONplc
October is #liverawarenessmonth. MASH affects 115M+ globally, yet >80% remain undiagnosed. Linked to obesity, type 2 diabetes & metabolic syndrome, MASH is a silent epidemic. Let’s raise awareness: healthverity.com/symphony-health/understand-the-patient-j…
-
ICON Plc
@ICONplc
PubsHub Journals & Congresses scans for predatory practices, and suspicious journals and congresses. Trust it to protect your research work and help you make better informed publishing decisions. Get more info and a demo. www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
Visit ICON at #obesityweek, Nov 4–7 (Booth 520) to discover how our AI-powered site selection and Accellacare Network accelerate obesity trials with ready-to-go sites and diverse patient populations. obesityweek.org
-
ICON Plc
@ICONplc
We will be at #isporeurope in Glasgow! Stop by Booth 824 and let’s talk about HEOR, RWE, and patient-centered value strategies. www.ispor.org/conferences-education/conferences/past-conf…
#valueinhealthcare #marketaccess -
ICON Plc
@ICONplc
By integrating drug substance, formulation development, real-time manufacturing, and clinical testing, we streamline the entire process—cutting up to 12+ months in development time and significantly reducing costs.
www.iconplc.com/solutions/manufacturing-pharmacy-services -
ICON Plc
@ICONplc
Join us on Nov 6 to explore how formulation choices impact study success, data integrity, and regulatory readiness. www.iconplc.com/news-events/events/webinars/beyond-bench-…
#pharma #earlyphase #gmp #clinicalresearch -
ICON Plc
@ICONplc
We will be at #isporeurope in Glasgow! Stop by Booth 824 and let’s talk about HEOR, RWE, and patient-centered value strategies. www.ispor.org/conferences-education/conferences/past-conf…
#valueinhealthcare #marketaccess -
ICON Plc
@ICONplc
ICON experts Simon Bruce and Jack Martin share how developers can more effectively leverage RWE to demonstrate a therapy's value, safety and effectiveness across multiple indications in diverse real-world settings. Explore their insights. drug-dev.com/clinical-trials-keeping-pace-with-shifting-d…
-
ICON Plc
@ICONplc
ISO 14971 covers the application of risk management to medical devices. Historically there’s been disagreement as to its interpretation but more recently there’s been a drive to develop a common understanding. Read more www.iconplc.com/insights/blog/2025/10/16/managing-risk-me…
-
ICON Plc
@ICONplc
Patient voices matter more than ever in obesity research. Are your trials designed to meet today’s expectations?
Discover how to integrate COAs + DHTs effectively in this on-demand webinar led by our experts. www.iconplc.com/news-events/events/webinars/enhancing-cli… -
ICON Plc
@ICONplc
Why do stability studies matter in early drug development? Learn how early stability testing can de-risk your clinical program and support successful IND/IMPD submissions in our latest blog post.
www.iconplc.com/insights/blog/2025/08/20/importance-stabi… -
ICON Plc
@ICONplc
In 2024, we launched our Sustainable Procurement Policy and implemented sustainability engagement plans with key suppliers.
Helping our ICON Cares Sustainable Procurement Program to advance our commitment to responsible sourcing. www.iconplc.com/about/environmental-social-and-governance…
#iconcares -
ICON Plc
@ICONplc
Open claims = broad coverage + fast insights.
Yes, disruptions happen—but they’re manageable.
•Monitor supplier shifts
•Adjust business rules
•Choose a data partner
Read: www.iconplc.com/insights/blog/2025/10/16/mitigating-data-… -
ICON Plc
@ICONplc
Reach clinical trial participants faster. Our integrated oncology solutions reduce barriers,
enhance engagement, and boost recruitment and retention. www.iconplc.com/solutions/all-case-studies/therapeutics-c… -
ICON Plc
@ICONplc
Meet the ICON team at #acr25, booth #1501 to learn how we apply flexible partnership and delivery models, supported by robust tools and technologies, to help clients achieve their rheumatology clinical development goals. www.iconplc.com/therapeutics/internal-medicine-immunology…
-
ICON Plc
@ICONplc
The #biosimilar era in #oncology is shifting rapidly. Fast movers will be best positioned to capitalise on first-to-market advantage. #esmo25 Read the article icon.widen.net/s/kbpcpsbmnj
-
ICON Plc
@ICONplc
AI may be able to provide a fuller understanding of tumour biology and to identify viable biomarkers. Read the article to find out how machine learning and deep learning are being used to find oncology biomarkers in our new article. pharmaphorum.com/digital/precision-medicine-meets-machine…
-
ICON Plc
@ICONplc
#biosimilars offer cost savings & increased patient access to lifesaving therapies such as #oncology. Their future is bright but only with the right strategy. Download our whitepaper: www.iconplc.com/insights/therapeutics/oncology/future-onc…
This media couldn't be displayed. See it on the original post. -
ICON Plc
@ICONplc
In this PharmaTimes article, Dr. Quintin van Wyk considers how automation is being thoughtfully integrated into post-marketing safety processes.
Read more: magazine.pharmatimes.com/collections/0c4bd6bf-9a0a-11f0-b… -
ICON Plc
@ICONplc
CMC is a critical and a ‘first step’ component in the creation of a development strategy for an asset. Failure to provide due consideration will impact health authorities’ approvals. Read more: www.iconplc.com/insights/blog/2025/10/03/cmc-drug-develop…
#regulatoryaffairs #regulatorycompliance #cmc #clinicaltrials -
ICON Plc
@ICONplc
Join us on Nov 6 to explore how formulation choices impact study success, data integrity, and regulatory readiness. www.iconplc.com/news-events/events/webinars/beyond-bench-…
#pharma #earlyphase #gmp #clinicalresearch -
ICON Plc
@ICONplc
Strategic compliance starts with knowing your gaps. Our latest #pharmatimes article breaks down how to assess #ich #gcp E6(R3) impact across systems, people & processes. magazine.pharmatimes.com/collections/0c4bd6bf-9a0a-11f0-b…
#clinicaltrials #ichgcp #impactassessment -
ICON Plc
@ICONplc
In the fields of #oncology and rare diseases, patients often face limited treatment options and urgent clinical need. Regulatory agencies are responding.
Come visit us at #esmo25 or read our whitepaper to learn how: www.iconplc.com/insights/regulatory-intelligence/accelera…This media couldn't be displayed. See it on the original post. -
ICON Plc
@ICONplc
In a survey of oncology researchers, nearly half (49%) identified biomarker detection as the area where AI and ML could most accelerate oncology drug development. Learn how AI is impacting oncology biomarker discovery, present and future. pharmaphorum.com/digital/precision-medicine-meets-machine…
-
ICON Plc
@ICONplc
ICON’s Alan Baldridge explores the prevalence of #masld in obese patients and the significance of weight loss in managing hepatic complications. Read the article to learn more. journalforclinicalstudies.com/wp-content/uploads/2024/07/… #nationalliverawarenessmonth
-
ICON Plc
@ICONplc
By integrating a short term stability program, formulation development, real-time drug product manufacturing, and clinical testing, we help you streamline the entire process—cutting up to 12+ months in development time and saving significant costs. www.iconplc.com/solutions/early-clinical/accelerated-phar…
-
ICON Plc
@ICONplc
ADCs are transforming cancer treatment — but measuring free payload concentrations is critical to ensure their safety and efficacy. Discover how advanced analytical strategies are helping to navigate the complexities of ADC development in our latest blog: www.iconplc.com/insights/blog/2025/09/24/challenges-free-…
-
ICON Plc
@ICONplc
ICON is heading to Copenhagen for #octnordics on 21–22 October. Stop by booth #41 to meet our team and explore how we’re supporting sponsors across the Nordics with faster, smarter, and more patient-focused clinical trials. Learn more: www.arena-international.com/event/octctsnordics/
-
ICON Plc
@ICONplc
Meet ICON experts at #aasld2025, booth 1041 to discuss how we can support your medical imaging and central lab requirements for MASH clinical trials: www.aasld.org/tlm-26/home
-
ICON Plc
@ICONplc
Journals & Congresses offers rejection rate insights. You can review rejection rates by journal, helping target the best fit for your submission. Check out our interactive dashboard and see for yourself. www.iconplc.com/solutions/consulting/commercial-positioni…
-
ICON Plc
@ICONplc
ICON helped a sponsor tackle rare disease recruitment challenges and complex endpoints in two pivotal HCM trials using targeted site strategy and operational precision to exceed goals. www2.iconplc.com/Case_Study_CVOT
#clinicaltrials #cardiovascularresearch -
ICON Plc
@ICONplc
Sponsors do best when their trial designs evolve alongside paradigm-shifting therapies. Early consideration of unconventional trial formats and patient screening approaches may introduce much-needed efficiencies into multi-indication development. drug-dev.com/clinical-trials-keeping-pace-with-shifting-d…
-
ICON Plc
@ICONplc
ICON is heading to ACOP 2025 in Aurora, CO! Meet Yi Zhang, our new Scientific Director of PK, at booth #9 and during the NONMEM Advanced Workshop on Oct 17. Learn more: acop2025.eventscribe.net
-
ICON Plc
@ICONplc
On November 4-7, connect with ICON experts at #obesityweek, booth 520 to discuss how we
deliver ready-to-deploy infrastructure, market intelligence, and deep expertise to support early decisions and accelerate high-quality study delivery of obesity trials. obesityweek.org -
ICON Plc
@ICONplc
By easing the burden of participating in a clinical trial, In-Home Services improves patient recruitment and retention with a patient centric approach. Speak with ICON experts at #esmo25, booth #3034 to learn more. www.esmo.org/meeting-calendar/esmo-congress-2025
-
ICON Plc
@ICONplc
Biomarker identification has become a cornerstone of oncology, particularly in precision therapy development. Read the article to discover how AI is changing the identification of viable biomarkers, and the challenges faced by developers who use it. pharmaphorum.com/digital/precision-medicine-meets-machine…
-
ICON Plc
@ICONplc
Symphony Health, an ICON plc company, shows why integrating open + closed claims is the future of life sciences strategy. #patientsourceduo
Read the full article in R&D World: www.rdworldonline.com/the-claims-conundrum-why-integratio…
#healthcaredata #iconplc #symphonyhealth #realworldevidence #rdworld -
ICON Plc
@ICONplc
The therapeutic landscape for obesity is changing rapidly.
Watch our recent webinar to learn how integrating COAs and DHTs can result in more patient-centred obesity trials. www.iconplc.com/news-events/events/webinars/enhancing-cli… -
ICON Plc
@ICONplc
Join us on Nov 6 to explore how formulation choices impact study success, data integrity, and regulatory readiness. www.iconplc.com/news-events/events/webinars/beyond-bench-…
#pharma #earlyphase #gmp #clinicalresearch -
ICON Plc
@ICONplc
We’re looking forward to joining the conversation at #octnewengland.
On October 15 at 11:30 AM, our General Partner and VP of Operations, Stacey Flattery, will speak on: “Maneuvering with agility in a challenging landscape.”
Join us: www.arena-international.com/event/octnewengland/ -
ICON Plc
@ICONplc
From molecule to market - see how ICON supports oncology sponsors with tailored strategies, from logistics to regulatory, across every phase.
Explore oncology case studies: www.iconplc.com/solutions/all-case-studies/therapeutics-c… -
ICON Plc
@ICONplc
Are your systems and processes ready for ICH GCP E6(R3)? We identified 727 potential impacts.
Gain expert insights from ICON’s line-by-line analysis and get practical guidance in our whitepaper:
www.iconplc.com/insights/regulatory-intelligence/preparin…This media couldn't be displayed. See it on the original post. -
ICON Plc
@ICONplc
Introducing LabView360: The future of sample management. Paper-based manual requisitions are time-consuming and error-prone. LabView360 replaces them with a seamless digital process that improves data accuracy and reduces query resolution times. www.iconplc.com/solutions/technologies/labview360
-
ICON Plc
@ICONplc
Why do stability studies matter in early drug development? Learn how early stability testing can de-risk your clinical program and support successful IND/IMPD submissions in our latest blog post.
www.iconplc.com/insights/blog/2025/08/20/importance-stabi… -
ICON Plc
@ICONplc
Speak with ICON experts at #acr25, booth #1501 to learn how our Central Review Services team is advancing clinical trial development in Systemic Lupus Erythematosus and Lupus Nephritis. www.iconplc.com/therapeutics/internal-medicine-immunology…
-
ICON Plc
@ICONplc
#biosimilars in #apac are poised for growth — but trust is the key to adoption. ICON breaks down how education and engagement can overcome barriers and build clinical confidence. Read the blog: www.iconplc.com/insights/blog/2025/09/30/driving-biosimil…
#biologics #healthcareinnovation #clinicalresearch -
ICON Plc
@ICONplc
From tighter timelines to greater regulatory expectations, today’s clinical trials demand more from programming. Discover why R is becoming central to delivering results with speed and confidence. www.iconplc.com/insights/blog/2025/09/18/reimagining-clin…
#clinicaltrials #rstats #clinicalprogramming -
ICON Plc
@ICONplc
Join our webinar to learn about the regulatory strategies when developing pediatric clinical trials and an interactive “first step” tool for risk identification and mitigation. Register today. xtalks.com/webinars/identify-and-mitigate-risks-in-pediat…
-
ICON Plc
@ICONplc
Did you know 1 in 8 people live with a #mentalhealth condition such as #anxiety or #depression. Learn how ICON can help sponsor efficiently operationalise mood disorder and schizophrenia clinical trials is to reduce the burden for sites and patients: www.iconplc.com/therapeutics/central-nervous-system/cns-p…
-
ICON Plc
@ICONplc
ICON combines strategy, rigor & therapeutic expertise to deliver high-impact SLRs that support pharma success. Read the article in PME: pme.pmlive.com/collections/759f9ff2-9493-11f0-bd64-4201ac…
#slr #medicalwriting #pharmainsights #iconplc -
ICON Plc
@ICONplc
ICON is proud to sponsor #octnordics on 21–22 Oct in Copenhagen. Visit booth #41 to meet our experts and explore how we’re advancing clinical development through innovation and operational excellence. Let’s connect: www.arena-international.com/event/octctsnordics/
-
ICON Plc
@ICONplc
Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest clinical trial regulatory authority updates current: www.iconplc.com/insights/regulatory-intelligence/regulato…
-
ICON Plc
@ICONplc
ICON offers proven expertise in complex oncology trials, supporting sponsors from trial design through execution. Discover our success stories. www.iconplc.com/solutions/all-case-studies/therapeutics-c…
-
ICON Plc
@ICONplc
ICON is heading to ACOP 2025 in Aurora, CO! Meet Yi Zhang, our new Scientific Director of PK, at booth #9 and during the NONMEM Advanced Workshop on Oct 17. Learn more: acop2025.eventscribe.net
-
ICON Plc
@ICONplc
By easing the burden of participating in a clinical trial, In-Home Services improves patient recruitment and retention with a patient centric approach. Speak with ICON experts at #esmo25, booth #3034 to learn more. www.esmo.org/meeting-calendar/esmo-congress-2025
-
ICON Plc
@ICONplc
Finding the optimal drug formulation can be the difference between success and delay.
ICON’s formulation screening and optimisation process ensures the best exposure levels—reducing trial iterations and increasing clinical success.
www.iconplc.com/solutions/manufacturing-pharmacy-services -
ICON Plc
@ICONplc
Discover the value of strategic early engagement during Stacey Flattery Vice President, General Partner, speaker session on Wednesday, 15 October at 11:30am at #octnewengland2025. Drop by booth #69 and meet the team of ICON experts. www.arena-international.com/event/octnewengland/
-
ICON Plc
@ICONplc
Women face unique health challenges, yet most outcome measures still reflect male-centric norms. Gender-specific COAs can close the gap in diagnosis, treatment, and outcomes. Explore the insights: pharmaphorum.com/rd/mind-gap-need-gender-specific-outcome…
#genderequity #rwe #clinicalresearch #pharmaleadership -
ICON Plc
@ICONplc
Why do stability studies matter in early drug development? Learn how early stability testing can de-risk your clinical program and support successful IND/IMPD submissions in our latest blog post.
www.iconplc.com/insights/blog/2025/08/20/importance-stabi… -
ICON Plc
@ICONplc
We’re looking forward to participating in and hosting C-Path's annual eCOA Consortium EU meeting on October 8–9 at ICON’s Dublin office.
We’re excited to contribute to shaping the future of outcome measurement in clinical trials.
c-path.org/program/electronic-clinical-outcome-assessment… -
ICON Plc
@ICONplc
Meet ICON experts at #acr25, booth 1501 to learn how our In-Home services make it convenient for patients in autoimmune trials to complete the protocol assessments and stay engaged throughout clinical studies. www.iconplc.com/therapeutics/internal-medicine-immunology…
-
ICON Plc
@ICONplc
TOMORROW! Join ICON experts for a live webinar covering:
• Evidence-based selection of measures in obesity trials
• Best practices in ensuring data quality
COAs and DHTs are essential for capturing outcomes that reflect the true patient journey. xtalks.com/webinars/enhancing-clinical-trials-in-obesity-… -
ICON Plc
@ICONplc
#rapsconvergence 2025 is less than a week away! Join ICON in Pittsburgh, 7 - 9 October at booth 409 and learn how we can facilitate end-to-end regulatory solutions, help you streamline approvals and reduce time to market. www.iconplc.com/news-events/events
-
ICON Plc
@ICONplc
Women live longer—but spend 25% more time in poor health than men.
Why? Because clinical trials still use tools designed for men.
It’s time to fix the measurement gap. pharmaphorum.com/rd/mind-gap-need-gender-specific-outcome…
#genderequity #clinicalresearch #womenshealth -
ICON Plc
@ICONplc
#ich #gcp E6(R3) is live! Impact assessments are the first step to smart compliance. Read our #pharmatimes article: magazine.pharmatimes.com/collections/0c4bd6bf-9a0a-11f0-b…
#clinicaltrials #ichgcp #impactassessment -
ICON Plc
@ICONplc
#nationalliverawarenessmonth takes place in October. Learn how ICON helps sponsors bring liver disease treatments to life across a range of hepatology indications including #mash and # MASLD. www.iconplc.com/therapeutics/hepatology
-
ICON Plc
@ICONplc
We’re looking forward to participating in and hosting C-Path's annual eCOA Consortium EU meeting on October 8–9 at ICON’s Dublin office.
We’re excited to contribute to shaping the future of outcome measurement in clinical trials.
c-path.org/program/electronic-clinical-outcome-assessment… -
ICON Plc
@ICONplc
LabView360 provides real-time visibility, reducing manual errors, and accelerating results. With an intuitive mobile-responsive app, sites can scan barcodes, streamline workflows, and ensure high-quality data collection. Discover more: www.iconplc.com/solutions/technologies/labview360
-
ICON Plc
@ICONplc
A recent peer-reviewed study co-authored by Tim Clark, VP Clinical Sciences at ICON, reviewed UK HRA submissions to evaluate how estimands are being defined post-ICH E9(R1).
The study highlights the need for better training and regulatory oversight: www.iconplc.com/insights/blog/2025/09/18/measuring-impact… -
ICON Plc
@ICONplc
Visit ICON at booth 6.1F95 at #cphifrankfurt from 28–30 October at Messe Frankfurt to learn how our Accelerated Pharmaceutical Solutions help bring therapies to market faster, smarter, and with greater impact. www.cphi.com/europe/
-
ICON Plc
@ICONplc
Pediatric trials differ from adult trials—but spotting the differences isn't always easy. Join our webinar to explore the regulatory key strategies and an interactive tool to identify and mitigate pediatric trial risks. Register now. xtalks.com/webinars/identify-and-mitigate-risks-in-pediat…
-
ICON Plc
@ICONplc
A thoughtful, agile study design is the first step to a successful cardiovascular outcomes trial. Read the article for an overview of #cvot design approaches, including enrichment, adaptive trials and emerging tools for CVOT success.
magazine.pharmatimes.com/collections/12176b0a-832b-11f0-b… -
ICON Plc
@ICONplc
With ADCs and BsAbs approaching patent cliffs, #biosimilar sponsors must prepare for complex development and #regulatory shifts. Read the article icon.widen.net/s/kbpcpsbmnj
-
ICON Plc
@ICONplc
Accelerating enrollment through smarter access. Explore how ICON’s extensive patient access network and tailored recruitment strategies helped a sponsor meet enrollment goals faster and more efficiently. www.iconplc.com/solutions/all-case-studies/extensive-pati…
-
ICON Plc
@ICONplc
Meet the ICON team at #acr25, booth #1501 to learn how we apply flexible partnership and delivery models, supported by robust tools and technologies, to help clients achieve their rheumatology clinical development goals. www.iconplc.com/therapeutics/internal-medicine-immunology…
-
ICON Plc
@ICONplc
Join our live webinar to explore how the complementary tools of COAs + DHTs can deliver richer patient insights, enhancing obesity clinical trials.
📅 October 7, 11am EDT
Register here: xtalks.com/webinars/enhancing-clinical-trials-in-obesity-…
#clinicaltrials #obesityresearch #digitalhealth -
ICON Plc
@ICONplc
Adaptive trial designs are underutilised in neurodegenerative drug development. We provide insights on when and how to use adaptive designs to accelerate and de-risk clinical trials. Learn more www.iconplc.com/sectors/biotech/advancing-alzheimers-and-…
#worldalzheimersmonth -
ICON Plc
@ICONplc
As #oncology #biosimilars enter clinical trials, defining and recruiting the most appropriate patient cohort presents a critical challenge. Find key considerations and strategies for navigating this and other #oncology #biosimilar obstacles in the article. www.drugdiscoverytrends.com/what-sets-oncology-biosimilar…
-
ICON Plc
@ICONplc
Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest clinical trial regulatory authority updates current: www.iconplc.com/insights/regulatory-intelligence/regulato…
-
ICON Plc
@ICONplc
Join our webinar to learn about the challenges and critical success factors when developing pediatric clinical trials and an interactive “first step” tool for risk identification and mitigation.
Register today – www.iconplc.com/news-events/events/webinars/pediatric-ris…
#childhoodcancerawarenessmonth -
ICON Plc
@ICONplc
Our comprehensive formulation screening and optimisation process identifies the best exposure levels, enabling data-driven decisions that enhance early phase clinical trial success rates. www.iconplc.com/solutions/manufacturing-pharmacy-services
-
ICON Plc
@ICONplc
Meet ICON experts at #esmo25, booth #3034 to learn about our Centre for Pediatric Clinical Development’s expertise in supporting oncology studies involving pediatric participants including neonates, children, adolescents, young adults, and pregnant women. www.esmo.org/meeting-calendar/esmo-congress-2025
-
ICON Plc
@ICONplc
Symphony Health, an ICON plc company, stands with those living with heart failure. We honour your strength and the progress in care. See how real-world data drives smarter decisions healthverity.com/symphony-health/overview/
-
ICON Plc
@ICONplc
Cardiovascular disease remains the leading cause of death globally. In the past 5 years, ICON has participated in 122 clinical studies enrolling 19,900+ patients and healthy volunteers (HV) at 2,800+ sites across the world. www.iconplc.com/therapeutics/cardiovascular
-
ICON Plc
@ICONplc
From early planning to execution, ICON supports your obesity trials with strategic insight, operational excellence, and proven infrastructure. See how in our case studies. www.iconplc.com/solutions/all-case-studies/therapeutics-c…
-
ICON Plc
@ICONplc
Why do stability studies matter in early drug development? Learn how early stability testing can de-risk your clinical program and support successful IND/IMPD submissions in our latest blog post.
www.iconplc.com/insights/blog/2025/08/20/importance-stabi… -
ICON Plc
@ICONplc
The therapeutic landscape for obesity is changing rapidly.
Join ICON experts on October 7 at 11am EDT to learn how integrating COAs and DHTs can:
•Improve data relevance
•Support regulatory alignment
•Enhance patient-centered trial design
Register: xtalks.com/webinars/enhancing-clinical-trials-in-obesity-… -
ICON Plc
@ICONplc
Pediatric trials differ from adult trials—but spotting the differences isn't always easy. Join our webinar to explore the regulatory key strategies and an interactive tool to identify and mitigate pediatric trial risks. Register now. xtalks.com/webinars/identify-and-mitigate-risks-in-pediat…
-
ICON Plc
@ICONplc
Cardiovascular outcomes trials are critical for assessing health impacts, ensuring drug safety, and meeting regulatory requirements. Explore the key elements of successful #cvots, including study design, endpoint capture and execution, in our article. magazine.pharmatimes.com/collections/12176b0a-832b-11f0-b…
-
ICON Plc
@ICONplc
As clinical trials grow in complexity, programming strategies must evolve. Learn how R is helping sponsors improve quality, accelerate timelines and unlock new opportunities for data driven decision making. www.iconplc.com/insights/blog/2025/09/18/reimagining-clin…
#clinicaltrials #rstats #clinicalprogramming -
ICON Plc
@ICONplc
As global pressures reshape the pharmaceutical and biotech landscape, sponsors are re-evaluating their outsourcing strategies. In this article, Maria DiPietro shares insights from ICON’s recent survey of industry stakeholders. Read the article: pharmatimes.com/thought_leadership/promised-land/
-
ICON Plc
@ICONplc
For the third year in a row, ICON is on #time & #statista’s World’s Best Companies list! A huge shoutout to our amazing teams who make this possible. time.com/7315547/worlds-best-companies-of-2025/
#worldsbestcompanies -
ICON Plc
@ICONplc
Using digital health technologies in cardiovascular studies can allow decentralisation, decrease patient burden, and improve adherence. Find out what types of DHTs can be used in CV studies, and how they can enhance patient centricity, in the blog:www.iconplc.com/insights/blog/2025/09/18/modern-tools-car…
-
ICON Plc
@ICONplc
At the SCRS Global Site Solutions Summit, discover how Accellacare and FIRECREST are delivering integrated site support and digital enablement to drive trial success.
Contact us to schedule time with ICON Site & Patient Solutions experts. www.accellacare.com/contact -
ICON Plc
@ICONplc
How can sponsors approach the challenge of maximising opportunities to accelerate their #oncology and rare disease treatments to market?
Learn more: www.iconplc.com/insights/regulatory-intelligence/accelera…This media couldn't be displayed. See it on the original post. -
ICON Plc
@ICONplc
Avoid delays and improve compliance in your #fda and #pmda #datasubmissions. Our whitepaper offers practical guidance for regulatory teams: www.iconplc.com/insights/regulatory-intelligence/navigati…
-
ICON Plc
@ICONplc
Innovation and insight come together at #scdmus! Visit ICON at booth 308, 27–30 Sept, Baltimore Convention Center, and hear from our experts Diego Rodriguez Mendez, Rhonda Hines, Kimberly Dley, Stephen Cameron, and Lori Zellman. scdmlive.org/annual-conference-2025/
-
ICON Plc
@ICONplc
World Cancer Research Day is about supporting new innovative therapies. However, consideration should also be given to biosimilars' ability to expand patient access to cancer treatment. Read more www.iconplc.com/insights/therapeutics/oncology/future-onc…
-
ICON Plc
@ICONplc
ICON’s Regulatory Affairs team is proud to sponsor #rapsconvergence 2025, 7 – 9 October in Pittsburgh. Visit booth 409 to explore how we support regulatory strategy, global submissions, CMC, medical devices etc across all therapeutic areas. www.iconplc.com/news-events/events
-
ICON Plc
@ICONplc
From selecting the right COAs and DHTs to ensuring clean, high-quality data, every choice impacts trial outcomes.
Our upcoming live webinar will provide evidence-based approaches to identify appropriate measures.
Save your seat: xtalks.com/webinars/enhancing-clinical-trials-in-obesity-… -
ICON Plc
@ICONplc
Biomarkers are driving drug development. This expert-led report produced in conjunction with Drug Target Review explores how biomarker science is advancing trial design, accelerating clinical decisions and driving the future of precision medicine.
www.drugtargetreview.com/whitepaper/179538/beyond-the-lab… -
ICON Plc
@ICONplc
Register to learn about the challenges and critical success factors when developing pediatric clinical trials and an interactive “first step” tool for risk identification and mitigation. www.iconplc.com/news-events/events/webinars/pediatric-ris… #childhoodcancer
-
ICON Plc
@ICONplc
We’re delighted to announce that Deepali Suri has joined as President of ICON Biotech. With a proven track record in clinical development, operational excellence, and digital innovation, Deepali will lead our support for emerging and mid-sized biotechnology clients.
-
ICON Plc
@ICONplc
Connect with the ICON team at #esmo25, booth #3034 to learn how we apply flexible partnership and delivery models, supported by robust tools and technologies, to help clients achieve their oncology clinical development goals. www.esmo.org/meeting-calendar/esmo-congress-2025 www.esmo.org/meeting-calendar/esmo-congress-2025
-
ICON Plc
@ICONplc
ICON will be launching our new multiplex immunofluorescence services at Biomarkers & Precision Medicine. Come to booth #51 to find out how our comprehensive services can generate richer biological insights. www.iconplc.com/MIF
-
ICON Plc
@ICONplc
Efficiently capturing and managing cardiovascular outcomes trial data takes agility and preparedness. Read ICON’s article to learn about considerations and tools for endpoint capture and review, data cleaning, and other elements of a successful #cvot. magazine.pharmatimes.com/collections/12176b0a-832b-11f0-b…
-
ICON Plc
@ICONplc
Explore our case study library to see how we help sponsors overcome obesity trial challenges with our industry-leading, flexible, end-to-end clinical development solutions. www.iconplc.com/solutions/all-case-studies/therapeutics-c…
-
ICON Plc
@ICONplc
#worldcancerresearchday highlights the importance of research to drive new treatments, improve outcomes, and bring hope to millions facing cancer. www.iconplc.com/therapeutics/oncology
-
ICON Plc
@ICONplc
ICON’s near-term, long-term and #netzero targets have been validated by #sbti. In 2024 we decreased Scope 3 emissions 7.56% compared to 2022. Read more www.iconplc.com/about/environmental-social-and-governance…
#iconcares #sustainability #esg #sdg13 #climateaction #climateweeknyc #uniteinaction -
ICON Plc
@ICONplc
Why wait months when you can get results in weeks?
Our real-time GMP manufacturing and clinical testing process accelerates decision-making, saving time and costs while improving early phase trial outcomes.
Let’s get your drug to market faster & smarter. www.iconplc.com/solutions/manufacturing-pharmacy-services -
ICON Plc
@ICONplc
ICON named to @TIME World’s Most #sustainable Companies 2025. Amazing recognition for our #iconcares #esg programme: www.iconplc.com/about/environmental-social-and-governance
-
ICON Plc
@ICONplc
ICON’s Victoria DeVeaugh-Geiss will participate in this panel hosted by Citeline, discussing how to embed risk-based strategies across clinical research. Don’t miss this opportunity to connect and learn. discover.pharmaignite.com/eclinical-september-23-event
-
ICON Plc
@ICONplc
The countdown is on! The 15th World Clinical Biomarkers & CDx Summit is in Boston, 22–25 September. Visit booth #13 to meet ICON’s biomarker & CDx specialists and learn how we turn insights into real-world patient impact. world-cdx.com
-
ICON Plc
@ICONplc
In recent years, cardiovascular outcomes trials have become prominent in studies of GLP-1 drugs, but they also serve a number of other crucial roles. Discover what it takes to successfully design and execute a modern #cvot in the article. magazine.pharmatimes.com/collections/12176b0a-832b-11f0-b…
-
ICON Plc
@ICONplc
The #biosimilar era in #oncology is shifting rapidly. Fast movers will be best positioned to capitalise on first-to-market advantage. Read the article icon.widen.net/s/kbpcpsbmnj
-
ICON Plc
@ICONplc
Are weight loss endpoints enough to demonstrate the true impact of obesity treatments?
Join ICON experts for a live webinar addressing how integrating COAs and DHTs can:
•Improve data relevance
•Support regulatory alignment
Reserve your spot: xtalks.com/webinars/enhancing-clinical-trials-in-obesity-… -
ICON Plc
@ICONplc
Join our webinar to learn about the regulatory strategies when developing pediatric clinical trials and an interactive “first step” tool for risk identification and mitigation. Register today. xtalks.com/webinars/identify-and-mitigate-risks-in-pediat…
-
ICON Plc
@ICONplc
As clinical trials become more complex, risk management must evolve. Join Victoria DeVeaugh-Geiss and fellow industry experts as they explore the evolution of RBQM. discover.pharmaignite.com/eclinical-september-23-event
-
ICON Plc
@ICONplc
Sponsors face sweeping changes with ICH GCP E6(R3). Our regulatory experts detail impacts, the top 5 areas affected and key approaches for compliance.
Read now: www.iconplc.com/insights/regulatory-intelligence/preparin… -
ICON Plc
@ICONplc
LabView360 provides real-time visibility, reducing manual errors, and accelerating results. With an intuitive mobile-responsive app, sites can scan barcodes, streamline workflows, and ensure high-quality data collection. Discover more: www.iconplc.com/solutions/technologies/labview360
-
ICON Plc
@ICONplc
Cut 12+ months from your development timeline and save on R&D costs with ICON’s Accelerated Pharmaceutical Solutions.
Our integrated approach streamlines formulation, manufacturing, and clinical testing—bringing life-changing therapies to patients faster. www.iconplc.com/solutions/early-clinical/accelerated-phar… -
ICON Plc
@ICONplc
ICON's new CEO speaks to BioXconomy on industry challenges - and opportunities - ahead. Discover more: www.bioxconomy.com/clinical-and-research/icon-s-new-ceo-c…
-
ICON Plc
@ICONplc
A thoughtful, agile study design is the first step to a successful cardiovascular outcomes trial. Read the article for an overview of #cvot design approaches, including enrichment, adaptive trials and emerging tools for CVOT success.
magazine.pharmatimes.com/collections/12176b0a-832b-11f0-b… -
ICON Plc
@ICONplc
Discover how ICON’s #drug development experts, using advanced modelling and simulation, assessed the clinical hypothesis and identified opportunities to simplify the development path. www.iconplc.com/solutions/all-case-studies/protocol-optim…
-
ICON Plc
@ICONplc
ICON’s Victoria DeVeaugh-Geiss, Director of Clinical Operations, will share insights on holistic risk management in clinical trials and explore how evolving RBQM and RBDM strategies can drive cross-functional success. discover.pharmaignite.com/eclinical-september-23-event
-
ICON Plc
@ICONplc
Global regulators are streamlining access to innovative therapies, navigating these pathways takes strategic know-how. From FDA’s Breakthrough Therapy designation to Japan’s Sakigake designation, early planning and expert partnerships make the difference. www.iconplc.com/insights/blog/2025/08/19/rising-challenge…
-
ICON Plc
@ICONplc
By integrating COAs and DHTs, sponsors can capture real-world, patient-centered insights that improve both regulatory alignment and trial value.
Join us on October 7 to understand current trends in COA + DHT use.
Register Today: xtalks.com/webinars/enhancing-clinical-trials-in-obesity-… -
ICON Plc
@ICONplc
Biomarkers are driving drug development. This expert-led report produced in conjunction with Drug Target Review explores how biomarker science is advancing trial design, accelerating clinical decisions and driving the future of precision medicine.
www.drugtargetreview.com/whitepaper/179538/beyond-the-lab… -
ICON Plc
@ICONplc
Join ICON at Biomarkers & Precision Medicine UK, 30 Sept–1 Oct, QEII Centre, London. Meet our experts at booth #51 and discover how our biomarker, clinical, and consulting expertise accelerates development and drives better patient outcomes. oxfordglobal.com/precision-medicine/events/pmeurope
-
ICON Plc
@ICONplc
Cardiovascular outcomes trials are critical for assessing health impacts, ensuring drug safety, and meeting regulatory requirements. Explore the key elements of successful #cvots, including study design, consistency, endpoint capture and execution. magazine.pharmatimes.com/collections/12176b0a-832b-11f0-b…
-
ICON Plc
@ICONplc
ICON understands the rapidly advancing landscape and the unique challenges of navigating the patient, site, product and regulatory journeys in delivering CGT therapies. Meet us at #esmo25, booth #3034 to learn how we can help support your trial. www.esmo.org/meeting-calendar/esmo-congress-2025
-
ICON Plc
@ICONplc
ICON is proud to be named one of #time & #statista’s World’s Best Companies of 2025 — for the third year running! A huge thank you to our teams worldwide time.com/7315547/worlds-best-companies-of-2025/
#worldsbestcompanies -
ICON Plc
@ICONplc
Attending #easd2025 in Berlin on 15-19 Sept? Meet ICON experts at booth E102 to learn how we can support your diabetes trials with optimal program design, proactive planning, and high-quality study delivery. www.easd.org/home/
-
ICON Plc
@ICONplc
Diversity in clinical trials isn’t optional — it’s essential. We’re proud to have Erica Johnson speaking at the upcoming @RAPSorg workshop on building more inclusive research.
Learn more and register: www.raps.org/learn-develop/events.html -
ICON Plc
@ICONplc
Discover how our strong relationship with the sponsor, our proven track record of partnering with small #biotech firms, and our clear understanding that biotech companies require a different approach made ICON the ideal partner for this study. www.iconplc.com/solutions/all-case-studies/small-biotech-…
-
ICON Plc
@ICONplc
ICON is excited to be part of #conspic 2025, organized by #iasct. We look forward to seeing you there! iasct.net/conspic2025/moreinfo
-
ICON Plc
@ICONplc
Despite their central role in glucose metabolism, native GLP-1 and GIP make poor therapies. Now, long-lasting, potent nutrient-stimulated hormone receptor agonists are prompting a shift to multi-indication metabolic therapies. Explore why. www.appliedclinicaltrialsonline.com/view/embracing-proact…
-
ICON Plc
@ICONplc
ICON is sponsoring #scdmus! Join us 27–30 Sept at the Baltimore Convention Center. Stop by booth 308 to meet our team and explore how ICON is shaping the future of clinical data. Don’t miss the conversations that matter most. See you in Baltimore! scdmlive.org/annual-conference-2025/
-
ICON Plc
@ICONplc
Visit ICON at #octsocal2025, booth #26 and see how biotech & pharma sponsors can accelerate study start-up, optimize patient recruitment & retention, and leverage digital solutions for efficient, high-quality trials. www.arena-international.com/event/octsocal/
-
ICON Plc
@ICONplc
The final ICH GCP E6(R3) guideline is here.
ICON experts decode the updates, assess risk impacts and outline compliance strategies in our new #regulatoryintelligence whitepaper.
Download today: www.iconplc.com/insights/regulatory-intelligence/preparin… -
ICON Plc
@ICONplc
The escalating cost and prolonged timelines of drug development have lead #regulatory authorities to focus on ways to accelerate the availability of innovative therapies to market. Learn more: www.iconplc.com/insights/regulatory-intelligence/accelera…
This media couldn't be displayed. See it on the original post. -
ICON Plc
@ICONplc
Are your obesity trials designed to meet today’s expectations?
Discover how to integrate COAs + DHTs effectively in our live session.
Reserve your spot: xtalks.com/webinars/enhancing-clinical-trials-in-obesity-…
#clinicaltrials #obesityresearch #digitalhealth -
ICON Plc
@ICONplc
ICON is sponsoring the 15th World CB & CDx Summit, September 22–25 in Boston. Visit booth #13 to meet our biomarker & bioanalytical experts and learn how ICON accelerates CDx strategies, optimizes trials & drives precision medicine. world-cdx.com
-
ICON Plc
@ICONplc
ICON’s Accelerated Pharmaceutical Solutions provide a seamless, end-to-end approach to formulation development for small molecules and biologics.
Our comprehensive services cover everything from formulation screening to labelling and distribution. www.iconplc.com/solutions/early-clinical/accelerated-phar… -
ICON Plc
@ICONplc
September is #childhoodcancerawareness month. Approx. 400k children are diagnosed with cancer every year.
FIRECREST helps decode complex science into compelling visuals to better understand new therapies that bring hope. Discover more: www.iconplc.com/solutions/technologies/firecrestThis media couldn't be displayed. See it on the original post. -
ICON Plc
@ICONplc
In just a few days, ICON will be at #dpharm2025, 16 -17 September. Visit booth #305 to learn how we accelerate trial success and don’t miss Faith Gabel’s session on site networks.
dpharmconference.com -
ICON Plc
@ICONplc
Biomarkers are driving drug development. This expert-led report produced in conjunction with Drug Target Review explores how biomarker science is advancing trial design, accelerating clinical decisions and driving the future of precision medicine.
www.drugtargetreview.com/whitepaper/179538/beyond-the-lab… -
ICON Plc
@ICONplc
Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest clinical trial regulatory authority updates current: www.iconplc.com/insights/regulatory-intelligence/regulato…
-
ICON Plc
@ICONplc
The theme for Childhood Cancer Awareness Month 2025 is “Together for Hope: Bridging Gaps, Saving Lives”. Learn how ICON is supporting research in #childhoodcancer and other #pediatric diseases www.iconplc.com/therapeutics/pediatrics/
-
ICON Plc
@ICONplc
The biologics’ patent cliff presents opportunity particularly in the #oncology space. But there are also pitfalls for #biosimilar drug developers. Learn more: www.iconplc.com/insights/therapeutics/oncology/future-onc…
-
ICON Plc
@ICONplc
Patient voices matter more than ever in obesity research.
Join our upcoming webinar to learn how to combine COAs and digital health technologies to capture the full patient experience. xtalks.com/webinars/enhancing-clinical-trials-in-obesity-…
#clinicaltrials #obesityresearch #digitalhealth -
ICON Plc
@ICONplc
Meet the ICON team and explore our central lab capabilities at #easd2025, booth E102.
From Type 1 to Type 2 diabetes, adult to pediatric populations—we support your metabolic disorder trials. www.easd.org/home/
#clinicalresearch #diabetestrials -
ICON Plc
@ICONplc
Early-stage biotech companies face unique #challenges in clinical development.
Read the story of how the #vc fund required flexibility and strategic alignment from the CRO, and how ICON successfully met those needs. www.iconplc.com/solutions/all-case-studies/building-scala… -
ICON Plc
@ICONplc
With patents on many prominent oncology biologics set to expire, there are plentiful opportunities for biosimilar sponsors. Learn what unique challenges to expect from the #oncology #biosimilar development process and strategies to overcome them. www.drugdiscoverytrends.com/what-sets-oncology-biosimilar…
-
ICON Plc
@ICONplc
Symphony Health, an ICON plc company, are looking forward to Fierce Pharma Week (Sept 8–11) in Philadelphia.
Visit us at booth #1320 to explore how our medical affairs, commercial, and promotional solutions help connect the dots across the patient journey.
www.fiercepharmaweek.com -
ICON Plc
@ICONplc
Many developers aiming to capitalise on multi-indication metabolic assets would benefit from adopting trials designed to generate more holistic insights on therapeutic efficacy. Explore these innovative trial designs in our article. www.appliedclinicaltrialsonline.com/view/embracing-proact…
-
ICON Plc
@ICONplc
The UK offers an alternative path if the EU’s joint scientific consultation (JSC) process is not meeting your trial timelines. Learn more in our latest UK series blog www.iconplc.com/insights/blog/2025/08/19/avoid-htar-bottl…
-
ICON Plc
@ICONplc
#globaldatasubmissions do not have to be inefficient. Learn how to align with #fda and #pmda standards in our latest whitepaper: www.iconplc.com/insights/regulatory-intelligence/navigati…
-
ICON Plc
@ICONplc
ICON announces CEO transition effective 1 October. Read more www.iconplc.com/news-events/press-releases/icon-announces…
-
ICON Plc
@ICONplc
Join ICON at the 15th World CB & CDx Summit, 22–25 September in Boston. Meet our experts at booth #13 to learn how ICON’s biomarker expertise drives smarter trials, accelerates CDx strategies & delivers patient impact. world-cdx.com
-
ICON Plc
@ICONplc
Each year, an estimated 400,000 children and adolescents develop cancer. Learn how ICON has been supporting research in #childhoodcancer and other #pediatric diseases. www.iconplc.com/therapeutics/pediatrics
#childhoodcancer #childhoodcancerawarenessmonth #throughtheirhands -
ICON Plc
@ICONplc
If your company requires urgent rescue assistance – consider changing CRO. Impossible?
Read the full story and learn how the ICON and Sponsor teams had to rapidly prepare for data cuts, while simultaneously transitioning the studies. www.iconplc.com/solutions/all-case-studies/exceeding-expe… -
ICON Plc
@ICONplc
Biotechs and pharma companies in Asia Pacific face rising costs of drug development and diminishing returns on investment.
ICON's Suhail Ali shares considerations on the risks, rewards and path ahead.
Read the article in Biospectrum Asia: www.biospectrumasia.com/opinion/54/26575/collaborative-rd… -
ICON Plc
@ICONplc
Join ICON experts live to learn how integrating COAs and DHTs in obesity trials supports:
•Stronger regulatory alignment
•Patient-centered outcomes
•Better trial efficiency
📅 Oct 7 | 11am EDT | xtalks.com/webinars/enhancing-clinical-trials-in-obesity-…
#clinicaltrials #obesityresearch #digitalhealth -
ICON Plc
@ICONplc
Symphony Health, an ICON plc company, are looking forward to Fierce Pharma Week (Sept 8–11) in Philadelphia.
Visit us at booth #1320 to explore how our medical affairs, commercial, and promotional solutions help connect the dots across the patient journey.
www.fiercepharmaweek.com -
ICON Plc
@ICONplc
Have you moved beyond the traditional stepwise model of sequential label expansion? Learn why drug developers are now proactively deploying multi-indication strategies in our article. www.appliedclinicaltrialsonline.com/view/embracing-proact…
-
ICON Plc
@ICONplc
Biomarkers are driving drug development. This expert-led report produced in conjunction with Drug Target Review explores how biomarker science is advancing trial design, accelerating clinical decisions and driving the future of precision medicine.
www.drugtargetreview.com/whitepaper/179538/beyond-the-lab… -
ICON Plc
@ICONplc
By integrating a short term stability program, formulation development, real-time drug product manufacturing, and clinical testing, we help you streamline the entire process—cutting up to 12+ months in development time and saving significant costs. www.iconplc.com/solutions/early-clinical/accelerated-phar…
-
ICON Plc
@ICONplc
From FDA’s Project Orbis to EMA’s PRIME, early planning & strategic partnerships are key to streamline approvals. Learn how: www.iconplc.com/insights/blog/2025/08/19/rising-challenge…
-
ICON Plc
@ICONplc
Attending #easd2025 in Berlin on 15-19 Sept? Meet ICON experts at booth E102 to learn how we can support your diabetes trials with optimal program design, proactive planning, and high-quality study delivery. www.easd.org/home/
-
ICON Plc
@ICONplc
Introducing LabView360: The future of sample management. Paper-based manual requisitions are time-consuming and error-prone. LabView360 replaces them with a seamless digital process that improves data accuracy and reduces query resolution times. www.iconplc.com/solutions/technologies/labview360
-
ICON Plc
@ICONplc
Our upcoming webinar, titled “Enhancing Clinical Trials in Obesity by Integrating COAs and DHTs,” will highlight how sponsors can meet all of these expectations and bring more effective drugs to market.
📅 October 7 at 11am EDT
Secure your seat: xtalks.com/webinars/enhancing-clinical-trials-in-obesity-… -
ICON Plc
@ICONplc
Why systematic literature reviews (SLRs) matter in life sciences?
Research is exploding—doubling every 14 years. SLRs help cut through the noise with structured, reproducible methods. Learn how to conduct them: www.iconplc.com/insights/transforming-trials/demystifying…
#slr #medicalresearch #pharmaevidence -
ICON Plc
@ICONplc
ICON has analysed ECG data from over 22,000 healthy volunteers to compare four widely used QT correction formulae. Come along to our poster session on 1st September at the European Society of Cardiology conference in Madrid to hear more. esc365.escardio.org/esc-congress/sessions/15512-genetics-…
-
ICON Plc
@ICONplc
Oncology #biosimilars present unique potential and distinct challenges to sponsors. Read our blog to learn more about unique clinical pathways, study design and more. www.iconplc.com/insights/blog/2025/07/21/oncology-biosimi…
-
ICON Plc
@ICONplc
Emerging vaccine approaches may use one of three emerging vaccine delivery systems: viral vectors, virus-like particles and nanoparticles. Read the blog to find out their promises and pitfalls. www.iconplc.com/insights/blog/2025/08/28/beyond-tradition…
#nationalimmunisationmonth -
ICON Plc
@ICONplc
Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest clinical trial regulatory authority updates current: www.iconplc.com/insights/regulatory-intelligence/regulato…
-
ICON Plc
@ICONplc
Compounds that mimic incretin hormones hold significant promise as therapies and research tools. Read our article to learn more about the multi-indication potential of drugs that modulate glucose metabolism. www.appliedclinicaltrialsonline.com/view/embracing-proact…
-
ICON Plc
@ICONplc
RBQM + QbD = a smarter trial from day one. Explore how the new GCP guidance empowers sponsors to optimise design, oversight and outcomes. www.iconplc.com/insights/blog/2025/08/11/how-gcp-updates-…
#rbqm #qbd #clinicaldevelopment #pharmaleadership -
ICON Plc
@ICONplc
The therapeutic landscape for obesity is changing rapidly.
Join our experts on October 7 at 11am EDT to learn how integrating COAs and DHTs can:
• Improve data relevance
• Support regulatory alignment
• Enhance patient-centered trial design
xtalks.com/webinars/enhancing-clinical-trials-in-obesity-… -
ICON Plc
@ICONplc
ICON Biotech agile models are designed to support biotech companies from molecule to medicine offering the scale of a global CRO with the focus of a dedicated team.
Watch the video to see how our partnership model empowers biotech success #partnership
www.iconplc.com/sectors/biotech -
ICON Plc
@ICONplc
Transforming partnerships through flexibility and focus.
Discover how ICON helped a sponsor transition to a blended model—combining FSO, FSP and standalone services for greater control and efficiency. www.iconplc.com/solutions/all-case-studies/transforming-p… -
ICON Plc
@ICONplc
Antibody-Drug Conjugates (ADCs) combine potent cytotoxins with selective antibodies for targeted cancer therapy.
As ADC development rapidly evolves, so must our bioanalytical strategies. Discover key insights and solutions to support ADC drug development. www2.iconplc.com/ADC_Bioanalytics -
ICON Plc
@ICONplc
ICON is delighted to partner with #octsocal2025. Visit booth #26 to explore strategies for faster study start-up, better patient recruitment & retention, and advanced digital solutions. www.arena-international.com/event/octsocal/
-
ICON Plc
@ICONplc
ICON will be at #dpharm2025 this 16–17 September. Visit booth #305 to learn how our clinical, consulting, and commercial expertise drives trial efficiency and delivers better patient outcomes. Join us to transform clinical research through innovation. dpharmconference.com
-
ICON Plc
@ICONplc
Reducing patient burden is important in diabetes trials. Speak with ICON experts at #easd2025, booth E102 to learn how our In-Home services make it convenient for the patient to complete the protocol assessments and stay engaged throughout the study. www.easd.org/home/
-
ICON Plc
@ICONplc
How can sponsors approach the challenge of maximising opportunities to accelerate their #oncology and rare disease treatments to market?
Learn more: www.iconplc.com/accelerating-access -
ICON Plc
@ICONplc
Multi-indication has become the new normal in obesity drug development. Is it becoming more strategic? Find out in our article. www.appliedclinicaltrialsonline.com/view/embracing-proact…
-
ICON Plc
@ICONplc
Life sciences research is booming—doubling every 14 years. Want to cut through the clutter? Learn how to master systematic literature reviews (SLRs).
Download the whitepaper: www.iconplc.com/insights/transforming-trials/demystifying…
#slr #pharmaresearch #clinicalevidence #lifesciences -
ICON Plc
@ICONplc
Have you considered the benefits of a “broad first” launch for your multi-indication drug? This strategy targets larger populations for early market share, though often with lower pricing. Learn about the commercial implications in our article. www.pharmexec.com/view/strategic-commercialization-multi-…
-
ICON Plc
@ICONplc
The therapeutic landscape for obesity is changing rapidly.
Join our experts on October 7 at 11am EDT to learn how integrating COAs and DHTs can:
• Improve data relevance
• Support regulatory alignment
• Enhance patient-centered trial design
xtalks.com/webinars/enhancing-clinical-trials-in-obesity-… -
ICON Plc
@ICONplc
Biomarkers are driving drug development. This expert-led report produced in conjunction with Drug Target Review explores how biomarker science is advancing trial design, accelerating clinical decisions and driving the future of precision medicine.
www.drugtargetreview.com/whitepaper/179538/beyond-the-lab… -
ICON Plc
@ICONplc
From protocol design to intelligent monitoring, RBQM is no longer optional. Learn how early integration drives agility, efficiency and participant safety. www.iconplc.com/insights/blog/2025/08/11/how-gcp-updates-…
#rbqm #ichgcp #clinicalresearch #biotechinnovation -
ICON Plc
@ICONplc
Customised collaboration -- Discover how we helped sponsors transition to blended models, drive efficiency and create impactful outcomes.
Learn more across a range of real-world case studies. Explore the outcomes here: www.iconplc.com/solutions/all-case-studies/blended-soluti… -
ICON Plc
@ICONplc
Exit interviews = powerful patient insights. This qualitative study on cold urticaria shows how patients define meaningful change across PROs.
link.springer.com/article/10.1007/s40271-025-00754-6?erro…
#patientvoice #coldurticaria #clinicalresearch -
ICON Plc
@ICONplc
ICON is pleased to join industry leaders at #dpharm2025 this 16 - 17 September. Connect with our experts at booth #305 and see how our clinical, consulting, and commercial solutions accelerate innovation and improve patient outcomes. dpharmconference.com
-
ICON Plc
@ICONplc
Antibody-Drug Conjugates (ADCs) combine potent cytotoxins with selective antibodies for targeted cancer therapy.
As ADC development rapidly evolves, so must our bioanalytical strategies. Discover key insights and solutions to support ADC drug development. www2.iconplc.com/ADC_Bioanalytics -
ICON Plc
@ICONplc
Why are 700+ AI medical devices in radiology—but only 30 in neurology?
Our new article in Med-Tech Insights breaks down the regulatory and technical reasons behind the imbalance. med-techinsights.com/2025/08/08/navigating-global-regulat…
#medtech #ai #fda #samd #healthcareinnovation -
ICON Plc
@ICONplc
In the fast-paced world of pharma, making informed decisions starts with understanding the evidence.
Our new whitepaper, “Demystifying the SLR: ‘S’ Stands for Systematic,” breaks down how Systematic literature reviews can help you.
Download your copy: www.iconplc.com/insights/transforming-trials/demystifying… -
ICON Plc
@ICONplc
The ICH GCP E6(R3) update is here and it’s a game changer. Discover how RBQM is reshaping trial oversight with smarter, risk-proportionate strategies. www.iconplc.com/insights/blog/2025/08/11/how-gcp-updates-…
#rbqm #clinicaltrials #gcp #biotech #pharma -
ICON Plc
@ICONplc
Antibody-drug conjugates (ADCs) represent a growing class of targeted therapies, but their pharmacokinetic assessment presents unique challenges due to structural complexity, multiple analytes, and the need for diverse assay types.
Read more: www.iconplc.com/insights/blog/2025/07/10/why-assessing-ph… -
ICON Plc
@ICONplc
The UK offers an alternative path if the EU’s joint scientific consultation (JSC) process is not meeting your trial timelines. Learn more in our latest UK series blog www.iconplc.com/insights/blog/2025/08/19/avoid-htar-bottl…
-
ICON Plc
@ICONplc
In a few days at #scdm 2025 South Africa in Bloemfontein, ICON will lead talks on clinical data excellence—governance, secure access, digital innovation & regulatory impacts on data management.
Details: scdm.org/scdm-2025-south-africa-sde/ -
ICON Plc
@ICONplc
When commercialising a multi-indication drug, a narrow first launch strategy targets high-value populations for premium pricing but may slow accumulation of real world evidence.
Understand these trade-offs in our article. www.pharmexec.com/view/strategic-commercialization-multi-… -
ICON Plc
@ICONplc
Medical writing teams play a central role in regulatory submissions, but success depends on more than writing skill alone.
In this IBI article, our experts explore how planning and collaboration support high quality, timely submissions.
Read more: issuu.com/senglobal1/docs/ibi_-_volume_8_issue_2_-_summer… -
ICON Plc
@ICONplc
How do cold urticaria patients define meaningful change?
New study uses exit interviews to validate PROs - highlighting the power of patient voice in clinical research. link.springer.com/article/10.1007/s40271-025-00754-6?erro…
#clinicaltrials #coldurticaria #pros #patientexperience -
ICON Plc
@ICONplc
Pharma literature is exploding - SLRs help you make sense of it all.
New whitepaper: “Demystifying the systematic literature review”
- When & how to use SLRs
- Avoid common pitfalls
- Boost evidence quality
Download here: www.iconplc.com/insights/transforming-trials/demystifying…
#pharma #slr #medicalaffairs #heor -
ICON Plc
@ICONplc
From complexity to clarity. See how ICON’s blended delivery model provides flexible, scalable solutions to suit or partners’ evolving clinical needs.
Explore real results in our blended solutions case studies: www.iconplc.com/solutions/all-case-studies/blended-soluti… -
ICON Plc
@ICONplc
Submitting #clinicaldata to both the #fda and #pmda can be complex. Our whitepaper shows how to simplify the process and reduce duplication. Read the whitepaper for expert insights: www.iconplc.com/insights/regulatory-intelligence/navigati…
-
ICON Plc
@ICONplc
AI in medical devices is booming—over 1,000 FDA approvals and counting. But are global regulations ready? New from ICON experts in Med-Tech Insights: How developers can navigate evolving expectations for AI-enabled SaMD. med-techinsights.com/2025/08/08/navigating-global-regulat…
#medtech #ai #samd #fda -
ICON Plc
@ICONplc
Real-world data. Real patient impact.
For #psoriasisawarenessmonth, discover how Symphony Health, an ICON plc company, helped a brand navigate free drug programs, prescriber behaviour & market expansion with RWE.
Learn more: icon.widen.net/s/dhc5fxr8cn -
ICON Plc
@ICONplc
How should you launch a multi-indication therapy? Developers face a key strategic question: choose a "narrow first" approach for premium pricing, or a "broad first" strategy for early market share? Our article explores the distinct trade-offs of each. www.pharmexec.com/view/strategic-commercialization-multi-…
-
ICON Plc
@ICONplc
For #niam2025 we look at the recent history and the future of vaccine development and assess the important role of long-term follow up (LTFU) to demonstrate vaccine efficacy and safety. Learn why LTFU should start early on in trials. www.iconplc.com/insights/blog/2025/08/06/why-long-term-fo…
-
ICON Plc
@ICONplc
Keep your knowledge of the latest clinical trial regulatory authority updates current, by subscribing to our free newsletter. www.iconplc.com/insights/regulatory-intelligence/regulato…
-
ICON Plc
@ICONplc
The success of GLP-1 receptor agonists, first for diabetes and then expanded to obesity and CVD, laid crucial groundwork for the widespread adoption of multi-indication clinical development. Learn more in our article. international-pharma.com/wp-content/uploads/2025/07/IPI-S…
-
ICON Plc
@ICONplc
ICON’s near-term, long-term and #netzero targets have been validated by #sbti. In 2024 we decreased Scope 3 emissions 7.56% compared to 2022. Read more: www.iconplc.com/about/environmental-social-and-governance…
-
ICON Plc
@ICONplc
ICON is pleased to be a sponsor at #amcp2025.
Meet the Symphony Health team at booth #505 and gain valuable perspectives on current trends, emerging challenges, and strategic insights needed to navigate the ever-evolving landscape of managed care. amcpannual.org -
ICON Plc
@ICONplc
When women win, we all win. At ICON, we #embraceequity and celebrate diversity across our organisation – today and every day. #iwd2023
-
ICON Plc
@ICONplc
Congratulations to ICON’s Pam Howard, Vice President, Biostatistics & Programming and Medical Writing on her appointment to the @CDISC Board of Directors. Read more www.cdisc.org/news/new-global-leaders-join-cdisc-board-di…













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































